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The transient receptor potential vanilloid channel 1 (TRPV1) is a non-selective ion 
channel capable of being activated by multiple factors such as noxious stimuli, heat 
(>42 °C), low pH and pungent agents. Due to its pivotal role in pain perception 
TRPV1 has extensively been studied in the context of nociception in sensory 
neurons. Although TRPV1 has been discovered in the hippocampus, the exact 
cellular and subcellular expression as well as the function of the channel is still 
subject of strong debate. Using multiple techniques our study confirms the 
functional expression of TRPV1 in hippocampal neurons and provides information 
about the localization of the receptor. We found that the expression of TRPV1 was 
upregulated by NGF and high neuronal activity. TRPV1 was highly expressed in 
reelin/somatostatin-positive interneurons of the oriens lacunosum moleculare 
(OLM) that concomitantly express NGF (that likely increases TRPV1 expression). 
TRPV1 promotes high excitatory innervation of OLM neurons; when activated the 
channel recruits more excitatory terminals but if the channel is blocked or removed 
OLM neurons receive substantially less excitatory input. Such impairment is 
reflected in a significant decrease in LTP in the Schaffer collateral pathway in the 
TRPV1 KO mouse. This deficit in LTP is bypassed when OLM neurons are 
activated with nicotine - which selectively activates only OLM neurons in the 
hippocampus. This demonstrates functionally that TRPV1 is specifically expressed 
in OLM neurons. We also report some drawbacks detected in the TRPV1 knockout 
and the TRPV1 cre/lox P reporter mouse, two commercially available mouse lines 
commonly used in the field. Our findings may encourage other researchers to be 
more cautious with conclusions drawn using these animals. Together this thesis 







The transient receptor potential (TRP) channel family comprises a wide variety of 
ionic channels that are involved in multiple neurosensory mechanisms (e.g, photo, 
osmotic, mechanical, thermal, acidic and pain perception) (Bevan et al., 2014; 
Caterina et al., 1997; Clapham, 2003; Liedtke and Kim, 2005; O‘Neil and Heller, 
2005; Patapoutian, 2005; Pedersen et al., 2005; Tominaga and Caterina, 2004). 
This family has been found in almost all phyla, being absent only in plants and 
bacteria (Nilius and Owsianik, 2011; Vriens et al., 2009). Traditionally, this family 
has been divided into six subfamilies: TRPC (canonical) TRPA (ankyrin), TRPM 
(melastatin), TRPV (vanilloid), TRPML (mucolipin) and TRPP (polycystin) 
(Clapham, 2003; Nilius and Owsianik, 2011; Vriens et al., 2009; Wu et al., 2010). 
Within the transient receptor potential vanilloid subfamily six different channels 
have been characterized (TRPV1-6) (Caterina, 2007; Caterina et al., 1997, 1999; 
Clapham, 2003; Smith et al., 2002). TRPV1 is by far the most investigated member 
of the vanilloid subfamily and perhaps of the entire TRP family.  
 
The TRPV1 channel is a non-selective, ligand-gated cation channel permeable to 
monovalent, divalent as well as to polyvalent cations such as Na+, Fe+, K+, Cs+, Li+, 
Rb+, Ca2+, Mg2+, guanidinium, N-methyl-D-glucamine and tetraethylammonium 
(Bevan et al., 2014; Caterina et al., 1997; Cesare and McNaughton, 1996; Hellwig 
et al., 2004; Kauer and Gibson, 2009; Oh et al., 1996; Samways and Egan, 2011; 
Winter et al., 1990); polyamines such as putrescine, spermine and spermidine 
have also been reported to be also permeate through TRPV1 channels (Ahern et 
al., 2006). Permeability to larger cations has been suggested to occur during pore 







Perhaps the most striking outstanding fact about TRP channels is their 
polymodality, that is, the capability of coping with a wide variety of endogenous and 
exogenous stimuli. As explained in section 2.3 TRPV1 activation or inhibition is 
gated and regulated by thermal, protonic and voltaic energy, by pungent molecules 
(e.g. capsaicin), enzymes (e.g. PKA and PKC), endocannabinoids, phospholipids 
and many more molecules. How does TRPV1 integrate all of these signals in 
different tissues? Which physiological phenotypes are affected by the signaling of 
TRPV1? These are central questions of high relevance to medical science and 
neuroscience. 
2.1. TRPV1 GENE TRANSCRIPTION AND PROTEIN 
STRUCTURE 
2.1.1. The Trpv1 Gene 
The trpv1 gene is located in Homo sapiens on chromosome 17 p3, in Mus 
musculus on chromosome 11 45.25 cM and in Rattus norvegicus on chromosome 
10 q24. The gene consists of 19 exons in humans, 17 exons in the house mouse, 
and 16 exons in the Norway rat. In humans and the house mouse, the resulting 
protein is predicted to be 839 amino acids long, and in Norway rats it is 838 amino 
acids. The approximate molecular mass of the full length TRPV1 is 95,000 Da 
(Birnbaumer et al., 2003; Caterina et al., 1997, 2000). 
2.1.2. Trpv1 transcription 
The mechanism of TRPV1 transcription is still unclear. It is known that during 
inflammation and hyperalgesia the expression of growth factors, such as NGF as 
well as other inflammatory agents is increased in nociceptors, subsequently 





al., 2002; Malin et al., 2006) (see section 2.7.1). TRPV1 transcription is prompted 
by the activation of two putative promoters (located either distally or proximally to 
the trpv1 gene sequence) in a 2826 bp sequence upstream of the TRPV1 gene. 
Activation of a GC box enriched sequence located on the more distal upstream 
regulatory element, by Sp1/Sp4 transcription factors is essential for NGF-mediated 
TRPV1 upregulation (Chu et al., 2011; Xue et al., 2007). Alternatively, binding of 
Runx1 and CEBP/β transcription factors (separately or cooperatively) to nucleotidic 
sequences present in a 480 bp-long promoter, overlapping with the distal 
regulatory element previously described, also induces trpv1 gene expression 
(Ugarte et al., 2013). These studies describe alternative regulatory cascades by 
which TRPV1 expression can be regulated. As mentioned in section 2.7.1, TRPV1 
expression can be modulated through multiple pathways, thus is likely that the 
interplay of additional transcription factors and regulatory elements could maintain 
and modulate TRPV1 expression. 
2.2. TRPV1 STRUCTURE 
The topology of TRPV1 (as all TRP channels) includes three main components:  
1) the intracellular amino (N-) and carboxyl (C-) termini, 2) six transmembrane 
domain helices (TM 1-6) and 3) a pore region (loop) consisting of a pore “turret”, a 
pore helix and an ion selectivity domain ((Bevan et al., 2014; Latorre et al., 2009; 
Liao et al., 2013; Moiseenkova-Bell et al., 2008; Nagy et al., 2014; Salazar et al., 
2009). The TRPV1 channels are known to form tetrameric ion channel complexes 
with other proteins or subunits. Usually TRPV1 is expressed as self-associating 
homotetramers (Kedei et al., 2001), however TRPV1 can also form 
heterotetrameric structures with splice isoforms and other TRP channels like 
TRPA1, TRPV2 and TRPV3 (Nagy et al., 2014; Rutter et al., 2005; Schumacher 






Akin to other TRPV channels, the N-terminus of TRPV1 possesses an ankyrin 
domain of six repeats. This domain is essential for protein-protein interactions and 
channel assembly (Li et al., 2006; Liao et al., 2013; Lishko et al., 2007); for 
instance, calmodulin and ATP binding to specific ankyrin regions leads to Ca2+-
mediated sensitization (Hung et al., 1998; Koplas et al., 1997; Lishko et al., 2007). 
The Src-kinase-dependent phosphorylation of the Y199 ankyrin residue (upon NGF 
stimulation) has been implicated in TRPV1 insertion in the plasma membrane 
(Zhang et al., 2005). Besides the ankyrin repeats, other N-terminal residues 
influence TRPV1 dynamics. For instance, the residue H378 has been implicated in 
the activation of TRPV1 upon intracellular alkalinization (Dhaka et al., 2009). Also, 
as mentioned in section 2.3.3, phosphorylation sites for PKA and de-
phosphorylation sites for calcineurin in the N-terminus are needed for sensitization 
and desensitization, respectively (Bhave et al., 2002; Jeske et al., 2006; Mohapatra 
and Nau, 2005). 
 
One of the most fundamental structural components of the TRPV1 channel is the 
TRP box present in the C-terminus; a hydrophobic amino acid stretch that is 
conserved in TRPV, TRPM and TRPC channel subfamilies (Montell, 2001). The 
TRP domain is crucial for TRPV1 channel homotetramerization (García-Sanz et al., 
2004) and contributes to channel gating by integrating stimuli and downstream 
signals that ultimately lead to the opening of the aqueous channel pore (García-
Sanz et al., 2007). Specifically, residues I696, W697 and R701 define the gating 
energy upon TRPV1 channel activation with capsaicin, heat and voltage (Valente 
et al., 2008). Besides the TRP domain, specific regions of the C-terminus have 
been implicated in TRPV1 affinity for ATP and the gating of the channel in 
response to low pH, heat and voltage; other residues give TRPV1 its specific 
thermal sensitivity (Brauchi et al., 2006; Kwak et al., 2000; Vlachová et al., 2003). 
Phosphorylation at the C-terminus of TRPV1 is mainly mediated by PKC (Bhave et 
al., 2003; Nagy et al., 2014; Numazaki et al., 2002), although phosphorylation by 
PKA has been reported to occur at certain motifs in the C-terminus (Mohapatra and 





terminus but their possible role in either TRPV1 channel sensitization or 
desensitization, remains unclear (Brauchi et al., 2007; Numazaki et al., 2003). 
 
The most fundamental structure of the TRPV1 channel, the pore region, lies 
between TM 5 and 6. The amino acidic composition of the pore loop has a major 
impact in the selectivity and transport of ions through the pore. The pore itself has 
been calculated to be 10.1 Å in diameter (Chung et al., 2008) and residue D646N 
has been hypothesized to form a negatively charged ring that would allow cationic  
permeation through the aqueous pore. Two intracellularly located amino acid 
sequences in the pore domain restrict the passage of ca. 9 Å and ca. 6 Å 
molecules, where residue I679 is at the tightest point (5.3 Å) of the permeation filter 
(Liao et al., 2013). This residue also aids channel gating upon capsaicin and heat 
stimulation (Cao et al., 2013; Salazar et al., 2009). The pore turret partially confers 
thermal activation through a conformational rearrangement that allows gating of the 
channel (Yang et al., 2010). On the extracellular side of the pore region some 
residues show affinity for proton-binding in conditions of low pH (Aneiros et al., 
2011; Jordt et al., 2000). TRPV1 activation by nitric oxide has been less studied 
but it seems that cysteine s-nitrosylation of two proximal pore domains causes 
nitric oxide evoked channel gating (Yoshida et al., 2006). 
 
Another important regulatory domain of the TRPV1 channel is the vanilloid domain 
located within TM 1-4, which is thought to be the most important binding region for 
endogenous and exogenous vanilloids (Nagy et al., 2014). Intracellularly, 
anandamide and capsaicin - that has passed into cells through the plasma 
membrane - bind to the Y511 residue; the vanillyl site of capsaicin specifically 
binds Y511, whereas the hydrophobic portion of capsaicin binds to T550 (Gavva et 
al., 2004; Jordt and Julius, 2002). Resiniferatoxin also specifically binds via its 
vanillyl domain to at least the L547M residue, and via its orthophenyl group to 
Y511 (Gavva et al., 2004; Lee et al., 2011). The vanilloid domain, in part, is also 
responsible for TRPV1 sensitivity to low pH (Jordt and Julius, 2002); together with 





channel activation by protonation into gating (Ryu et al., 2007). Additionally, the 
vanilloid domain bears various phosphorylation sites. For instance, residue S502 
undergoes PKA-dependent phosphorylation to sensitize channels to heat (Rathee 
et al., 2002), whereas phosphorylation by PKC sensitizes TRPV1 channels by 
intensifying capsaicin responses (Numazaki et al., 2002). 
2.3. TRPV1 LIGANDS 
Substantial research over the last two decades has been dedicated to understand 
the molecular mechanism of TRPV1 channel activity and its dynamics upon direct 
interaction with exogenous and endogenous ligands. The tremendous multimodal 
nature of TRPV1 confers a high complexity to the molecular cascades underlying 
activation, blockade, sensitization, desensitization and tachyphylaxis of the 
channel’s activity. 
 
Recently two models have been proposed to explain the multimodal signaling 
integration of the TRPV1 receptor. The first model describes a sequential 
mechanism of channel activation from an “inactive” to a more dynamic state, 
predicting that every stimulation of the channel would shift its sensitivity to voltage 
to a more functional state (Nilius and Voets, 2005). A second allosteric model 
postulates that specific sensors for different stimulants are each independently 
linked to the gating system, thus allowing different stimuli to separately activate 
TRPV1 (Latorre et al., 2007). 
2.3.1. Agonists 
Sensing of thermal and acidic external cues must be indispensable for an organism 
to survive. It is likely that such cellular receptors would be perceptive to a multitude 
of environmental cues. TRPV1 is a promiscuous receptor, binding to a wide variety 





known to be activated by various exogenous stimuli such as heat (>43 °C), noxious 
stimuli, acidic conditions (pH<5.9), natural pungent agents such as trans-8-methyl-
Nvanillyl-6-nonenamide (capsaicin) found in fruits of many Capsicum plants 
(Thresh, 1876), and other plant and animal toxins such as resiniferatoxin (Caterina 
et al., 1997, 2000; Holzer, 1991; Jancsó-Gábor et al., 1970a; Kauer and Gibson, 
2009; Szolcsányi, 1977; Tominaga et al., 1998; Vriens et al., 2008). Interestingly 
the TRPV1 channel is also gated by endogenous agonists both in the PNS and 
CNS. These endogenous activators have been referred to as endovanilloids 
(Bevan et al., 2014; Kauer and Gibson, 2009; Martins et al., 2014; van der Stelt 
and Di Marzo, 2004; Vriens et al., 2009). Arachidonylethanolamide, also known as 
anandamide, was the first endogenous ligand to be discovered to activate TRPV1 
(Tóth et al., 2009; Zygmunt et al., 1999). Although one can refer to anandamide as 
an endovanilloid, it was originally described as an endocannabinoid, since it was 
first discovered to bind to the cannabinoid receptor 1 (Devane et al., 1992). After 
this discovery, the list of “endovanilloids” found to activate TRPV1 especially in the 
PNS has been continuously growing. Endogenous activators include 
endocannabinoids (e.g. NADA), ethanolamides (e.g. anandamide and N-
oleoylethanolamide) oxygenated eicosatetraenoic acids, lypogenase products, 
several endogenous phospholipids (e.g. lysophosphatidic acid), oxidation products, 
prostaglandins, adenosine, ATP, polyamines, protons and inflammatory agents 
(Ahern, 2003; Bevan et al., 2014; Huang et al., 2002; Nieto-Posadas et al., 2012; 
Vriens et al., 2009). Initially TRPV1 sensitivity to voltaic changes was not observed 
(Caterina et al., 1997). Subsequently, another study suggested that the channel’s 
C-T motif could contribute to changes in voltage sensitivity upon plasma 
membrane depolarization (Vlachová et al., 2003). Regulation of TRPV1 due to 
changes in voltage, as during neuronal depolarization, could in principle lead to 
dramatic changes in the activity of the receptor. 
 
Most of the identified TRPV1 activators were discovered in the PNS (where most of 
the research has been developed). In the CNS less is known about the factors that 





molecules that regulate TRPV1 activity in the PNS also control it in the CNS. 12S-, 
15S- and 5S-HPETE, anandamide, 2-arachidonylglicerol (2-AG), N-
oleoylethanolamide, and N-arachidonoyldopamine (NADA) are examples of 
endovanilloids that activate TRPV1 in the PNS and have been found to be 
expressed in the CNS (including the hippocampus); anandamide and NADA are 
more abundant in the CNS than in the PNS (Ahern, 2003; Goswami et al., 2010; 
Huang et al., 2002; Hwang et al., 2000; Martins et al., 2014; Movahed et al., 2005; 
Musella et al., 2010; van der Stelt and Di Marzo, 2004; Zygmunt et al., 1999, 
2013). Interestingly, the endovanilloids mentioned above (also categorized as 
endocannabinoids) are capable of activating both CB1 and TRPV1 suggesting a 
narrow interplay between these two systems thus postulating TRPV1 as a 
polymodal receptor integrating copious amounts of neurosensory information 
(Chávez et al., 2010; Grueter et al., 2010; Marzo, 2010; Marzo and Petrocellis, 
2012).  
 
Many other factors have been found to gate and regulate TRPV1 channel activity 
leading to different changes on the conformational state of the channel some of 
them include bradykinin, NGF, histamine, adenosine, spermine and ATP, which 
are also found in the CNS, thus become feasible candidates to regulate TRPV1 
channel activity in the brain (Kauer and Gibson, 2009; Shu and Mendell, 1999; 
Szallasi et al., 2007).  
2.3.2. Antagonists 
Compared to the immense number of reported TRPV1 agonists, fewer antagonists 
have been discovered. Perhaps the most commonly known and applied TRPV1 
antagonists are ruthenium red and capsazepine (a TRPV1 competitive blocker) 
(Caterina et al., 1997; Gunthorpe et al., 2004; Vriens et al., 2009; Walpole et al., 
1994). Despite their extensive use in traditional pharmacological studies, ruthenium 
red and capsazepine have some disadvantages, compared to recently synthesized 





(Dray et al., 1990; Garcıá-Martıńez et al., 2000) that has been found to inhibit other 
TRP and TRPV channels such as TRPV3 and TRPV4 which are known to interact 
or dimerize with TRPV1 (Brown et al., 2013; Gunthorpe et al., 2004; Hoenderop et 
al., 2001; Nilius et al., 2001; Smith et al., 2002; Vincent and A.J. Duncton, 2011; 
Vriens et al., 2009). Capsazepine, on the other hand, has reduced metabolic 
stability and diverse pharmacokinetic properties in different species (Walker et al., 
2003). Due to the medical relevance of a TRPV1 specific antagonist for treatment 
of pain, in recent years a wide variety of TRPV1-specific antagonist have been 
synthesized and catalogues have been developed to guide research due to the 
heterogeneity of the mechanism of action of different inhibitors on TRPV1 (Szallasi 
et al., 2007; Vriens et al., 2009). In our study we decided to use a small molecule 
discovered to be a potent TRPV1-selective antagonist, called SB-366791, which 
was proven to block the effects of capsaicin on TRPV1 activity and to cause more 
efficient inhibition than capsazepine (Gunthorpe et al., 2004; Varga et al., 2005). 
 
Recently some molecules that are endogenously expressed have also been found 
to block the gating of TRPV1, thus reducing the receptor’s activity. For instance: 
cholesterol enrichment decreases capsaicin and heat evoked-responses in 
TRPV1-transfected HEK293 cells (Picazo-Juárez et al., 2011). Sphingomyelinase 
and resolvins (omega 3 derivates) are two more molecules recently suggested to 
inactivate TRPV1 channels or at least to inhibit TRPV1 activation in sensory 
neurons (Park et al., 2011a; Sántha et al., 2010). Adenosine has also been 
proposed to act as a competitive antagonist of TRPV1, by directly binding to the 
channel leading to a blockade of capsaicin-mediated TRPV1 responses 
(Puntambekar et al., 2004).  
2.3.3. Modulators 
TRPV1 is not only activated or directly regulated by ligands; multiple factors such 
as protein kinases, inflammatory agents, calcineurin, calmodulin and 





and N-termini leading either to sensitization through channel phosphorylation or to 
Ca2+-dependent desensitization, mainly via de-phosphorylation (Bevan et al., 2014; 
Bhave et al., 2002, 2003; Docherty et al., 1996; Kim et al., 2008; Lishko et al., 
2007; Malin et al., 2006; Shu and Mendell, 1999).  
 
Sensitization of TRPV1, which makes the channel more susceptible to its 
activators (e.g. heat and capsaicin), is driven by the binding of protein kinases A 
and C and other inflammatory agents (e.g. bradykinin, NGF and GDNF) directly to 
TRPV1 (Amadesi et al., 2006; Bhave et al., 2003; Malin et al., 2006; Mohapatra 
and Nau, 2003; Shu and Mendell, 1999; Sugiura et al., 2002).  
 
Conversely, TRPV1 is known to be desensitized (have a decreased sensitivity to 
activators) by constant or repetitive channel activation, which causes a 
downregulation in channel activity (Liu and Simon, 1996; Novakova-Tousova et al., 
2007). Desensitization of TRPV1 is most likely achieved by multiple mechanisms, 
either by activation of calcineurin after Ca2+ influx upon TRPV1 channel opening 
(Docherty et al., 1996; Mohapatra and Nau, 2005), phospholipase-C (PLC)-
dependent PI(4,5)P2 hydrolysis (Jeske et al., 2011; Kim et al., 2008) or by a direct 
binding of calmodulin to TRPV1 (Lau et al., 2012; Lishko et al., 2007; Numazaki et 
al., 2003). 
 
In summary TRPV1 channels regulate a multitude of signaling cascades in 
response to various activators and modulators. Still much of the knowledge 
acquired for this receptor has been obtained from studies in the peripheral nervous 
system. Since pH and temperature are mostly at “normal” physiological levels in 
higher neuronal regions (i.e. the brain), the question of the functionality of the 
channel in these areas arises. The precise role of TRPV1 in the CNS and 





2.4. TRPV1 EXPRESSION 
Although TRPV1 expression has been reported in various neuronal and non-
neuronal tissues including the skin (cutaneous sensory nerve fibers, mast cells, 
epidermal keranocytes, dermal blood vessels, differentiated sebocytes and sweat 
glands) pancreas (B-cells), bladder (urothelium, smooth muscle, blood vessels and 
neurons), blood (mononuclear cells and synoviocytes), adipose tissue, vascular 
smooth muscle, arteriolar smooth muscle cells, mesenteric arteries, endothelial 
cells, pulmonary artery smooth muscle, laryngeal epithelium, nasal vascular 
endothelium, epithelials and submucosal glands (reviewed in Fernandes et al., 
2012; Nilius and Owsianik, 2011), TRPV1 expression is best characterized in 
neuronal cell types of the PNS.  
 
TRPV1 was first reported and characterized in the PNS; specifically in the dorsal 
root, vagal and trigeminal ganglia, where it was found to be expressed in small and 
medium-sized afferent Aδ and C-fibers of peptidergic nociceptive neurons, which in 
turn project to innervate nearly all organs and tissues (Bevan et al., 2014; Caterina 
et al., 1997; Holzer, 1991; Jancsó et al., 1977; Tominaga et al., 1998). In the DRG, 
TRPV1 was originally detected in two groups of neurons; one responding to NGF 
and positive for CGRP and substance P, and another expressing the glial derived 
nerve factor (GDNF) (Tominaga et al., 1998). It is well-established that NGF has a 
major role in sustaining the expression of TRPV1 in nociceptors. Under certain 
conditions such as during inflammation, increased expression of NGF upregulates 
the expression of TRPV1 (Bevan and Winter, 1995; Ji et al., 2002) (see section 
2.7.1) 
 
The original study that identified the TRPV1 receptor to be activated by noxious 
heat and capsaicin (see section 2.3.1), failed to detect TRPV1 expression in brain 
and spinal cord (Caterina et al., 1997). However earlier studies had already found 





hypothermia in rats (through TRPV1-dependent desensitization) (Gavva, 2008; 
Jancsó-Gábor et al., 1970a). Later studies confirmed the expression of TRPV1 in 
the hypothalamus and its pivotal role for the maintenance of body temperature 
(Cavanaugh et al., 2011; Gavva, 2008; Roberts et al., 2004; Sharif-Naeini et al., 
2008). Due to the heterogeneity of information regarding the expression of TRPV1 
in the CNS there has been a constant disagreement in the scientific community 
regarding whether TRPV1 functions in the brain. One problem could be that 
TRPV1 has been reported to be expressed in lower levels in the brain (Han et al., 
2012; Sanchez et al., 2001; Szallasi et al., 1995) than in nerves from the PNS, 
which can lead to misinterpretation, depending on technique employed (Kauer and 
Gibson, 2009; Martins et al., 2014). Yet the list of CNS and brain regions where 
TRPV1 expression has been detected has been increasing. Through a wide variety 
of methodologies, TRPV1 has been identified in many areas of the CNS including 
the spinal cord, hypothalamus, thalamic nuclei, amygdala, cerebellum, 
telencephalon (entorhinal cortex, olfactory nuclei as well as in the frontal, piriform, 
parietal and retrosplenial cortices), midbrain (periaqueductal gray, the 
interpeduncular and raphe nuclei, and substantia nigra), hindbrain (superior 
colliculus, locus coeruleus, vagus dorsal motor nucleus and nucleus of the solitary 
tract), septal regions and the hippocampus, where some studies have confirmed a 
broad expression of the channel in the brain (Cavanaugh et al., 2011; Cristino et 
al., 2006a; Han et al., 2012; Mezey et al., 2000; Roberts et al., 2004; Sanchez et 
al., 2001; Sasamura et al., 1998; Tóth et al., 2005). 
 
Most of the studies suggesting the presence of TRPV1 in hippocampal neurons 
have only provided functional evidence of the channel’s activity in synaptic 
plasticity in synaptic transmission by neuropharmacologically modulating TRPV1 
channel activity; only a few studies have addressed the cellular and subcellular 





2.5. TRPV1 IN THE BRAIN: PHYSIOLOGICAL RELEVANCE 
In the PNS, TRPV1 has been extensively studied due to its medical relevance 
treatment of pain and inflammation. In the CNS, TRPV1 has also been found to be 
important in physiological processes such as pain, thermoregulation and synaptic 
plasticity. 
2.5.1. TRPV1 in nociceptive brain circuits 
The involvement of TRPV1 in peripheral nociceptive circuits has long been known. 
Later studies show that TRPV1 is expressed in brain areas known to participate in 
the nociceptive system, such as the periaqueductal gray, locus coeruleus, rostral 
ventromedial medulla, anterior cingulate nucleus, and medial prefrontal cortex 
(Calejesan et al., 2000; Cristino et al., 2006a; Marinelli et al., 2002; McGaraughty 
et al., 2003; Mezey et al., 2000). TRPV1 was found to be expressed in 
glutamatergic neurons in the ventrolateral periaqueductal gray, where activation by 
capsaicin or anandamide causes anti-nociceptive effects by promoting glutamate 
release and binding to postsynaptic metabotropic glutamate receptor 1 (mGluR1) 
at the rostral ventromedial medulla, leading to the activation of “anti-nociceptive 
neurons” and inhibition of “nociceptive” neurons (Maione et al., 2007; Palazzo et 
al., 2002). These effects were blocked by the opioid receptor antagonist naloxone, 
suggesting an interaction of both the opioid and vanilloid mechanisms (Maione et 
al., 2009). Contrary to this anti-nociceptive effect of TRPV1 activation, glutamate 
release to the anterior cingulate cortex upon TRPV1 activation has rather been 
linked to persistent pain induction (Calejesan et al., 2000). More recent studies 
have suggested that TRPV1 might be involved in other brain areas, for example in 
morphological changes of the pre- and anterior limbic areas, where TRPV1 
blockade stopped such changes and the behavioral responses seen after traumatic 





2.5.2. Central thermal regulation 
In the early 1970s the role of TRPV1 (still uncharacterized at that time) in the 
maintenance of body temperature within a physiological range was discovered. In 
these studies rats and guinea pigs were either generally or locally injected in the 
hypothalamic preoptic area with capsaicin, which caused hypothermia (Jancsó-
Gábor et al., 1970a, 1970b). Later studies showed that injection of TRPV1-specific 
inhibitors elicits a rise in body temperature (hyperthermia) in different species, 
including humans (Gavva et al., 2007, 2008). Surprisingly, TRPV1 KO mice do not 
have impaired maintenance of body temperature (Szelényi et al., 2004; Tóth et al., 
2010), but neither TRPV1-specific agonists nor antagonists were able to induce 
hypo- or hyper-thermia, respectively, in knockout mice; fever responses were also 
attenuated in TRPV1 KO mice (Iida et al., 2005; Tóth et al., 2010). Although the 
mechanism of action of TRPV1 in maintenance of body temperature is still not fully 
understood, its role in thermoregulation (in the PNS as well as in the CNS) has 
been established by many studies from various labs. 
2.5.3. Osmosensing 
Magnocellular neurosecretory cells (MNC) of the supraoptic nucleus of the 
hypothalamus are known to participate in osmoregulation of the body, mainly 
through vasopressin (Dreifuss et al., 1971; Sudbury et al., 2010) which is released 
when MNC are activated during hypertonicity, and ultimately causes basal water 
reabsorption (thirst) when it interacts with vasopressin 2 receptors in the kidney. 
On the other hand during hypotonicity MNC activity is inhibited, decreasing 
vasopressin release that subsequently leads to water excretion (Brimble and 
Dyball, 1977). 
 
Recently a TRPV1 splice isoform lacking the N-terminus was discovered to be 





reinforcing the notion of a novel capsaicin-insensitive TRPV1 splice variant with 
unique function in MNC. The depolarization of MNCs during hypertonicity can be 
stopped by the TRPV1 antagonist ruthenium red (TRPV1 antagonist), and the 
MNC of TRPV1 KO mice have no cellular shrinking and have reduced vasopressin 
secretion upon hypertonicity (Naeini et al., 2006; Sharif-Naeini et al., 2008). 
Notably, TRPV1 has been suggested to be in part controlling thirst, since TRPV1 
KO mice show reduced water intake compared to WT animals when confronted 
with hyperosmotic conditions (Ciura and Bourque, 2006). 
2.5.4. Behavior and emotional states 
TRPV1 has been implicated the in various behavioral and emotional states such as 
mood, aggression, social interaction, drug addiction and addictive behavior, and 
depressive-like states such as anxiety and stress (Adamczyk et al., 2012; Ho et al., 
2012; Marinelli et al., 2004; Martins et al., 2014; You et al., 2012). 
2.5.4.1. Anxiety, stress and addiction 
TRPV1 KO mice have reduced anxiety (determined by the elevated plus maze 
test) and fear conditioning (identified by less “freezing behavior”) as well as 
reduced stress sensitization (Marsch et al., 2007). Some studies have linked 
TRPV1 activity with the induction of anxiety-related behavior, since 
intraperitoneally or ventral hippocampal injections with TRPV1 antagonists reduced 
anxiety and treatment with exogenous agonists induced anxiogenic responses 
(Hakimizadeh et al., 2012; Kasckow et al., 2004; Santos et al., 2008). TRPV1 
activation by injection of anandamide in the prefrontal cortex also elicited anxiety-
related responses, whereas anandamide-dependent CB1 activation and TRPV1 







It has been reported that the activity and expression of TRPV1 (sometimes 
together with the cannabinoid system) is altered in some aspects of 
metamphetamine-, nicotine-, ethanol- and cocaine-induced addictive behavior 
(Adamczyk et al., 2012; Grueter et al., 2010; Hayase, 2011; Renteria et al., 2014; 
Tian et al., 2010). TRPV1 KO animals have a preference for the consumption of 
ethanol, higher ethanol intake, less sensitization to sedation and faster recovery 
from ethanol-induced motor incoordination (Blednov and Harris, 2009). In the 
nucleus accumbens TRPV1 activation counteracts the attenuation in LTD induction 
caused by ethanol. TRPV1 is known to influence the neuronal “reward” circuit that 
is involved in addictive behavior and acute stress. This system comprises 
dopaminergic inputs from the ventral tegmental area (VTA) to both the nucleus 
accumbens and the prefrontal cortex (Bonci et al., 2003; Chiara and Imperato, 
1988; Maeda and Mogenson, 1982; Marinelli et al., 2004; Schultz, 1986). Both 
capsaicin application in the VTA, and noxious stimuli, enhance dopaminergic 
secretion onto the nucleus accumbens, which is facilitated by an increase in 
glutamatergic release onto VTA-dopaminergic neurons (Marinelli et al., 2004). 
Recently TRPV1 was suggested to engage in the “indirect” reward circuit that 
induces LTD in medium spiny neurons of the nucleus accumbens (Grueter et al., 
2010). In this study, low frequency stimulation and activation of mGluR1 receptors 
in medium spiny neurons elicited LTD, which subsequently causes a mGluR5-
dependent anandamide production, where anandamide ultimately binds to pre-
synaptic CB1 (decreasing glutamate release) and postsynaptic TRPV1 receptors 
(elevating intracellular Ca2+). Postsynaptic calcium elevation by anandamide leads 
to calcineurin-mediated AMPA receptor endocytosis that together with reduced 
pre-synaptic glutamate release leads to LTD in medium spiny neurons. This form 
of LTD was absent in animals that consumed cocaine 24h prior to the experiment. 
The exact role of TRPV1 in the clinical symptoms of drug addiction has not been 
dissected, but TRPV1 has been hypothesized to reinforce cocaine-seeking 





2.6. TRPV1 IN THE HIPPOCAMPUS: EXPRESSION AND 
ROLE IN SYNAPTIC PLASTICITY 
2.6.1. TRPV1 expression pattern 
Perhaps one of the most discussed issues in the field of research of TRPV1 is how 
the expression and possible function of the channel contributes to modifications in 
synaptic plasticity in the hippocampus (see section 2.6). 
 
As mentioned above, the original study that characterized TRPV1 (and many 
subsequent studies) did not find TRPV1 expression in hippocampus (Benninger et 
al., 2008; Caterina et al., 1997; Köfalvi et al., 2006). However, TRPV1 expression 
at mRNA and protein levels has been detected in the hippocampus using a wide 
variety of techniques including RT-PCR (for mRNA), ELISA, IHC, in situ 
hybridization, electron microscopy, western blot, radioactive resiniferatoxin (TRPV1 
ligand) for detection of protein levels and more recently, using a TRPV1 reporter 
mouse line (Bennion et al., 2011; Cavanaugh et al., 2011; Cristino et al., 2006a, 
2008; Han et al., 2012; Huang et al., 2014; Merrill et al., 2012; Mezey et al., 2000; 
Puente et al., 2014; Roberts et al., 2004; Sanchez et al., 2001; Schumacher et al., 
2000; Tóth et al., 2005). TRPV1 has been detected in the dentate gyrus 
(prominently in the molecular layer), and in pyramidal cell somas of the CA1 and 
CA3 regions of the hippocampus, where it is expressed in ca. 50% of the CA3 
neurons (Cristino et al., 2008; Merrill et al., 2012). Interestingly, TRPV1 was also 
found in some unidentified interneurons of the stratum oriens (Cristino et al., 
2006a, 2008). 
 
Functional assays have found TRPV1 in brain and hippocampus at pre- and post-
synapses of both excitatory and (to a lesser extent) inhibitory synapses, and 
possibly on synaptic vesicles (Cristino et al., 2006a; Goswami et al., 2010; Kauer 





synaptic transmission by boosting excitatory neurotransmitter release in the 
substantia nigra (Marinelli et al., 2003; Starowicz et al., 2007) and hypothalamus 
(Sasamura et al., 1998). On the other hand, in the hippocampus TRPV1 has been 
related to a novel mechanism of LTD; TRPV1 activation in the pre-synapse 
decreased glutamate release (Gibson et al., 2008), whereas post-synaptically, its 
activation caused calcineurin/dynamin-dependent AMPA receptor endocytosis 
(Chávez et al., 2010). Two studies have shown (using electron microscopy) the 
post-synaptic localization of TRPV1 both at excitatory and inhibitory synapses in 
the mouse hippocampal dentate molecular layer (Canduela et al., 2015; Puente et 
al., 2014) and in CA1 pyramidal neurons at inhibitory interneurons of the stratum 
radiatum (Lee et al., 2015). The specificity of the TRPV1 antibodies used in these 
studies, however, was not verified using TRPV1 knockouts. Since most studies to 
date have addressed the pre- or post-synaptic localization through functional 
assays, there is still a lack of proof of TRPV1 expression at pre or post-synaptic 
sites. 
 
The expression of TRPV1 in DRGs during embryogenesis has been reported to 
start at E13 and gradually increase during later embryonic and postnatal stages, 
reaching its peak postnatally at P3, where its expression remains constant at least 
until P56 (Funakoshi et al., 2006; Hjerling-Leffler et al., 2007). In brain and 
hippocampus, the postnatal expression of TRPV1, at both mRNA and protein 
levels, was found in two week old mice and steadily increased, reaching maximum 
levels 8 weeks after birth; interestingly in DRG, brain and hippocampus TRPV1 
expression has been reported to be severely decreased in elderly animals (older 
than 16 weeks) (Huang et al., 2014; Wang et al., 2006). Lack of signal in different 
brain areas (e.g. hypothalamus and motor nuclei) of adult TRPV1-PLAP-LacZ 
reporter mice compared to abundant signal in TRPV1-Cre/Rosa26-LacZ reporter 
mice could reflect a transient expression of TRPV1 during earlier development 
stages, which could greatly exceed that during adulthood (Cavanaugh et al., 2011). 
It has been argued that TRPV1 expression in adult mice is far lower in the brain 





the lowest levels of TRPV1 protein in the CNS (Han et al., 2012; Menigoz and 
Boudes, 2011; Roberts et al., 2004; Sanchez et al., 2001). 
2.6.2. TRPV1 splice isoforms 
Alternative splicing is a fundamental mechanism of eukaryotic cells that plays a 
central role in transcriptome variation allowing proteomic diversity by removing or 
inserting exons of the transcribed mRNA resulting in the translation of isoforms or 
splice variants of the full-length protein. Since isoforms have different amino acid 
sequence and even conformational states, they generally have different function 
than the full-length protein (Black, 2003; Gamazon and Stranger, 2014). At least 5 
different isoforms of TRPV1 have been found in mammals: VR.5’ sv (Schumacher 
et al., 2000), TRPV1β (Wang et al., 2004), TRPV1var (Tian et al., 2006), ∆-N-
TRPV1 (Naeini et al., 2006) and TRPV1-S (Gracheva et al., 2011). VR.5’ sv is the 
most likely splice isoform to be present in the CNS (Sanchez et al., 2001; 
Schumacher et al., 2000). Messenger RNA levels of TRPV1β were present in the 
same amounts as TRPV1 in DRG and brain but the protein for this splice isoform 
was much lower than TRPV1, denoting a possible instability of the protein; 
TRPV1β negatively regulates TRPV1 gating upon capsaicin and low pH (Wang et 
al., 2004). The unique osmosensing nature of the ∆-N-TRPV1 splice isoform 
confirms that transcriptome diversity of a single protein can profoundly change the 
functionality of the spliced variant. The C-terminal TRPV1 splice isoform TRPV1-S, 
which is exclusively found in the trigeminal ganglia of the vampire bat Desmodus 
rotundus is a rare case of alternative splicing of TRPV1 in the animal kingdom. 
TRPV1-S lacks 62 amino acids of the carboxyl terminus, is activated at 30°C and 
strikingly, is proposed to confer the unique ability of vampire bats to sense infrared 







2.6.3. VR.5’ sv 
The first discovered TRPV1 isoform was the 2,768 bp vanilloid receptor 5’ splice 
variant (VR.5’ sv) (Schumacher and Eilers, 2010; Schumacher et al., 2000). The 
identified cDNA lacks the first four exons of the full-length protein and the 60-amino 
acid long seventh exon (Schumacher et al., 2000; Xue et al., 2001). Relative to the 
TRPV1 cDNA sequence the VR5’sv sequence starts at the 588th bp. TRPV1 and 
VR5’ sv cDNA are identical from the bp 681 to the end of the TRPV1 cDNA 
(nucleotide 2,847), except for one VR.5’ sv-specific insertion and one deletion 
(Schumacher et al., 2000). The VR.5’ sv sequence has an extra 575 bp stretch 
(including a polyadenylation signal sequence) but this represents a non-coding 
region (Schumacher et al., 2000). Apart from the extra non-coding VR.5’ sv stretch, 
the VR.5’ sv cDNA sequence has 2 major differences compared to TRPV1. First, 
after the VR.5’ sv nucleotide 246 there is a 100 bp-long divergent VR.5’ sv region 
and second, there is a deletion of TRPV1 nucleotides 1121 to 1301 that 
corresponds to the open reading frame (Schumacher et al., 2000). 
 
The transcriptional start site of the full-length TRPV1 transcript is within exon 2 (not 
present in VR.5’ sv), while the transcriptional start site of VR.5’ sv is within exon 6, 
specifically at Met 308, thus the resulting VR.5’ sv protein would have a shorter N-
terminus lacking almost all of the ankyrin repeats (except for a portion of the third 
one) that are crucial for the interaction with different ligands (Xue et al., 2001). 
Apart from the truncation of the N-terminus, VR.5’ sv is identical to TRPV1 
containing the same transmembrane domains, pore region and C-terminus 






Even though there is compelling evidence that the N-terminus is necessary for the 
insertion of TRPV1 in the plasma membrane upon NGF treatment and Ca2+ influx 
(Hellwig et al., 2005; Zhang et al., 2005), transfected VR.5’ sv has been observed 
to co-localize with TRPV1 inserted in the plasma membrane were it is proposed to 
heteromerize with TRPV1 (Eilers et al., 2007). Unlike TRPV1, monomeric VR.5’ sv 
is not activated by noxious heat or vanilloids such as capsaicin or resiniferatoxin, 
however when TRPV1 and VR.5’ sv are co-transfected in either Xenopus oocytes 
or HEK cells there is a 70% reduction in the response to these stimuli, which 
prompted the notion that VR.5’ sv acts as a dominant negative TRPV1, stabilizing 
the channel in a more closed state (Eilers et al., 2007; Schumacher et al., 2000).  
 
Interestingly, mRNA transcripts of VR.5’ sv were found in the PNS as well as in the 
CNS (Sanchez et al., 2001; Schumacher et al., 2000). In DRGs TRPV1 mRNA 
levels have been found to exceed those of VR.5’ sv by twelve to twenty times, 
however the ratio of mRNA for both transcripts is 1:1 in the brain (Sanchez et al., 
2001; Schumacher et al., 2000) as well as in individual brain regions such as the 
hypothalamus, hippocampus, cerebellum, cerebral cortex, pons and medulla 
oblongata (Schumacher et al., 2000). As stated above the expression of TRPV1 
has been reported to be greater in the PNS compared to the CNS. Interestingly, 
 
Figure 1. Diagram of the putative structure of TRPV1 and VR.5’ sv. When compared VR.5’ sv 
has the complete C-Terminus of TRPV1 but lacks most of the N-Termins. VR.5’ sv has an insert in 






VR.5’ sv mRNA levels are the same in PNS (DRGs) and the brain (Sanchez et al., 
2001; Schumacher et al., 2000). 
2.6.4. TRPV1 and synaptic plasticity 
2.6.4.1. Synaptic plasticity 
With his observations almost one and a half centuries ago, Ramón y Cajal 
proposed a radical way to store information in neural tissue: changes in the 
connections between neurons (Cajal, 1894), later defined as synapses. Two 
different kinds of synapses have been described: electrical and chemical 
synapses. Typically chemical synapses consist of axon-dendrite connections; 
neurotransmitter is released from synaptic vesicles at the axonal pre-synapse and 
binds to receptors in the post-synapse on the dendrite. While synaptic transmission 
is unidirectional (pre- to post- synaptic), retrograde messengers (post- to pre 
synaptic) were later identified that modulate, for instance, presynaptic 
neurotransmitter release (Bailey et al., 2015).  
 
The term synaptic plasticity was first proposed as a theoretical model to explain 
learning and memory (Hebb, 1949), whereby potentiation of the connection 
between two neurons results from the coincident activity of both neurons. The two 
best-characterized forms of synaptic plasticity are long-term potentiation (LTP) and 
long-term depression (LTD) of synaptic strength. Both LTP and LTD are important 
for memory formation. LTP is likely to underlie the formation and/or reactivation of 
memories, whereas LTD has been proposed to deactivate the same “remembered” 
memory attained by LTP (Nabavi et al., 2014). LTP can be induced by high 
frequency stimulation (50-100 Hz) leading to enhanced synaptic transmission. On 
the other hand, LTD is induced by low frequency stimulation (1-5 Hz) and leads to 
a decrease in synaptic transmission. Both types of synaptic plasticity are mediated 





either LTP or LTD in the hippocampus. Recently TRPV1 has been reported to 
mediate LTP and LTD in the hippocampus. 
2.6.4.2. TRPV1: LTP and LTD 
TRPV1 was first reported to influence hippocampal synaptic plasticity following the 
observation that induction of LTP after high frequency stimulation (100Hz/s) was 
reduced in TRPV1 KOs compared to WT (Marsch et al., 2007). In addition, 
capsaicin and resiniferatoxin facilitate the induction (but not the maintenance) of 
LTP induced by high frequency (Li et al., 2008) and theta burst (Bennion et al., 
2011) stimulation, and suppress LTD (induced by 10Hz/s low frequency 
stimulation), and these effects were blocked by the TRPV1 antagonists 
capsazepine and SB366791. Besides facilitating LTP, intrahippocampal capsaicin 
injections also improved spatial memory retrieval in rats subjected to stressful 
conditions (Li et al., 2008).. 
 
These findings support the idea that TRPV1 is expressed in the hippocampus. But 
they did not explain where in the hippocampus TRPV1 is expressed and how it 
affects LTP. One possible mechanism has been identified: it appears likely that 
TRPV1-modulated LTP acts on hippocampal inhibitory interneurons that may affect 
LTP induction. HFS (two trains of 1 sec at 100 Hz with 20 sec interval) and 1µM 
capsaicin caused LTD of interneurons in the stratum radiatum, which was blocked 
by TRPV1 antagonists and did not occur in TRPV1 KOs (Gibson et al., 2008; 
McMahon and Kauer, 1997). According to the findings of Gibson et al., 2008 a 
model was proposed: LTD in inhibitory interneurons is independent of NMDA and 
AMPA receptors but is rather dependent on activation of mGluR1 receptors (and 
subsequent Ca2+ influx) known to be postsynaptically present in these neurons 
(Ferraguti et al., 2004). Postsynaptic mGluR1 activation upon HFS leads to 
synthesis of 12-HPETE by the 12-lipoxygenase enzyme using arachidonic acid as 
a metabolic substrate (Gibson et al., 2008); 12-HPETE was then proposed to 





the release of glutamate from CA1 and/or CA3 pyramidal neurons onto the 
interneuron (detected by alterations in the paired pulse ratio) (Gibson et al., 2008). 
LTD of interneurons of the stratum radiatum upon HFS and/or direct TRPV1 
activation would then decrease the effects of feedforward inhibition from these 
neurons to CA1 pyramidal neurons, thus facilitating LTP, and explaining the 
reduction of LTP in TRPV1 KOs (Kauer and Gibson, 2009).  
 
In fact, the enhanced LTP following TRPV1 activation with 1µM capsaicin or 
resiniferatoxin in the CA1 region of the hippocampus were reverted by GABAA 
receptor blockade with picrotoxin (Bennion et al., 2011). Moreover the decrease in 
LTP observed in TRPV1 KO hippocampal slices was rescued with picrotoxin 
(Brown et al., 2013). Together these studies suggest that TRPV1 modulates LTP 
by reducing fast GABAergic feedforward inhibition from inhibitory interneurons onto 
CA1 pyramidal neurons. 
 
In the dentate gyrus, an important center in the hippocampus that receives 
information from the entorhinal cortex, TRPV1 was found to underlie a form of 
post-synaptic LTD - induced by a 1 Hz paired pulse protocol or 1 µM capsaicin - in 
granule cells innervated by the medial perforant path. This LTD was reverted with 
pretreatment with capsaicin to desensitize TRPV1, or with 10 µM capsazepine 
(Chávez et al., 2010). Furthermore, this form of LTD was absent in acute 
hippocampal slices of TRPV1 KO mice (Chávez et al., 2010) and in slices from 
animals subjected to intrahippocampal injection of TRPV1 knockdown shRNA 
(Chávez et al., 2014). In contrast to the TRPV1-dependent LTP mechanism 
proposed in the CA1 region, in the dentate gyrus, activation of post-synaptic 
mGluR5 receptors by pre-synaptic glutamate release led to synthesis of post-
synaptic anandamide that intracellularly activates TRPV1 inserted either in the 
plasma membrane or in the endoplasmic reticulum, subsequently causing an 
elevation of Ca2+ that ultimately induces calcineurin and dynamin-dependent 
endocytosis of AMPA receptors (Chávez et al., 2010; Marzo, 2010). This form of 





the nucleus accumbens (Grueter et al., 2010), although the induction protocols 
vary;  LTD in the nucleus accumbens was induced by low frequency stimulation, 
while LTD in the dentate gyrus was induced by pre-synaptic burst stimulation of 
neurons from the perforant path together with post-synaptic depolarization (Chávez 
et al., 2010). 
 
TRPV1 activation and inhibition respectively attenuate and increase LTD of 
inhibitory interneurons in the CA1 region of the hippocampus (Bennion et al., 2011; 
Li et al., 2008). Two different effects of capsaicin were observed during LTD 
induction in the CA1 region. Earlier studies showed that 1 mM capsaicin causes a 
decrease in LTD (Li et al., 2008). However, 1 mM capsaicin greatly exceeds the 
more physiological concentration that is sufficient to elicit gating of the channel 
(Gibson et al., 2008), In later studies, using more physiological concentrations of 
capsaicin (1-10 µM) no significant alteration in the induction of LTD was detected 
(Bennion et al., 2011).  
 
A recent study provides evidence that TRPV1 also influences inhibitory synaptic 
plasticity in the dentate gyrus. In this study, TRPV1 activation with 2 µM capsaicin 
and 30 µM anandamide (co-applied with the FAAH synthesis inhibitor URB597) 
depressed somatic but not dendritic inhibitory postsynaptic currents (IPSCs) in 
both the rat and mouse dentate gyrus. Pre-application of 10 µM capsazepine - a 
competitive antagonist of capsaicin -, TRPV1 knockdown, and TRPV1 knockout, 
blocked this depression (Chávez et al., 2014). This TRPV1-mediated depression of 
inhibitory synaptic plasticity was proposed to occurred post-synaptically, via 
Ca2+/calcineurin-dependent internalization of GABA receptors (Chávez et al., 
2014), similar to the mechanism described for TRPV1-mediated post-synaptic LTD 
in the dentate gyrus, which was proposed to occur through AMPA receptor 
endocytosis (Chávez et al., 2010). 
 
Even though recent discouraging studies have denied the presence of TRPV1 in 





player in modulating and/or mediating synaptic plasticity in the hippocampus, 
compelling new studies continue to confirm TRPV1 as a novel participant in 
synaptic plasticity in the hippocampus, opening the field to the possibility that not 
just TRPV1 but other TRP channels might account for finely tuning different forms 
of synaptic plasticity in multiple regions, subregions and neuronal populations. 
2.7. TRPV1 AND NEUROTROPHINS 
Neurotrophins can be defined as proteins that promote neuronal cell survival and 
differentiation. Yet, mounting evidence shows that neurotrophins are not limited to 
these actions but they are also involved in modulating synaptic plasticity and other 
physiologically relevant mechanisms such as pain processing and transduction, 
acting directly or indirectly on TRPV1 channels (Lewin and Nykjaer, 2014; Park 
and Poo, 2013).  
 
Four types of neurotrophins have been characterized; the first one to be 
discovered was NGF (Levi-Montalcini and Hamburger, 1951), followed by BDNF 
(Barde et al., 1982) and finally neurotrophin 3 (NT3) and 4 (NT4) (Lewin and 
Barde, 1996; Park and Poo, 2013). All neurotrophins bind to the transmembrane 
receptor p75 and individually each neurotrophin binds to its specific 
transmembrane tropomyosin receptor; NGF binds to TrkA, BDNF and NT4 bind to 
TrkB and NT3 binds to TrkC (Chao, 2003; Lewin and Nykjaer, 2014; Park and Poo, 
2013).  
 
For each neurotrophin both the immature (pro) and mature forms exist. Although it 
was traditionally thought that pro-neurotrophins were only an uncleaved precursor 
of mature neurotrophins, increasing evidence suggests that pro-neurotrophins, 
actively participate in different biological functions in addition to their mature 
counterparts (Lee et al., 2001; Teng et al., 2010). Most of the literature suggests 





receptor complex and not the tropomyosin kinase receptors (Boutilier et al., 2008). 
Still it is unknown if certain conditions allow the activation of Trk receptors by pro-
neurotrophins (Nykjaer et al., 2004) 
 
Neurotrophins and their receptors are expressed in a cell-specific manner cell; 
depending on their localization they can exert different physiological functions. 
Neurotrophins are necessary for the normal development and function of neuronal 
networks. They promote neuronal differentiation and proliferation, including the 
specification of neuronal diversity; they are also involved in axonal and dendritic 
growth as well as in synaptogenesis and activity-dependent synaptic plasticity 
(Lewin, 1996; Lu et al., 2005; Park and Poo, 2013). Of all neurotrophins, NGF and 
BDNF have been most studied. Here I will focus on these two neurotrophins and 
the interactions of their mature forms with TRPV1 and TRPV1-related 
mechanisms.  
2.7.1. NGF as a regulator of TRPV1 
2.7.1.1. NGF and TRPV1 expression: sensory neurons and 
hippocampus  
NGF is an integral component of nociception and neuropathic pain. It also is a 
crucial factor during inflammation and post-inflammatory symptoms like 
hyperalgesia (increased sensitivity to pain) (Lewin and Mendell, 1994; Lewin and 
Nykjaer, 2014). During early development NGF is an essential trophic factor for 
neuronal survival and differentiation (Cohen et al., 1954; Levi-Montalcini and 
Hamburger, 1951). During adulthood neurons stop depending on NGF for survival 
but neurons continue to express the TrkA receptor (for example in small-sized 
primary afferent δ and C neurons in the DRG, which are also positive for TRPV1). 
Upon tissue and nerve injury (and subsequent inflammation) NGF is increased de 
novo in keranocytes and mast cells from where it is rapidly released into the 





nociceptors thus serving as a molecular messenger that ultimately elicits pain and 
hyperalgesia (Woolf and Costigan, 1999).  
 
The undeniable requirement of NGF in pain perception and thermal hyperalgesia 
has long been recognized, but how NGF signaling is transduced into increased 
pain is still not completely understood. During thermal hyperalgesia, sensitization 
of nociceptors (i.e TRPV1) by NGF has been proposed to happen in two ways. As 
NGF increases it binds to the high-affinity TrKA receptor, which activates PKC and 
PIP3, which are considered to be the most likely candidates for sensitization of 
sensory neurons to pain (Lewin and Nykjaer, 2014). PKC is thought to directly 
sensitize TRPV1 through phosphorylation, thus leading (for example) to an 
increased neuronal response upon capsaicin stimulation (Numazaki et al., 2003). 
On the other hand PIP3 activation also activates Src kinase that in turn 
phosphorylates intracellularly located TRPV1 channels leading to their 
translocation to the plasma membrane (Zhang et al., 2005). 
 
Although PIP3 increases the insertion of TRPV1 channels into the plasma 
membrane without affecting TRPV1 expression, other studies have reported 
increased expression of TRPV1 at both mRNA and protein levels (Anand et al., 
2006; Winston et al., 2001). Upregulation of TRPV1 expression has been detected 
during nerve injury (Hudson et al., 2001) hyperalgesia (Davis et al., 2000; Miranda 
et al., 2007) and inflammatory pain (Ji et al., 2002; Luo et al., 2004; Schicho et al., 
2004; Schwartz et al., 2013). In the case of inflammatory pain, NGF is as an 
important factor that mediates the upregulation of TRPV1 expression (Anand et al., 
2006; Ji et al., 2002; Winston et al., 2001).  
 
Information regarding the regulation of TRPV1 expression in the CNS, especially in 
the hippocampus is scarce and information about a possible mechanism causing 
an increase in TRPV1 expression is to my knowledge absent. Only a few studies 
have pointed out that TRPV1 expression is increased in patients with mesial 





temporal lobe epilepsy (Bhaskaran and Smith, 2010). A more recent study found 
that mRNA levels of TRPV1 (together with receptors of the endocannabinoid 
system) were increased in brain and hippocampus of adult rats subjected to stress 
in early life (Marco et al., 2014). 
 
NGF is expressed in brain and hippocampus (Gall and Isackson, 1989; Korsching 
et al., 1985). In the hippocampus NGF expression has been observed in inhibitory 
neurons expressing TRPV1 in the human hippocampus (Sun et al., 2012), and in a 
subset of inhibitory interneurons in multiple regions including neurons in the 
stratum oriens (SO) (Bizon et al., 1999; Pascual et al., 1998) that receive axonal 
projections from cholinergic septohippocampal neurons (Rocamora et al., 1996); 
these NGF expressing neurons in the SO correspond to high-expressing TRPV1-
OLM neurons. Thus it is likely that NGF could drive TRPV1 expression in OLM 
neurons, since it is known that neurons expressing TRPV1 in DRGs, in addition to 
a wide variety of nociceptive modulators, co-express TrKA (Ernsberger, 2009), 
which is necessary for proper maintenance of TRPV1 expression levels in 
nociceptors (upon its binding to NGF) (Luo et al., 2007). 
2.7.2. BDNF 
Evidence of BDNF affecting TRPV1 activity and/ or expression levels or vice versa 
is scarce, compared to the information regarding NGF driven TRPV1 expression 
and sensitization. However one can hypothesize that an interaction between BDNF 
and TRPV1 is likely, considering that in DRGs BDNF is expressed in a population 
of small- to medium-sized sensory neurons (Barakat-Walter, 1996; Merighi et al., 
2008; Obata and Noguchi, 2006; Wetmore and Olson, 1995) including a population 
of TRPV1-positive cells (Xia et al., 2012) and TrkA-expressing neurons (Apfel et 
al., 1996; Michael et al., 1997). BDNF has been associated with neuro-
inflammatory pain (Xia et al., 2012; Zhao et al., 2006), hyperalgesia (Groth and 
Aanonsen, 2002), neuropathic pain (Fukuoka et al., 2001; Khan and Smith, 2015; 





neurons from the DRG, NGF – in addition to driving TRPV1 expression - can also 
regulate expression of BDNF (Apfel et al., 1996; Merighi et al., 2008; Michael et al., 
1997). Similar to TRPV1, BDNF is also upregulated during inflammation (Cho et 
al., 1997a, 1997b), axotomy (Michael et al., 1997; Tonra et al., 1998), hyperalgesia 
(Yajima et al., 2002) and neuroinflammatory pain (Xia et al., 2012). In neuronal 
pain models, BDNF is known for its pronociceptive properties (reviewed in Khan 
and Smith, 2015) possibly by decreasing desensitization of TRPV1 channels 
(Ciobanu et al., 2009; Obata and Noguchi, 2006); activation of TRPV1 on the other 
hand has been reported to cause an increase in BDNF release (Lever et al., 2001). 
Although one study suggested that BDNF increases TRPV1 expression in DRG 
cells (Ciobanu et al., 2009), whether BDNF could potentially control TRPV1 
expression remains uncertain (Price et al., 2005).  
 
In the mammalian brain BDNF as well as NGF expression is regulated by neuronal 
activity (Park and Poo, 2013; Zafra et al., 1990). For instance BDNF expression 
upon depolarization is in part achieved through the activation of Ca2+-dependent 
transcription factors such as the cAMP response element-binding protein (CREB) 
that binds to corresponding regulatory elements upstream of the bdnf gene 
sequence (Tao et al., 1998, 2002).  
 
BDNF promotes neuronal differentiation (rather than survival) of neural stem cells 
in brain and hippocampus, including the differentiation of inhibitory interneurons 
(Ahmed et al., 1995; Jones et al., 1994). BDNF also promotes the formation of 
neurites into axons during axon-dendrite differentiation (Shelly et al., 2007). In 
addition, BDNF stimulates synaptogenesis of both excitatory and inhibitory 
synapses in hippocampal neurons (Vicario-Abejón et al., 1998). Interestingly BDNF 
also aids to the maturation of excitatory and inhibitory synapses, since both a 
depolarization-induced release of endogenous BDNF, as well as exogenous BDNF 
application turn non-functional contacts between hippocampal neurons into 






In mature developmental stages BDNF differentially regulates excitatory and 
inhibitory synaptic efficiency by facilitating glutamatergic and depressing 
GABAergic synaptic transmission by modifying either pre- or postsynaptic strength 
(Bolton et al., 2000; Boulanger and Poo, 1999; Levine et al., 1995). BDNF is 
essential for LTP in the hippocampus; BDNF KO animals have an impairment in 
LTP induction that can be rescued with exogenous application of recombinant 
BDNF (Korte et al., 1995; Kovalchuk et al., 2002; Patterson et al., 1996). 
 
There is increasing evidence that neuronal activity has a pivotal role in synaptic 
transmission that can ultimately lead to changes in the number and strength of 
synapses (Bliss and Collingridge, 1993; Linden, 1994; Malenka and Nicoll, 1999). 
Neuronal activity also promotes BDNF expression and secretion (Patterson et al., 
1992; Zafra et al., 1990) especially at synapses where it contributes to an 
enhancement in synaptic transmission (Bonhoeffer, 1996; Katz and Shatz, 1996; 
Thoenen, 1995); in excitatory synapses BDNF release can also occur from the 
post- to the pre-synaptic part, thus serving as a retrograde messenger modulating 
pre-synaptic neurotransmitter release.(Hartmann, 2001; Matsuda et al., 2009).  
 
Although the literature of BDNF and its actions during the elevation of neuronal 
activity in synaptic plasticity and plasticity is extensive, there is currently no 
evidence for a link between BDNF and TRPV1 expression in the hippocampus. 
2.8. ORIENS LACUNOSUM MOLECULARE (OLM) 
INTERNEURONS 
OLM interneurons are a subclass of interneurons located in the CA1 and CA3 
region of the stratum oriens, close to the border with the alveolus; they were 
described already by Ramón y Cajal as neurons with big somatas with axons 





2014). They have horizontal dendrites projecting through the stratium oriens but 
also to further areas of the CA1 region (Freund and Buzsáki, 1996).  
 
OLM neurons seem to be a typical feedback inhibitory interneuron, predominantly 
receiving inputs from pyramidal neurons of the CA1 region (with few synapses from 
the CA3) (Sun et al., 2014) (Figure 2). Furthermore as they also receive cholinergic 
input from the medial septum and diagonal band of Broca. OLM neurons express 
both nAChr2 and nAChr7, thus making them sensitive to nicotine and acetylcholine 
(Leão et al., 2012) (Figure 2). The inhibitory input of OLM neurons has not been 
fully described, however it has been noted that they receive inhibition from other 
OLM neurons and bistratified neurons (Acsády et al., 1996; Ferraguti et al., 2004; 
 
 
Figure 2. Diagram of a CA1 microcircuit involving OLM neurons. OLM neurons (purple) located 
in the stratum oriens (s.o.) receive glutamatergic input from pyramidal neurons (PC; grey) and 
cholinergic input coming from septal regions (dark green). OLM neurons send inhibitory projections 
to putative bistratified (BiC; blue) interneurons in the stratum radiatum (s.r.) and to distal dendrites 






Kogo et al., 2004; Leão et al., 2012). OLM interneurons mostly inhibit distal 
dendrites of CA1 pyramidal neurons in the stratum lacunosum moleculare but in 
less proportion they also contact basal dendrites located in the stratum oriens 
(Freund and Buzsáki, 1996; Sik et al., 1995). Although most of the projections of 
OLM neurons are sent to pyramidal neurons, they also contact inhibitory 
interneurons, including feedforward inhibitory (presumably bistratified) interneurons 
in the stratum radiatum (Bezaire and Soltesz, 2013; Katona et al., 1999; Leão et 
al., 2012) (Figure 2).  
 
OLM neurons are thought to be a key player in the generation of theta oscillations 
(4-12 Hz), and appear to create cross frequency coupling (from slow theta to fast 
spiking gamma frequency) and to gate LTP (Gloveli et al., 2005; Müller and Remy, 
2014; Rotstein et al., 2005; Tort et al., 2007; Wulff et al., 2009). Specifically, OLM 
neurons control the information flow into pyramidal neurons of the CA1 from the 
entorhinal cortex and from the Schaffer collateral by directly inhibiting distal 
dendrites of CA1 neurons in the temporoammonic pathway from the entorhinal 
cortex, and disinhibiting the Schaffer collateral pathway via connections to other 
interneurons (Leão et al., 2012). Recently OLM neurons have been found to be 
recruited and activated during sharp wave ripple events of large amplitude and low 
frequency that simultaneously occur with reactivation of place cells correlated with 
high frequency ripple oscillations (Buzsáki et al., 1992; O’Neill et al., 2008; 














3. MATERIALS AND METHODS 
3.1. EXPERIMENTAL ANIMALS 
Lab rats used for experimentation were obtained from the UMG animal facility. All 
mice lines used for this research were bred and housed at the animal facility of the 
European Neuroscience Institute (ENI) Göttingen. Use of animals for 
experimentation was approved and performed following specifications of the 
Institutional Animal Care and Ethics Committees of Göttingen University (T10.31), 
and of the German animal welfare laws. 
3.1.1. Mouse lines 
TRPV1 -/- (TRPV1 KO) (Caterina et al., 2000) from B6/J strain. Purchased from 
Jackson Laboratory®. 
 
TRPV1tm1(cre)Bbm (TRPV1-Cre) (Cavanaugh et al., 2011) from B6/J strain. 
Purchased from Jackson Laboratory®. 
 
GT(Rosa)26Sortm14(CAG-tdTomato)Hze (Rosa26-tomato) (Madisen et al., 2010a) from 
B6/J strain. Provided by Jochen Staiger at the Department of Neuroanatomy of the 
UMG. 
 
TRPV1tm1(cre)Bbm X GT(Rosa)26Sortm14(CAG-tdTomato)Hze. These strains were interbred 
at the animal facility of the ENI Göttingen. We refer to the resulting mouse strain as 
the TRPV1-tdTomato mouse strain.  
 





Tips of tails were clipped from P21 or anesthetized mice (prior to perfusion fixation; 
see section 3.5.5.1). Tails were lysed with 500 µl lysis buffer (100 mM Tris-HCl (pH 
8.5), 5 mM EDTA (pH 8.0), 0.2 % [w/v] SDS and 200 mM NaCl) mixed with 7 µl 
proteinase K (10 mg/ml) overnight at 55 °C with agitation. Digested tails were then 
centrifuged at max speed with the Eppendorf centrifuge 5424 for 10 min at RT. 
Supernatant was precipitated with 500 µl isopropanol, mixed and centrifuged at 
max speed for 10 min. Precipitated DNA-pellet was washed with 70 % [v/v] ethanol 
by centrifuging for 10 min at max speed. Ethanol was discarded and the DNA-
pellet was allowed to dry. Pellet was re-suspended in 100 µl ddH2O. Specific DNA 
sequences were amplified using the polymerase chain reaction (PCR) (Mullis et al., 
1986; Saiki et al., 1988) using an Eppendorf MasterCycler EP Gradient S PCR 
machine (Eppendorf).  
 
Reaction mix used for qualitative PCR: 
2 µl   genomic DNA 
5 µl   10X DreamTaq Buffer (Thermo Fisher Scientific) 
1 µl   Forward primer (10 µM) 
1 µl   Reverse primer (10 µM) 
0.4 µl   dNTPs 
1.25 µl  Taq polymerase (Thermo Fisher Scientific) 
Reconstituted with ddH2O to a final volume of 50 µl 
 
25 µl of each PCR reaction was loaded in independent wells of a solid agarose gel 
(1 % [w/v] ultrapure agarose (Invitrogen) diluted in 1X TAE buffer) mixed with a 
1:1000 ratio of Roti-safe fluorescent gel stain (Carl Roth) for visualization. For 
estimating the size of amplified DNA fragments a GeneRuler marker (Thermo 
Fisher) was loaded in separate wells. Subsequently, standard nucleic acid 
electrophoresis was conducted under constant voltage using a Bio-rad power 
supply. Amplified DNA fragments were visualized using a UV lamp on the Gel iX20 




Imager (iNTAS). Amplicons obtained from DNA isolated from mutant mouse lines 
were always compared to the B6/J line (WT). 
3.1.2.1. PCR protocols and primers for genotyping 
Sequences of all primers for genotyping every mouse line used (see section 3.1.1), 
as well as the PCR cycling protocol for each primer pair were obtained from the 
JAX® Mice genotyping resource (The Jackson Laboratory). All primers (indicated 
below) were synthesized by and purchased from Sigma-Aldrich®. Primer pairs 
detecting WT and mutant genotypes were tested in both B6/J (WT) and mutant 
mouse DNA samples. 
 
Primers used for genotyping the TRPV1 KO line: 
WT Forward:   5’-cctgctcaacatgctcat-3’ 
Mutant Forward:  5’-tcctcatgcacttcaggaaa-3’ 
Common Reverse:  5’-tggatgtggattgtgtgcgag-3’ 
 
PCR protocol: 
94°C  3 min 
94°C  30 sec 
65°C  1 min  X 35 
72°C  1 min 
72°C  2 min 
4°C  hold 
 
Mutant = 450 bp 
Heterozygous = 450 and 984 bp 








Primers used for genotyping the TRPV1 Cre line: 
WT Forward:   5’-ttcagggagaaactggaagaa-3’ 
WT Reverse:  5’-tagtcccagccatccaaaag-3’ 
Mutant Forward:  5’-gcggtctggcagtaaaaactatc-3’ 
Mutant Reverse  5’-gtgaaacagcattgctgtcactt-3’ 
 
PCR protocol: 
94°C  2 min 
94°C  20 sec 
65°C  15 sec X 10 
68°C  10 sec 
94°C  15 sec 
50°C  15 sec X 28 
72°C  10 sec 
72°C  2 min 
4°C  hold 
 
Mutant = 102 bp 
Heterozygous = 102 and 490 bp 
WT = 490 bp 
 
Primers used for genotyping the Rosa26-tomato line: 
WT Forward:   5’-aagggagctgcagtggagta-3’ 
WT Reverse:  5’-ccgaaaatctgtgggaagtc-3’ 
Mutant Forward:  5’-ctgttcctgtacggcatgg-3’ 











94°C  2 min 
94°C  20 sec 
65°C  15 sec X 10 
68°C  10 sec 
94°C  15 sec 
60°C  15 sec X 28 
72°C  10 sec 
72°C  2 min 
4°C  hold 
 
Mutant = 196 bp 
Heterozygous = 297 and 196 bp 
WT = 297 bp 
3.2. PLASMIDS: DESIGN AND ISOLATION 
In initial experiments (Figure 16 A, Figure 17 A and Figure 24) we used TRPV1-
IRES-EGFP (provided by Gero Miesenboeck) compared to EGFP to test the 
effects of TRPV1 expression on synapse formation and function.  In subsequent 
experiments, we generated new plasmids to compare the effects of TRPV1 and 
VR.5’ sv, and their co-expression, under the same promoter, using the P2A site for 
efficient co-expression of fluorescent reporter proteins. Plasmid sequences were 
designed using the open source software “A plasmid editor” v2.0.47 (Copyright 
2003-2009 by M. Wayne Davis) (ApE©). The chicken β-actin promoter (Jun-ichi et 
al., 1989) was used to drive vector expression of TRPV1 and VR.5’ sv proteins. 
Because co-expression of a fluorescent reporter gene was necessary to identify 
expressing cells, we co-expressed EGFP (with TRPV1) or RFP (with VR.5’ sv) 
using the P2A multicistronic element (Kim et al., 2011) under the control of the 
same promoter, i.e. TRPV1-P2A-EGFP or VR.5’ sv-P2A-RFP. This results in 




intracellular cleavage at the P2A site and subsequent co-expression (at equal 
ratios) of untagged TRPV1 and cytosolic EGFP, or of untagged VR.5’ sv and 
cytosolic RFP. The β-actin promoter-driven TRPV1-P2A-EGFP and VR.5’ sv-P2A-
RFP plasmids were sub-cloned by GenScript (Piscataway, NJ, USA). 
 
For plasmid DNA isolation, electro-competent Escherichia coli bacteria were 
transformed with TRPV1, VR.5’ sv, RFP or EGFP DNA constructs by 
electroporation. After transformation the bacteria were plated on polystyrene petri 
dishes (CytoOne) containing solidified LB-Agar consisting of 0.5% [w/v] yeast 
extract, 1% [w/v] Tryptone (pH 7.0), 1% [w/v] NaCl and 1.5% [w/v] agar (Carl 
Roth). Transformed bacteria were allowed to grow overnight at 37°C. Individual 
bacterial colonies were picked with a pipette tip and placed into 100 ml LB medium 
including 50 µg/ml ampicillin (Carl Roth) for selection of bacteria with the plasmids 
above (which are ampicillin resistant) and cultured overnight at 37°C with shaking 
at 300 rpm until an OD600 of 2 to 3 was achieved. 100 ml of liquid LB medium 
containing bacterial cultures was used for plasmid DNA extraction with the 
NucleoBond Plasmid PC 500 maxi-prep kit (Macherey & Nagel).  
 
Following plasmid DNA isolation, double stranded DNA concentration was 
estimated using a spectrophotometer (NanoDrop ND-1000) with ND-1000 v3.5.2 
software (peQLabBiotechnologie) to determine the amount of DNA to use in 
transfections. 
3.3. CELL CULTURE METHODS 
3.3.1. Dissociated rat hippocampal neuron preparation 
E18 pregnant Wistar rats (UMG animal facility) were euthanized with CO2, the 
abdomen was opened and embryos were removed from the uterus. Embryos were 
collected from the amniotic sac; heads were cut off and placed in a 10 cm petri 




dish containing cold dissection media (HBSS (Gibco) + 10 mM Hepes (Gibco)). 
Brains were removed from the skull and collected in fresh dissection media. 
Hippocampi were separated from the brain and meninges were removed. 
Hippocampi were digested with 2 ml prewarmed 37ºC 0.05% [w/v] trypsin-EDTA 
(Gibco) for 20 minutes at 37ºC. Trypsin was removed and the tissue was washed 
three times with 4ºC dissection media. Dissection media was replaced with 1 ml 
pre-warmed NB+ (Neurobasal (Gibco) with 1X B-27 supplement (Gibco), 1X 
Glutamax (Gibco) and Penicillin (5000 U/ml)/Streptomycin (5000 µg/ml, Gibco)) 
and tissue was triturated by gentle pipetting. The tissue suspension was filtered 
with 100 µm cell strainer (BD Biosciences). 10 µl of cell suspension was mixed with 
an equal volume of trypan blue, the number of living cells were counted using a 
hemacytometer (excluding blue cells) and the final concentration of neurons was 
calculated. Cells were cultured on 12 mm glass coverslips (Thermo Scientific) 
coated with poly-D-lysine (PDL, Sigma) dissolved in 0.1 M borate buffer, in 24-well 
plates (CytoOne) at a density of 80,000 hippocampal neurons per cm2 and cultured 
in NB+ culture media in a Hera Cell 240i cell culture Incubator (Thermo Scientific) 
at 37°C and 5% [w/v] CO2. 
3.3.2. Dissociated mouse hippocampal neuron preparation 
Neonate P0 B6/J mice litters were used for hippocampal neuronal preparation. 
Each pup was decapitated, and the head was placed on a petri dish and sprayed 
with 70% [v/v] ethanol. The skin of the scalp was separated, skull was opened, the 
brain was removed and placed in a petri dish containing 4°C dissection media. 
Every decapitation and brain dissection was done successively for each pup. 
Hippocampal dissection from the brain was performed similar to the protocol for rat 
embryonic hippocampal dissection with only few modifications. Instead of trypsin-
EDTA, filtered papain-based enzymatic solution (11.39 mM L-Cysteine, 50 mM Na-
EDTA (pH=8), 100 mM CaCl2, 1 N NaOH, 100 µl papain (Worthington) (added to 
the solution 15 min before use) and 10 mg/ml of DNAseI added just before 
digestion) at 37°C was used for tissue digestion (for 30 min at 37°C). Following the 




incubation the enzymatic solution was removed and replaced by an inactivation 
solution (BSA, 5% serum medium and 10 mg/ml of DNAseI) to inactivate 
enzymatic components; the inactivation was achieved at 37°C for 15 min. 
Subsequently the tissue was triturated as mentioned before, with a minor 
adjustment: the tissue suspension was centrifuged in an Eppendorf 5810-12 
centrifuge (Eppendorf) at 500 g, the supernatant was discarded and replaced with 
fresh NB+, and the tissue pellet was re-homogenized before plating. The counting 
and plating procedure was identical to that for rat embryonic hippocampal neuron 
preparation. Neurons were plated at a density of 120,000 cells/cm2. 
3.3.3. Human embryonic kidney 293 (HEK) cell culture 
preparation 
Frozen (-80°C) HEK cells were thawed quickly at 37°C. After thawing, the cell 
suspension was re-homogenized in 10 ml HEK cell medium (DMEM (Gibco), 10% 
[v/v] FBS, 2% [v/v] Penicillin/Streptomycin). Suspended cells were centrifuged in 
an Eppendorf 5810-12 centrifuge (Eppendorf) at 4000 RPM for 3 min at RT. The 
supernatant was discarded and the cell pellet was re-suspended in 10 ml 37°C 
HEK cell medium and plated in a 10-cm tissue culture dish (Cellstar). Confluency 
was checked after 1-3 days in vitro; cells were normally split when cell confluency 
was approximately 50-60%. 
 
For splitting, culture medium was removed, cultures were washed once with sterile 
DPBS (Sigma-Aldrich) followed by trypsinization: 1 ml 0.25% Trypsin-EDTA at 
37°C was added to the cultures and incubated for 2-3 min at 37°C. Cultures were 
then washed off of the plate with a pipette and collected in 10 ml HEK cell medium. 
Cell suspension was centrifuged in an Eppendorf 5810-12 centrifuge (Eppendorf) 
at 4000 RPM for 3 min at RT. The supernatant was removed and the cell pellet 
was re-suspended in 10 ml HEK cell medium (37°C). 250 µl of the suspension was 
diluted in 9.75 ml HEK cell medium and plated in a new 10 cm tissue culture dish. 




HEK cell cultures were allow to grow in a Hera Cell 240i cell culture incubator 
(Thermo Scientific) at 37°C and 5% [w/v] CO2. 
 
HEK cell cultures were transfected 1-2 days after plating following a protocol 
similar to the one used for transfecting hippocampal neurons (explained in section 
3.4 ) with minor changes (i.e. HEK cell culture medium was used instead of NB or 
NB+). 
3.4. HETEROLOGOUS OVEREXPRESSION OF THE FULL 
LENGTH TRPV1 CHANNEL AND VR5 SPLICE ISOFORM. 
3.4.1. Transfection of dissociated rat hippocampal neurons  
In order to achieve single neuron heterologous expression of different plasmids 
(mentioned in 3.2), lipofectamine based transfections were performed in rat or 
mouse hippocampal neurons cultured in vitro (as previously mentioned). 
Transfections were conducted either at DIV 2 or DIV 10 (depending on the 
experiment). 
 
Single plasmid transfections were carried out with 0.75 µg/well of plasmid DNA (for 
co-transfections, 0.35 µg/well of DNA was used for each construct) and 1 µl/well of 
the cationic lipid-based transfection reagent lipofectamine 2000 (Invitrogen). These 
volumes of lipofectamine 2000 and of plasmid DNA were each diluted in 50 µl/well 
of 4°C Neurobasal in separate tubes and incubated for 5 min at RT. Subsequently, 
both dilutions were mixed together and incubated at RT for 20 min. During this 
incubation time, the culture medium from each well to be transfected was 
exchanged with 400 µl of new prewarmed NB+ at 37°C; the original culture 
medium was not discarded but stored in the cell culture incubator at 37ºC and 5% 
[w/v] CO2. After incubation, 100 µl of the lipofectamine-DNA mix was then added to 
each well for a final volume of 500 µl/well. Cultures were incubated for 2 hr at 37ºC 




and 5% [w/v] CO2 with the transfection medium. Afterwards, the transfection 
medium was removed, and wells were washed once with 500 µl NB at 37ºC and 
450 µl of the original culture medium at 37ºC was added back to the wells. 
Identification of reporter gene expression was normally detected 2 days after 
transfection. 
3.5. IMMUNOSTAINING METHODS 
3.5.1. Primary antibodies 
Table 1 details all primary antibodies used for immunostaining and western blots 
during this project. 
 
Table 1. List of primary antibodies. 































1:4000 ICC/IHC Millipore 
MAP2 Mouse 1:4000 ICC Millipore 




3.5.2. Secondary antibodies 
Table 2 indicates all secondary antibodies used in all immunostaining and western 




























1:2000 ICC/IHC Bachem 


















1:1000 ICC/IHC Millipore 




Table 2. List of secondary antibodies. 
3.5.3. Synaptotagmin 1 luminal domain antibody uptake  
Synaptotagmin 1 luminal domain antibody uptake (syt1u) is a method used to 
visually identify synaptic vesicle recycling, allowing us to estimate presynaptic 







α-guinea pig HRP Goat 1:10000 WB Biorad 
α-mouse HRP Goat 1:10000 WB Biorad 
α-rabbit HRP Goat 1:10000 WB Biorad 
α-chick Alexa 405 Goat 1:1000 ICC/IHC Abcam 
α-rabbit Alexa 405 Goat 1:1000 ICC/IHC Abcam 
α-chick Alexa 488 Goat 1:1000 ICC/IHC Invitrogen 
α-guinea pig Alexa 488 Goat 1:1000 ICC/IHC Invitrogen 
α-mouse Alexa 488 Donkey 1:1000 ICC/IHC Invitrogen 
α-rabbit Alexa 488 Goat 1:1000 ICC/IHC Invitrogen 
α-guinea pig Alexa 546 Goat 1:1000 ICC/IHC Invitrogen 
α-mouse Alexa 546 Donkey 1:1000 ICC/IHC Invitrogen 
α-rabbit Alexa 546 Goat 1:1000 ICC/IHC Invitrogen 
α-sheep Alexa 546 Donkey 1:1000 ICC/IHC Invitrogen 
α-guinea pig Alexa 647 Goat 1:1000 ICC/IHC Invitrogen 
α-mouse Alexa 647 Donkey 1:1000 ICC/IHC Invitrogen 
α-rabbit Alexa 647 Goat 1:1000 ICC/IHC Invitrogen 
α-rat Alexa 546 Goat 1:1000 ICC/IHC Invitrogen 




vesicles (Chapman, 2002; Koh and Bellen, 2003; Stein et al., 2007; Sutton et al., 
1995). Since the N-terminus of Syt 1 is in the lumen of synaptic vesicles, 
antibodies specifically targeting the N-terminus (luminal domain) of Syt 1 would 
bind and be taken up by recycling synaptic vesicles only when they fuse with the 
plasma membrane. 
 
For syt 1u, dissociated hippocampal neurons were incubated for 10 min at 37°C in 
250 µl high potassium “depolarizing” buffer (75 mM NaCl, 70 mM KCl, 20 mM 
Hepes, 2mM CaCl2, 5,5 mM glucose 2mM MgCl2, and 20 mM Hepes; pH 7.3) 
containing syt 1 luminal domain specific antibodies (see Table 1). Immediately 
afterwards, depolarizing buffer was removed and samples were fixed as detailed in 
section 3.5.4. 
3.5.4. Immunocytochemistry 
Dissociated hippocampal cultures growing on glass coverslips were fixed with 250 
µl 4% [w/v] Paraformaldehyde (PFA) diluted in 0.1 M phosphate buffer (PB) (0.1 M 
Na2HPO4, 0.1 M NaH2PO4 dissolved in ddH2O; pH 7.4) for 20-30 minutes at room 
temperature. Subsequently, fixed hippocampal cell cultures were washed three 
times with 500 µl 1X PBS (if necessary hippocampal cultures were stored up to a 
month at 4°C in 1X PBS). Dissociated cultures were then blocked for 20 minutes at 
room temperature by incubation in 250 µl blocking buffer containing Triton X-100 
for permeabilization (2% [v/v] donkey serum, 0,1% [v/v] Triton X-100 (Carl Roth), 
0,05% [v/v] NaN3 in 2X PBS). Subsequently, samples were incubated with primary 
antibodies (see Table 1) diluted in blocking buffer overnight at 4°C.  
 
The solution containing primary antibodies was then discarded and cells were 
washed three times for 5 minutes each with 500 µl 1X PBS. Cells were then 
incubated for 2 hr at room temperature in the dark in 250 µl blocking buffer 
containing secondary antibodies conjugated to a fluorophore (see Table 2). 
Secondary antibody solution was then removed and cells were washed three times 




for 5 min each with 1X PBS. If a DAPI staining was necessary samples were 
incubated for 10 minutes in 250 µl 1X PBS containing 10 µM DAPI (Invitrogen) at 
room temperature in darkness. Cells were again washed three times for 5 min 
each with 1X PBS. The same antibody mix (primary and secondary) was used for 
different conditions or treatments within the same experiment. Secondary 
antibodies used were crossed absorbed and previously tested to avoid cross-
reactivity. 
 
Finally, coverslips were mounted with a drop (10 µl) of Fluoromount/Plus 
(Diagnostic Biosystems) or Fluoromount-G (Sigma) on a glass slides (Carl Roth) 
for microscopy. Coverslips were sealed using transparent nail polish, and then 
imaged by epifluorescence and confocal microscopy (section 3.6). 
3.5.5. Immunohistochemistry 
3.5.5.1. Paraformaldehyde perfusion fixation 
2-3 month old WT (B6J), TRPVI KO and TRPV1-Cre-Tomato mice were 
anesthetized by intraperitoneal injection of a tranquilizer cocktail containing 10% 
ketamine, 2% xylazine and 0.9% saline solution; volume injected depended on the 
weight of the animal (0.1 ml/10 mg body weight). After anesthetization mice were 
placed on a perfusion chamber (abdomen side up) and fastened with needles on 
the chamber. The rib cage was removed and once the heart was successfully 
exposed, the right atrium was cut and a winged needle connected to a peristaltic 
pump (Masterflex) was inserted into the left ventricle. The blood was drained by 
perfusion of pre-filtered sucrose solution (10% [w/v] sucrose (Carl Roth) in ddH2O) 
for ca. 1 min followed by ca. 50 ml of pre-filtered 4% PFA at RT for ca. 20 min (for 
fixation). A successful perfusion was detected when the tail of the animal became 
stiff. The brain was subsequently dissected out of the skull, incubated in sterile-
filtered 4% PFA at 4°C for 2 hr, and washed twice for 15 min each with 0.1 M PB. 
Tissue was then used for IHC or stored in PB at 4°C for up to a month. All buffers 




and solutions used during this step were freshly prepared for every perfusion. Mice 
tails of all perfusions were clipped and genotyped (see 3.1.2). 
3.5.5.2. Acute brain slices 
Before tissue sectioning, fixed mouse brains (see section 3.5.5.1) were pre-
sectioned using an acrylic brain blocker (KOPF) to remove the most frontal and 
caudal parts of the brain to keep the starting point for slicing similar for every brain. 
Coronal brain slices were generated using a Leica VT 1200 vibratome (Leica 
Biosystems): Pre-sectioned brains were stabilized with glue Roti coll 1 (Carl Roth) 
caudally on a specimen disc fixed to the vibratome’s buffer tray. The tray was then 
filled with 4°C 0.1 M PB. The system was calibrated and 40 µm thick coronal brain 
slices were cut using a razor blade (Astra Platinum). Each slice was collected in 
individual wells of a 24-well cell culture plate containing 4°C 0.1 M PB and stored 
up to a month at 4°C. 
 
Brain slices were visually selected for immunohistochemistry using an Axiovert 40 
CFL (Zeiss). Comparable slices between different brains from different samples 
were sorted and classified depending on their approximate stereotactic coordinates 
according to Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates 
(2012). 
3.5.5.3. Immunohistochemistry of mouse brain slices 
Slices were washed first with 50 mM Tris buffer (TB) (38.5 mM Tris-HCl; 11.5 mM 
in ddH2O; pH 7.6), then with Tris buffered saline (TBS) (0.9% [w/v] NaCl in TB, pH 
7.6) and finally with Tris buffered saline with Triton X-100 (TBST) (0.5% [v/v] 100X 
triton in TBS; pH 7.6). Every washing step was done twice for 15 min each at RT. 
Afterwards, slices were incubated for 90 min with blocking buffer (as described in 
section 3.5.4). 
 




Following the blocking step, tissue was incubated in 500 µl blocking buffer 
containing primary antibodies for 48-72 hr at 4°C on an orbital shaker. 
Subsequently, tissue was washed 4 times for 15 min each with TBST at RT. Then, 
tissue was incubated for 2 hr in 500 µl blocking buffer mixed with secondary 
antibodies at RT in complete darkness. 
 
Following secondary antibody incubation, tissue was washed with TBST (2 X 15 
min) and with TBS (1 X 15 min) at RT. If a DAPI staining was needed the tissue 
was incubated for 10 minutes in 500 µl 1X PBS containing 10 µM DAPI (Invitrogen) 
at RT in darkness. Tissue was then washed at RT once for 15 min with TBS and 
then two times for 15 min each with TB. 
 
Brain slices were mounted on glass slides (Carl Roth) with a drop (10 µl) of 
Fluoromount-G (Sigma) and covered with 12 mm glass coverslips (Thermo 
Scientific). Coverslips were sealed using transparent nail polish and imaged by 
confocal microscopy (section 3.6). 
3.6. MICROSCOPY: IMAGE ACQUISITION AND ANALYSIS 
3.6.1. Epifluorescence microscopy 
Immunostained dissociated hippocampal neuronal cultures (see section 3.5.4) on 
glass coverslips were imaged using an upright epifluorescence Zeiss Axiovert.A1 
microscope (Carl Zeiss). Images were acquired with a 100X/1.4 oil Plan-
Apochromat objective (Carl Zeiss) (for ICC of synaptic vesicle markers) or a 
63X/1.4 oil Plan-Apochromat objective (Carl Zeiss) (for ICC of somatic protein 
expression). Images were captured with the Retiga-SRV camera (QImaging) and 
QCapture software (QImaging) and saved as 8-bit tiff files (RGB mode). Three to 
ten pictures of different neurons/regions of a given condition within the same 




experiment were acquired using identical settings for image size, light intensity, 
gain and exposure time. 
3.6.2. Confocal microscopy 
Confocal microscopy was conducted using a Zeiss LSM 710 confocal microscope 
(Carl Zeiss). Acute hippocampal slices (see section 3.5.5) and ICC of synaptic 
markers of hippocampal neurons in vitro were imaged with a 40X Plan-Neofluar oil 
immersion objective (for single frame image acquisition) and 20X Plan-Apochromat 
air objective (for tiled image acquisition of multiple frames, e.g. whole 
hippocampus). A diode laser was used to excite the Alexa 405 fluorophore 
(excitation-emission: 401-421 nm) and DAPI (emission: 410-495 nm). The Alexa 
488 fluorophore (excitation-emission: 493-520 nm) was excited with a 488 nm 
argon laser. The Alexa 546 fluorophore was excited with a DPSSL laser 
(excitation-emission: 556-573 nm) and the Alexa 647 fluorophore was excited with 
a HeNe laser (excitation-emission: 650-665 nm). 
 
A minimum of three images of hippocampal slices or neurons within the same 
experiment were acquired with identical frame size, scan speed, zoom, laser 
intensity, master gain, pinhole airy units, digital offset and digital gain. Images were 
captured and saved using the ZEN 2009 software and exported as 8 bit RGB tiff 
files. 
3.6.3. Immunocytochemistry analysis 
3.6.3.1. Synaptic strength quantitation 
Vesicular transporters are proteins in synaptic vesicle membranes that pump 
neurotransmitters into synaptic vesicles (Johnson et al., 2003). The vesicular 
glutamate transporter 1 (vGluT1) Bellocchio et al., 2000; Takamori et al., 2000) and 




the vesicular GABA/ glycine transporter (vGAT) (McIntire et al., 1997) transfer 
cytoplasmic glutamate and GABA into synaptic vesicles, respectively, and are 
commonly used to mark synaptic vesicles at excitatory and inhibitory synapses, 
respectively. 
 
In order to optically measure presynaptic modulations in synaptic strength of 
hippocampal neurons in vitro we conducted ICC co-staining for syt1 uptake 
(described in section 3.5.3) to mark recycling synaptic vesicles and vGluT1 (to 
mark synaptic vesicles at excitatory presynaptic terminals) or vGAT (to mark 
synaptic vesicles at inhibitory presynaptic terminals). The intensity of vGluT1 or 
vGAT signal corresponds to the number of synaptic vesicles per terminal and, in 
conjunction with syt1 uptake, gives a readout of presynaptic strength.  
 
A mask of transfected cells was created using Adobe Photoshop CS5 (Adobe 
Systems Incorporated). All synaptic puncta positive for vGlut1 or vGAT (on a single 
transfected neuron identified by GFP or RFP fluorescence or in a neuronal 
network) were selected using OpenView 3.0 software (provided by Noam Ziv, 
Technion, Israel Institute of Technology, Haifa, Israel). The fluorescent intensity of 
vGluT1 or vGAT signal was measured using the “place area over puncta” function; 
threshold and delta intensity were configured for an accurate selection of 
synapses. Fluorescence intensity of puncta within the transfected neuron mask 
reported presynaptic strength on the selected neuron “on neuron” and fluorescence 
intensity of puncta outside of this mask reported presynaptic strength in 
surrounding “off neurons”. The corresponding fluorescent intensity of the co-
stained syt1 taken up by recycling synaptic vesicles within selected areas was also 
measured. Blurry regions, puncta on somas and puncta not overlapping a visible 
neuronal process were excluded from analysis.  
 
The values for fluorescent intensity generated by OpenView 3.0 were imported into 
Microsoft Excel 2010 (Microsoft). The fluorescence intensities in different 
conditions (transfections, treatments, cell type) within a single experiment (a 




neuronal cell preparation in which ICC for all conditions was performed using the 
same antibody mix) were normalized to a range from 1-100 where 1 corresponded 
to the lowest and 100 to the highest fluorescence intensity detected in the 






Where x = normalized value, i = intensity value calculated by OpenView 3.0, min = 
lowest intensity value of the experiment and max = highest intensity value of the 
experiment. Since every experiment had slightly different cell density, antibody mix, 
microscope configurations, etc. this normalization allowed us to combine data from 
different experiments for comparison of conditions. 
 
The fluorescence intensity of puncta in every image was averaged and the mean of 
the average fluorescent intensity across all experiments for multiple images was 
calculated for each condition. Pooled data of all images for every condition was 
plotted with the standard error of the mean, and Student’s unpaired t-tests with 
Welch’s correction were conducted to determine statistical significance using Prism 
6 software (GraphPad). 
3.6.3.2. Excitatory and Inhibitory synapse number quantitation 
Synapse number analysis was performed by visual selection and counting of 
puncta positive for vGluT1 or vGAT immunofluorescence overlapping EGFP or 
MAP2 (a marker for dendrites of mature neurons (Kosik and Finch, 1987)). 
Synapses were counted along randomly selected 20-50 µm proximal dendritic 
processes.  
 
Since high expressing TRPV1 neurons possess a very dense excitatory and 
inhibitory synaptic innervation where synapses are tightly packed (making the 
identification of individual synapses difficult), MetaMorph (Molecular Devices) 




software was used to calculate the number of synapses contacting these neurons. 
The fluorescent signal of vGlut1 and vGAT positive immunostainings was selected 
by thresholding the signal (using the “set color threshold” function) to a specific 
level where only synapses were selected. Then, the “threshold” intensity value of a 
randomly selected 30-50 µm area of a proximal dendrite (as explained above) was 







Where n = number synapses, i = average fluorescence intensity in a selected 
thresholded area, d = average area of a single synapse (in pixels), l = length of the 
sample area (in pixels), and p = number of pixels per micron. 
 
Synapse number for every condition was then normalized to control conditions 
(EGFP transfected, or untreated condition). The normalized synapse number of 
every image was averaged and the mean of the average synapse number across 
all experiments was calculated for each condition. Pooled data from all images for 
every condition was plotted with the standard error of the mean and Student’s 
unpaired t-tests with Welch’s correction were conducted to determine statistical 
significance using Prism 6 software (GraphPad). 
3.6.3.3. Somatic protein expression 
In order to assess the somatic expression level of specific proteins (e.g. TRPV1, 
BDNF, NGF, etc.), the average fluorescence intensity in regions placed around 
somas was measured using the ImageJ or MetaMorph software. Fluorescence 
intensity in somas of each image was averaged and normalized to control. The 
mean of the average intensity of soma fluorescence intensity across all 
experiments was calculated for each condition. Pooled data of all images for every 
condition was plotted with the standard error of the mean and Student unpaired t-




tests with Welch’s correction were conducted to determine statistical significance 
using Prism 6 software (GraphPad). 
3.6.3.4. Quantitation of neuronal marker co-localization  
Quantitation of percent co-localization of high TRPV1-expressing neurons with 
different neuronal markers was performed by identifying cells expressing TRPV1, 
and then subsequently imaging the other co-immunostained marker, and vice 
versa – identifying cells expressing a marker and then imaging TRPV1 signal - in 
5-7 images each per experiment. The total percent of neurons with TRPV1 signal, 
neuronal marker signal, or both was plotted in Excel (Microsoft) or Prism 6 
(GraphPad) software. 
3.7. NEUROPHARMACOLOGICAL ASSAYS 
To examine the effects of TRPV1 channel activity in excitatory and inhibitory 
synaptic plasticity 50 nM or 1 µM capsaicin (Sigma-Aldrich) and 1 µM SB-366791 
(Sigma-Aldrich) (Gunthorpe et al., 2004) a selective TRPV1 antagonist were used 
individually or together. 
 
Two drugs were used to increase neuronal activity in vitro: 10 µM bicuculline 
(Tocris), a competitive antagonist of GABAA receptors (Johnston, 2013; Sillito, 
1975) and 50 µM forskolin (Sigma-Aldrich), which increases intracellular cAMP 
levels (Shoback and Brown, 1984) and reduces capsaicin-induced desensitization 
of TRPV1 channels (Schnizler et al., 2008). Neuronal activity was blocked with 1 
µM TTX (Tocris), which blocks voltage gated Na+ channels and prevents the firing 
of action potentials (Hwang and Noguchi, 2007; Narahashi et al., 1964). To 
determine if NGF affects TRPV1 expression hippocampal cultures were incubated 
with 1 ng/ml 2.5S NGF (Promega). 
 




All pharmacological treatments were for 21 hr. at DIV 2-4 (before synapse 
formation) or DIV 10 (after synapse formation). After treatment, cultures were fixed 
for immunocytochemistry or homogenized with 1X sterile DPBS (Sigma-Aldrich) for 
Western blots. 
3.8. ELECTROPHYSIOLOGY 
3.8.1. Miniature excitatory and inhibitory postsynaptic 
current recordings 
Whole cell patch clamp recordings from cultured rat hippocampal neurons (growing 
on individual glass coverslips) were performed at RT at DIV 12-14 in a custom-
made recording chamber. Transfected neurons were visualized with an 
epifluorescence upright microscope Olympus BX51WI (Olympus) equipped with a 
fluorescent light source Lumen 200 Pro (Prior Scientific) and the adequate filters 
for GFP detection (needed to identify transfected neurons). The localization of the 
neurons was done using either a 10x/0.3 water UMPlanFL N objective (Olympus) 
or a 40x/0.3 LUMPlanFL N objective (Olympus). For mEPSC and mIPSC 
recordings the artificial cerebrospinal fluid (ACSF) extracellular solution contained 
(136 mM NaCl, 2.5 mM KCl, 10 mM HEPES, 10 mM D-glucose, 2 mM CaCl2 and 
1.3 mM MgCl2; pH 7.4, adjusted with 10 M NaOH; 290-300 mOsm; 1 µM TTX 
(Tocris Bioscience)). ACSF was bubbled with carbogen (95% O2 and 5% CO2) to 
acidify it and achieve a pH of 7.2. For mEPSC recordings, the extracellular solution 
included 100 µM picrotoxin (Tocris Bioscience); for mIPSC recordings, 10 µM 
CNQX and 10 µM AP-5 were added to the ACSF. The intracellular solution 
contained (130 mM K-gluconate, 10 mM NaCl, 1 mM EGTA, 0.133 mM CaCl2, 2 
mM MgCl2, 10 mM HEPES, 3.5 mM Na-ATP, 1 mM Na-GTP; pH=7.3; 280 mOsm) 
for mEPSC detection and (136 mM CsCl, 10mM EGTA, 2 mM CaCl2, 0 mM MgCl2, 
10 mM HEPES, 2 mM Mg-ATP, 0.3 mM Na-GTP; pH=7.3, adjusted with CsOH; 
290-295 mOsm) for mIPSC detection. Recordings were performed with a HEKA 




EPC10 USB double patch clamp amplifier coupled to Patchmaster acquisition 
software (HEKA Electronics Inc.). Borosilicate glass micropipettes (resistance of 2-
5 MΩ) used for the recording were pulled using a P-97 micropipette puller (Sutter 
Instruments). Recorded neurons were held in a voltage-clamp mode at -60 mV for 
both mEPSC and mIPSC recordings. Data was filtered using a low pass Bessel 
filter at 2.9 kHz and digitalized at 5 kHz. Recorded traces were analyzed using Mini 
Analysis v6.0.3 software (Synaptosoft). The amplitude threshold for detection of 
mEPSCs was approximately 3.5 x RMS noise, i.e. 14 pA and for mIPSCs was 20 
pA. Only undisturbed traces of at least 1 min were considered for the analysis  
 
Average amplitude and frequency were then plotted with standard error of the 
mean, and statistical significance was calculated using unpaired, non-parametric 
Welch’s tests in Prism 6 software (GraphPad). 
3.8.2. Electrophysiological recording from hippocampal 
slices 
3.8.2.1. Slice preparation 
Acute hippocampal slices were prepared from 8-10 week old B6/J and TRPV1 KO 
adult mice as previously described (Ramachandran et al., 2015a). Animals were 
anesthetized with isoflurane and decapitated. The brain was removed from the 
skull and hippocampus was dissected. Transverse 400 µm thick hippocampal 
slices were obtained using a tissue chopper (Stoelting). Slices were collected in 
ice-cold artificial cerebrospinal fluid (ACSF) (124 mM NaCl, 4.9 mM KCl, 1.2 mM 
KH2PO4, 2.0 mM MgSO4, 2.0 mM CaCl2, 24.6 mM NaHCO3, 10.0 mM D-glucose; 
saturated with 95% O2 and 5% CO2; pH 7.4 and 305 mOsm). 
 
 




3.8.2.2. Field stimulation post-synaptic potential recordings 
Hippocampal slices were incubated for 3 h at 32 °C and high oxygen tension (by 
bubbling with 95% O2 and 5% CO2; 30 l/h) in an interface chamber containing 2 ml 
ACSF. A constant flow (0.76 ml/min) of ACSF was perfused continuously during 
the incubation. For recording and stimulation of the field excitatory post-synaptic 
potential (fEPSP), monopolar lacquer-coated stainless steel electrodes (571000, A-
M Systems) were positioned in the CA1 region (Figure 3). The fEPSP was 
recorded using a differential AC amplifier (Model 1700, A-M Systems) and a power 
(1401) analog to digital converter (Cambridge Electronic Design) and tracked using 
the PWIN software (IFN Magdeburg). For each input, a determination of the “test 
stimulation strength” was stipulated as the current necessary to cause a fEPSP of 
40% of the maximal slope. 30 min after incubation with ACSF, the baseline 
recording was started with test stimuli consisting of 4 biphasic pulses of constant 
current (0.2 Hz, 0.1 ms/polarity) every 5 min for at least 30 min. Long-term 
potentiation (LTP) was induced with one (1XTET) strong tetanization protocol 
consisting of 100 biphasic constant-current pulses at 100 Hz and 0.2 ms/polarity 
(1XTET) with an intertrain interval of 5 min. For the nicotine-dependent LTP 
experiments, 5 µM nicotine was applied 30 min prior to LTP induction and until the 
end of the recording (1 h). 
 
Long term depression (LTD) was induced with a low-frequency stimulus protocol of 
900 bursts, where each burst consisted of three stimuli at 20 Hz, with an interburst 
interval of 1 s and a stimulus duration of 0.2 ms per half-wave, for a total of 2700 
stimuli at 1 Hz (Ramachandran et al., 2015b) Test stimuli were given 1, 3, 5, 11, 
15, 21, 25 and 30 min after the TET train and every 5 min thereafter for a 
maximum of 1 h.  




3.9. CA2+ IMAGING 
To test if capsaicin activates hippocampal neurons in vitro we used the Fluo-4 (Gee 
et al., 2000) (Invitrogen) calcium indicator at a concentration of 1:1000 added to 
DIV 13-14 mouse hippocampal neurons. After 10-20 minutes of incubation, 
coverslips were placed on a field stimulation imaging chamber (Warner 
Instruments) in 100-150 µl of base solution (140 mM NaCl, 5 mM KCl, 2 mM 
CaCl2, 2 mM MgCl2, 5.5 mM glucose, 20 mM Hepes; pH=7). The stimulation 
chamber was then connected to a biphasic stimulator and positioned on a Zeiss 
Axio Observer A1 epifluorescence microscope (Carl Zeiss) with a DG-4 
wavelength switcher. A 40x/1.4 air Plan-Apochromat objective and a 488 nm 
wavelength filter was used to detect Fluo-4 fluorescence (excitation-emission: 494-
516 nm) Three-minute time series of 1 frame per second were acquired with an 
exposure time ≤ 200 ms using an Evolve Camera (Photometrics) controlled by 
MetaMorph software (Molecular Devices). After 1 min baseline recording, 30 1 ms 
+10 V pulses at 40 Hz were delivered by field stimulation. Following field 
stimulation (at frame 120) a final concentration of 1 µM capsaicin (or corresponding 
 
Figure 3. fEPSP recording protocol 
Illustration of the position of stimulating and recording electrodes during LTP and LTD experiments 
performed in the hippocampal Schaffer collateral pathway. 




volume of DMSO) was added by pipette and samples were imaged for an 
additional minute. 
 
For analysis of intracellular Ca2+ responses to capsaicin, only somas of neurons 
responding to field stimulation were selected with the region tool in MetaMorph. 
Background (the average intensity of 5 regions without visible neuronal processes 
or cell bodies) was subtracted and the average intensity in cell somas throughout 
the time course was determined in Metamorph and further analyzed using a 
custom written script in Matlab. Frames were clipped from individual traces such 
that time of field stimulation and time of addition of capsaicin or DMSO in each 
trace was aligned with respect to each other. Fluorescence averaged over first 50 
frames was taken as baseline (F0). The ΔF/F0 traces were calculated as (F-F0)/F0, 
where F is the Fluorescence at time (t). Cells that had <20% increase upon field 
stimulation were excluded from the analyses. From the cells reacted to field 
stimulation, only those that showed a >20% increase upon capsaicin addition were 
considered as responsive.  
3.10. RNA ISOLATION AND RT-PCR 
To detect if TRPV1 and its isoforms were expressed in hippocampus, brain, 
cerebellum and dorsal root ganglia (DRG), RNA was isolated from 2 to 3-month-old 
WT (B6/J) and TRPV1 KO mice. Animals were euthanized with CO2 and then 
decapitated and brains were collected in a 10-cm petri dish on ice containing sterile 
1X PBS. Hippocampi and dorsal root ganglia were isolated and collected in DNase 
and RNase free Eppendorf tubes (Thermo Fisher), snap-frozen with liquid nitrogen 
and stored at -80°C. Tissue was dissected from each mouse using separate tools 
in order to avoid tissue contamination.  
 
RNA was isolated using Trizol (Sigma-Aldrich). Hippocampi and DRGs were 
homogenized with 500 µl or 250 µl Trizol respectively and incubated at RT for 5 




min. Subsequently 100 µl (hippocampus) or 50 µl (DRGs) chloroform was added 
and mixed vigorously by inverting the tube 15 times and then allowing solution to 
settle for 3 min at RT. Samples were then centrifuged for 15 min at 4°C at 13,000 
rcf. The upper aqueous supernatant was transferred to a new micro-centrifuge 
tube, additional isopropanol was added (250 µl for hippocampus and 125 µl for 
DRGs) and mixed by gentle inversion followed by a -20°C incubation for 1 hr. 
Samples were then centrifuged at 13,000 rcf for 30 min at 4°C. The supernatant 
was discarded and the obtained RNA pellet was washed with 1 ml 75% ice cold 
70% ethanol. After washing, a final centrifugation step of 5 min at 4°C RT 13,000 
rcf was performed, supernatant was discarded and the RNA pellet was air-dried at 
RT until the ethanol was completely evaporated. The RNA pellet was finally 
dissolved with DNase- and RNase-free water (30 µl for hippocampus and 20 µl for 
DRGs). Samples were treated with DNase I (Ambion) to eliminate any remaining 
chromosomal DNA (Vanecko and Laskowski, 1961).  
 
Purity and concentration of extracted RNA was determined using a 
spectrophotometer (NanoDrop ND-1000) with ND-1000 v3.5.2 software 
(peQLabBiotechnologie). Only isolated RNA with an integrity value of more than 8 
was used. 
 
cDNA was synthesized using 2 µg (hippocampus) or 1 µg (DRGs) of the isolated 
RNA. Dissolved RNA samples were diluted with DNase and RNase free water to a 
final volume of 11 µl and mixed with 9 µl of the cDNA synthesis reaction mix (see 
below) for a final volume of 20 µl. RNA was reversed transcribed with the 
Transcriptor High Fidelity cDNA synthesis kit (Roche Applied Science) under the 
following cycling conditions: 1 cycle of 10 minutes at 25 °C, 1 cycle of 30 minutes 
at 55 °C and a final cycle of 5 min at 80 °C, followed by a hold at 4 °C. A reverse 
transcription – polymerase chain reaction (RT-PCR) without reverse transcriptase 
served as a negative control. Isolated RNA and negative controls were stored at -
20°C.  
 




Reaction mix for cDNA generation: 
 
4 µl   Reaction Buffer, 5x concentrated (Roche Applied Science) 
0.5 µl   RNase inhibitor 
2 µl   Deoxynucleotides 
0.5 µl   Reverse transcriptase 
2 µl   Random hexamer primer 
3.10.1. Primer design, PCR and Q-PCR 
Quantitative Q-PCR was performed on a light cycler 480 system (Roche Applied 
Science) using the LC480 SYBR green Master mix (Roche Applied Science). 2 µl 
of the synthesized cDNA library was used for Q-PCR with TRPV1 primers (see 
below) and 1:10 diluted cDNA for the reference control tubulin alpha-1B. All data 
obtained was normalized to the mRNA levels of tubulin alpha-1B. The Q-PCR 
reaction mix and cycling conditions for amplification were as follows: 
 
Reaction mix for Q-PCR 
2 µl   cDNA 
0.75 µl  Forward primer (10 µM) 
0.75 µl  Reverse primer (10 µM) 
7.5 µl   LC480 Master mix, 2x concentrated 
4 µl   DNase- and RNase-free water 
 
Q-PCR cycle conditions: 
95°C  5 min 
95°C  10 sec 
60°C  15 sec X 45 
72°C  10 sec 
95°C  15 sec 
67°C  30 sec 




95°C  15 sec 
40°C  10 sec 
4°C  hold 
 
Primers used for identification of expression of the TRPV1 channel pore region 
(deleted exon in the TRPV1 KO), the TRPV1 N-T and C-T, the TRPV1 channel 
splice isoforms vanilloid receptor 5’ splice variant (VR.5’sv) and for the 
housekeeping gene Tubulin alpha-1B were either custom designed or as described 
previously (Table 3). All primers were synthesized by and purchased from Sigma-
Aldrich®. 
 
Table 3. List of primers for Q-PCR. 
 
For VR.5’ sv, the only published sequence to our knowledge was reported for rat 
(rattus norvegicus) tissue (Schumacher et al., 2000) (GenBank™ accession 
number AF158248.2). These authors designed primers to detect VR.5’ sv or 
TRPV1 gene expression in rat tissue. We designed primers to detect the same 
region in mouse, by aligning the TRPV1 genomic mouse sequence (GenBank™ 
accession number NC_000077.6) with the rat TRPV1 genomic sequence 
(GenBank™ accession number NC_005109.4) using the open source software “A 
plasmid editor” v2.0.47 (Copyright 2003-2009 by M. Wayne Davis) (ApE©).  
 
Transcript  Forward primer (5’-3’) Reverse primer (5’-3’) Description 
TRPV1-N-1 gagtgtgcctgcacctagc tcagattcatccgagtctaagc 
TRPV1 N-Terminus 
specific  
TRPV1 KOr cttgtttggattttccacagc cacttgtgtggtggggact 
Specific TRPV1 KO 
deletion 
TRPV1-C ggcatgtccctaggacttca agctcgcttcccacacac TRPV1 C-Terminus 
VR.5’ sv-S tgaccctcttggtggagaatgg tgaggctagtccctggatgactg VR.5’sv specific 
Tuba1B aggagctggcaagcatgt agctgctcaggctggaagag Housekeeping gene 




For custom-designed primers for TRPV1 we obtained the mouse (Mus musculus) 
mRNA sequence of this gene from GenBank™ of the National Center of 
Biotechnology Information, U.S. (NCBI) (http://www.ncbi.nlm.nih.gov/nuccore) 
under the GenBank™ accession number: NM_001001445.2. For VR.5’ sv we 
obtained the coding sequence of the mouse gene as mentioned above. We then 
chose primers using the online tool “Universal Probe Library Assay Design Center” 
(Roche Diagnostics™) by entering the complete NCBI reference sequence or the 
specific exons we aimed to detect, such as those of amino and carboxyl termini, 
the pore region (to detect the expression of functional TRPV1 channels) and the 
unique VR.5’ sv sequences, to detect this isoform.  
3.11. BIOCHEMICAL METHODS 
3.11.1. Sample tissue collection and preparation 
For immunoblotting of hippocampal or HEK 293 cells grown on 10 cm tissue 
culture dishes (CellStar), the culture medium was removed, cells were washed 
once with sterile DPBS (Sigma-Aldrich) and scraped off the dish in 500 µl sterile 
DPBS (Sigma Aldrich) using a cell scraper (Sarstedt) into an Eppendorf tube and 
snap-frozen in liquid nitrogen.  
 
For preparation of whole brain and hippocampus homogenates, tissue was 
dissected from 2-4-month-old mice and collected in DNase and RNase free 
Eppendorf tubes and immediately frozen in liquid nitrogen. Tissue was 
homogenized in homogenization buffer (320 mM sucrose and 4 mM HEPES; pH 
7.4, adjusted with NaOH) made fresh right before use and kept at 4 °C. 
Homogenization was done in 9 ml of 4°C homogenization buffer (supplemented 
with protease inhibitors; 1:1000 dilution) using a glass-Teflon homogenizer with 8-
10 strokes at 900 rpm. 




3.11.2. Protein quantification 
Protein concentration in homogenized tissue was determined with a BCA protein 
assay kit (Novagen) (Brown et al., 1989; Kessler and Fanestil, 1986; Smith et al., 
1985; Wiechelman et al., 1988). Absorbance was measured at 562 nm on a plate 
reader. 
3.11.3. Protein separation (SDS-PAGE) 
Protein separation was performed following the Schägger protocol (Schägger and 
von Jagow, 1987). Proteins were denatured: samples were mixed with the 
Schägger sample buffer (50 mM Tris 4 % SDS, 0.01 % Serva Blue G, 12 % 
glycerol; pH 6.8, adjusted with HCl; for reducing 2 % mercaptoethanol) and heated 
at 99°C for 10 min. Equal amounts of protein were loaded into each lane and 
proteins were separated by 10% [w/v] SDS-PAGE under constant current using a 
Bio-rad electrophoresis power supply.  
3.11.4. Western blotting 
Proteins were transferred from a polyacrylamide gel to a nitrocellulose membrane 
as previously described (Towbin et al., 1979) at 100 mA for 1h. 
 
For immunoblotting, membranes were incubated for 1 hour at RT in WB blocking 
buffer (5% [w/v] lyophilized non-fat milk in 1X TBST). Primary antibody (targeting 
the desired protein) (see Table 1) was then added to the WB blocking buffer. The 
membrane was incubated ON at 4°C in primary antibody solution. The membrane 
was subsequently washed 3 times with TBST and then incubated for 1 h, at RT 
with HRP-conjugated secondary antibodies (see Table 2) in WB blocking buffer. 
After washing 3 times with TBST, the custom-made chemiluminescent substrate 
ECL consisting of 1 ml of solution A (2.42 g of Tris-HCl, 500 mg of luminol sodium 




salt (Sigma-Aldrich) dissolved in 200 ml ddH2O), 100 µl of solution B (11 mg of P-
coumaric acid (Sigma-Aldrich) dissolved in 10 ml DMSO) and 0.3 µl of solution C 
(30-35% [v/v] of H2O2) was poured to the membrane for at least 3 min and 
protected from daylight. For visualization, the signal was captured using a LAS 
reader (Fuji). The signal intensity was quantified using the open source software 
Image J, and values were plotted in Excel (Microsoft). Significance was determined 
using Student’s unpaired t-tests with Welch’s correction in Prism 6 software 
(GraphPad). 
3.11.5. Isolation of synaptic vesicles from mouse brain 
homogenates 
This method was performed by Saheeb Ahmed, a fellow post-doctoral scientist in 
the Trans-synaptic signaling Group of the ENI-Göttingen, as previously described 
(Ahmed et al., 2013; Pavlos et al., 2010). 
3.11.6. Protease treatment of synaptosomes 
Synaptosomes were isolated as previously described (Fischer von Mollard et al., 
1991). After Synaptosome purification, protease treatment was performed as 
described (Boyken et al., 2013). Immunoblots for detection of TRPV1 were done 














4.1. TRPV1 EXPRESSION IN BRAIN AND HIPPOCAMPUS 
Since the generation of a TRPV1 KO mouse line in the year 2000 (Caterina et al., 
2000) this mutant animal has become a model for understanding the mechanism 
underlying the process of nociception. Intensive research has been conducted in 
order to identify in which neural tissue TRPV1 is expressed in the peripheral and 
central nervous system. To date the expression profile of this channel in the brain 
is still unclear; especially in hippocampus, the existence of the TRPV1 channel is 
under debate. 
 
We started this research with the basic question: is TRPV1 expressed in brain, and 
hippocampus tissue? In order to assess if TRPV1 expression occurs in both brain 
and hippocampus we conducted biochemical and immunological assays in 
different neural tissues from WT and TRPV1 KO mouse lines.  
 
First, we ensured that the deletion of the TRPV1 gene resulting in loss of function 
was present in TRPV1 KO animals used for experimentation. WT primer pair for 
TRPV1 amplified a sequence of 984 bp only from isolated genomic DNA of WT 
animals, whereas the TRPV1-mutant primer pairs amplified the expected 450 bp 








4.1.1. TRPV1 and VR.5’ sv mRNA are differentially 
expressed in the hippocampus and DRG from WT and TRPVI 
KO mice 
We further assessed the expression at the mRNA level of TRPV1 and the TRPV1 
N-T alternative splice isoform (VR.5’ sv) in the hippocampus and DRG (used as a 
positive control for the expression of both isoforms) of 2-3-month-old adult mice. 
We confirmed the presence of both TRPV1 and VR.5’ sv transcripts in both DRG 
and hippocampus (Figure 4 A-C). 
 
As expected, primers designed to amplify part of the sequence that is deleted in 
the TRPV1 KO mouse model (TRPV1 KOr) corresponding to exon 13 (encoding 
part of the fifth and all of the sixth transmembrane domain, including the putative 
pore region) are absent in both DRG and hippocampus from TRPV1 KO animals 
(Figure 4 A-C), whereas in WT animals amplification of this sequence was 
detected in both tissues. Although in the hippocampus the expression was minimal 
it was still amplified in WT mice, contrasting with the negligible amplification 
observed in TRPV1 KO samples (Figure 4 C). 
 
Similar to the results observed with the primer pair TRPV1 KOr, the amplification of 
specific nucleotide sequences of the amino-end of TRPV1 mRNA using the primer 
pair TRPV1-N1 (encoding a sequence stretch from exon 1 and 2) showed that in 
WT animals TRPV1 mRNA levels are higher in DRG compared to the 
hippocampus (Figure 4 A). While in TRPV1 KO animals the amplification of this 
sequence was almost absent in DRG (Figure 4 B); in the hippocampus, the 
expression did not significantly change in TRPV1 KOs compared to WT. 
 
We also designed primers that amplify the putative region of exon 16 encoding for 
the carboxyl-terminus amino acid sequence recognized by the TRPV1 C-T 
antibody (Millipore). Similar to the levels of amplification observed by both the 





sequence was significantly higher in DRG than in hippocampus of WT animals 
(Figure 4 A) and in TRPV1 KO DRG the mRNA was significantly less than in WT 
(Figure 4 B). Surprisingly (unlike TRPV1 KOr and TRPV1-N1 primers) in the 
hippocampus the levels of mRNA corresponding to the C-T of TRPV1 was 
increased by 350 times compared to WT (Figure 4 C). 
 
This tremendous increase in the levels of the C-T sequence could mean that a 
TRPV1 splice isoform is compensating for the absence of TRPV1 in the knockouts. 
We therefore further tested the expression of the TRPV1 alternative N-T splice 
isoform (i.e. VR.5’ sv) known to lack most of the N-T but conserving the entire C-T. 
We designed VR.5’ sv mouse specific primers modified from previous studies in rat 
(Schumacher et al., 2000). These primers amplify one part of a VR.5’ sv-specific 
sequence (in exon 1 of VR.5’ sv) that is not present in TRPV1. As shown in (Figure 
4 A), our results show that in DRG this isoform is expressed (like TRPV1) at higher 
levels compared to hippocampus, and in TRPV1 KO DRG these levels are 
significantly reduced (Figure 4 B) Interestingly, in contrast to DRG, the level of 
amplification of the VR.5’ sv-specific stretch in hippocampus is significantly 
increased in TRPV1 KOs compared to WT. 
 
We further compared the relative levels of mRNA of TRPV1 (using the above-
mentioned primer pairs) and VR.5’ sv in either the DRGs or the hippocampus of 
adult mice. As depicted in Figure 5A our analyses show that in DRGs the mRNA 
levels for primer pairs amplifying either the pore region or the amino terminus were 
approximately 15 - 16 times higher than those of VR.5’ sv. Expression of the C-T 
TRPV1 mRNA stretch was 44 times higher than that of VR.5’ sv. Interestingly the 
mRNA levels of the C-T region of TRPV1 were significantly higher than those of 
the N-T and pore region (the latter two did not differ in amount). 
 
Opposite to the transcription profile in DRGs, in the hippocampus mRNA levels of 
the VR.5’ sv were 10-14 times higher than either the pore region or the N-T of the 





VR.5’ sv. Similar to DRGs, mRNA levels of TRPV1 C-T were also higher than the 
TRPV1 pore region and TRPV1 N-T mRNA levels in hippocampus (Figure 5 B). 
 
 
Figure 4. Differential mRNA expression of specific TRPV1 domains and VR.5’ sv in the 
hippocampus and DRG from WT and TRPV1 KO mice. A) Q-PCR showing the relative mRNA 
expression levels of the TRPV1 N-T, C-T and pore regions, and of VR.5’ sv, amplified by specific 
primer pairs in DRG (D) and hippocampus (H) normalized to DRG levels. In the hippocampus levels 
of all TRPV1 sequences are significantly less than in DRG except for TRPV1 C-T and VR.5’ sv in 
TRPV1 KOs. B) Q-PCR values for DRG samples of WT and TRPV1 KO mice normalized to WT 
levels. mRNA levels of all amplified sequences are significantly reduced in TRPV1 KO DRGs 
compared to WT. C) Q-PCR values for hippocampus samples of WT and TRPV1 KO mice 
normalized to WT levels. mRNA level of the pore domain is absent in TRPV1 KO hippocampus; the 
C-T of TRPV1 and the VR.5’ sv are significantly increased in TRPV1 KO hippocampus. (n=3 each 
for WT and TRPV1 KO samples of hippocampus and DRG; error = SEM, significance was 
determined by unpaired Student’s t-test * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). Q-PCR 






4.1.2. TRPV1 protein expression levels in the mouse brain 
and hippocampus 
In order to assess if the TRPV1 channel is expressed in brain and hippocampus at 
the protein level, WB were conducted using an N-terminus specific TRPV1 
antibody (NeuroMab) in whole brain and hippocampus homogenates. The 
molecular weight of TRPV1 is 94.976 kD, where the expected band size is 
approximately 90 kD. To test the specificity of this antibody for TRPV1 we did WB 
 
Figure 5. Differential mRNA expression of specific TRPV1 domains and VR.5’ sv in the DRG 
and hippocampus from WT mice. A) Q-PCR showing the relative mRNA expression levels of the 
TRPV1 N-T, C-T and pore regions compared to VR.5’ sv in DRG samples. Levels of TRPV1 N-T 
and KOr sequences are significantly higher than for VR.5’ sv, and TRPV1 C-T levels are 
significantly higher than for N-T or KOr sequences. B) Q-PCR showing the relative mRNA 
expression levels of the TRPV1 N-T, C-T and pore regions compared to VR.5’ sv in adult 
hippocampi. Levels of the N-T and KOr sequences are significantly lower than those of VR.5’ sv. 
TRPV1 C-T is expressed at the highest levels. For A and B values of mRNA expression were 
normalized to VR.5’ sv values (n=3 each for WT hippocampus and DRG; error = SEM, significance 
was determined by unpaired Student’s t-test, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001; black 
asterisks indicate significant difference compared to VR.5’ sv mRNA levels; blue asterisks indicate 





of TRPV1-transfected HEK cells in vitro; as shown in (Figure 6 B) the 90kD band 
corresponding to TRPV1 was detected only in transfected cells. 
 
Figure 6. TRPV1 expression in mouse brain and hippocampus. A) Western blot confirms that 
the N-T TRPV1 antibody (from NeuroMab) recognizes a specific band at the expected size for 
TRPV1 in WT but not in TRPV1 KO brain homogenates. Tubulin was used as a loading control; n=3 
repetitions. B) Western blot showing that the N-T TRPV1 antibody recognizes a band of the correct 
size in homogenates of HEK cells transfected the TRPV1-EGFP construct, but not in control 
untransfected cells; tubulin was used as a loading control. C) Western blot showing the expression 
profile of TRPV1 in brain homogenates during development. The onset of TRPV1 expression is late 
embryonic / early post-natal and persists during adulthood. Syt1 expression, which increases 
throughout development and remains constant in adulthood, is shown for comparison. D) 
Subcellular fractionation shows that TRPV1 expression is mainly present in plasma membrane 
fractions. (indicated fractions are homogenate (H), nuclear and large membrane pellets (P1), 
synaptosomal supernatant (S2), synaptosomes (P2’), presynaptic plasma membrane (LP1), 
synaptic cytosol (LS2), and crude synaptic vesicles (LP2)). E) Trypsin cleavage assay in purified 
synaptosomes (n=3). The TRPV1 antibody detected the full-length 90 kD band, but also a 65 kD 
cleavage product. The pre-synaptic marker syb2 was only detected as a full-length protein (18 kD). 
The post-synaptic marker PSD95 full-length protein (105 kD) was not detected following trypsin 
treatment. F) Western blot of synaptic proteins in whole brain (left) and hippocampus (right) from 
WT and TRPV1 KO mice. TRPV1 is expressed in WT but not in TRPV1 KO hippocampus; tubulin 
serves as a loading control. Western blots, subcellular fractionation and trypsin cleavage assays 





Next, we surveyed the expression profile of TRPV1 during neural development 
from embryonic stages to early adulthood in WT mice. As depicted in (Figure 6 C) 
we found that the expression of TRPV1 and syt1 (used as a control synaptic 
protein) was already present at embryonic day 14 (E14), E18 and postnatal day 0 
(P0). After birth the expression of TRPV1 and syt1 increased and the expression 
persisted until at least 2-3 months into adulthood. 
 
Brain and hippocampus homogenates from 2-3-month-old WT and TRPV1 KO 
mice allowed us to confirm that the observed band in fact corresponded to the 
TRPV1 protein. As shown in (Figure 6 A, F) the expected 90 kD band was 
observed in both brain and hippocampus tissue homogenates of WT mice but not 
in TRPV1 KOs. A lower molecular weight band (35 kD) was also consistently 
detected in most of the WB using the N-T TRPV1 antibody; the intensity of this 
band was always lower than the TRPV1-specific one. We also tested the 
expression levels of other synaptic proteins, neurotrophins (i.e. BDNF) and 
cytoskeletal proteins. We did not find any significant change in these proteins in 
TRPV1 KO tissue compared to WT (expected band sizes shown) (Figure 6 F). 
4.1.3. Pre- and post-synaptic expression of TRPV1 
After detecting TRPV1 protein expression in the adult mouse brain and 
hippocampus we were keen to clarify if TRPV1 is expressed synaptically. 
 
One way to determine if TRPV1 is expressed synaptically is by subcellular 
fractionation. As shown in Figure 6 D, immunoblots of subcellular fractions using 
the N-T TRPV1 antibody (NeuroMab) detected a 90 kD band corresponding to 
TRPV1 in mouse brain homogenate (H), the nuclear and large membrane pellet 
fraction (P) indicating that TRPV1 is expressed in the plasma membrane, the 
synaptosome fraction (P2’), the presynaptic plasma membrane fraction (LP1) and 
in the “crude” synaptic vesicle fraction (LP2). The N-T antibody did not recognize 





brain cytosol and small organelles (S2). The presynaptic protein synaptobrevin 2 
(syb2) as expected was present in all subcellular fractions except the LS2 fraction, 
and was enriched in the synaptic vesicle fraction. 
 
To further determine if TRPV1 is present in pre- or post-synaptic compartments we 
conducted a synaptosomal limited proteolysis assay (Figure 6 E). Isolated 
synaptosomes form in such a way that the presynaptic terminal reseals, enclosing 
presynaptic components inside, while the post-synaptic side of the synapse 
remains attached but does not reseal and is therefore accessible the solution. 
When isolated synaptosomes are subjected to limited proteolysis with trypsin, 
presynaptic proteins are protected and post-synaptic proteins are digested. The 
post-synaptic localization of PSD-95, as a positive control, and TRPV1 was 
confirmed by the detection of a lighter band corresponding to cleavage by trypsin. 
As shown in Figure 6 E a lower molecular weight band of  ̴ 65 kD was recognized 
by the N-T TRPV1 (NeuroMab) antibody (Table 1) in purified synaptosomes from 
adult mouse brain homogenates subjected to proteolysis for 10 – 90 min, indicating 
that at least some TRPV1 is embedded in post-synaptic membranes in isolated 
synaptosomes. Unlike PSD 95, which was largely digested, a full length TRPV1 
band at 90 kD remained, meaning that a portion of TRPV1 was not digested and is 
likely to be presynaptic. Synaptobrevin, a positive control for a presynaptic protein, 
was not digested at all (Figure 6 E).  
4.1.4. Expression of functional TRPV1 in hippocampal 
neuronal cultures 
Since its discovery, TRPV1 is known to be permeable to cations including Ca2+ 
(Caterina et al., 1997). Monitoring Ca2+ influx upon TRPV1 activation would then 
allow us to determine if TRPV1 is expressed in hippocampal neurons as active, 
functional channels. By examining the influx of Ca2+ in neurons upon 1 µM 
capsaicin stimulation we detected approximately 24% of all hippocampal WT 





Figure 7 A-B. Only neurons that responded with increases Ca2+ to 40 Hz field 
stimulation prior to addition of capsaicin were included in analysis and quantitation. 
Only 0.69% of analyzed TRPV1 KO cells showed a slight response to capsaicin. 





Figure 7. Functional TRPV1 expression in mouse hippocampal neurons in vitro. A) Fluo-4-
based intracellular Ca2+ imaging. 24% (B) of hippocampal neurons in WT cultures showed Ca2+ 
influx upon 1µM capsaicin treatment (red arrow), and TRPV1 KO cultures showed no Ca2+ influx in 
response to capsaicin (n=19 images each from 3 different cultures) (0% of neurons reacted to 
DMSO teatment) (scale bar = 20 µm). B) Representative (colored) and average (black) traces of 
intracellular Fluo-4 signal show Ca2+ levels rising upon electrical field stimulation (40 Hz) in both WT 
and TRPV1 KO  neurons. Ca2+ levels increased upon application of 1µM capsaicin in WT but not in 
TRPV1 KO hippocampal cell cultures (n=18 images each, from 3 different cultures); no intracellular 
Ca2+ elevation was observed in either WT (n=16 images from 3 different cultures) or in TRPV1 KO 
(n=10 images from 3 different cultures) cultures treated with DMSO solution. For B the development 





Although the peak of fluorescent signal of Ca2+ influx during electrical stimulation 
and upon capsacin treatment was variable among different neurons, usually, the 
capsaicin response was 50% lower than the response to electrical stimulation. The 
kinetics of the fluorescence signal for capsaicin-dependent Ca2+ influx was also 
different than those following 40 Hz stimulation. The decay was more abrupt after 
electrical stimulation than for capsaicin where the decay was more gradual and in 
some cases did not decay completely to baseline before the termination of 
recording (Figure 7 A-C). 
 
In cultured TRPV1 KO hippocampal neurons we did not detect a significant Ca2+ 
influx in response to 1 µM capsaicin treatment (Figure 7 A-C). Even if a minuscule 
rise was detected, it was similar to the insignificant increase upon DMSO addition 
used as a positive control. Intriguingly, the Ca2+ fluorescence signal detected in 
response to electrical stimulation was on average two times smaller in TRPV1 KO 
neurons compared to WT (Figure 7 A-C). 
 
So far, our results confirmed that TRPV1 channels are expressed in the rat and 
mouse brain during embryonic and postnatal development, continuing throughout 
adulthood. In the hippocampus, channels are expressed in an active state; possibly 
in a small subpopulation of neurons. To investigate the specific sub-population of 
neurons that express TRPV1, we used immunofluorescence techniques in 
hippocampal neurons in vitro as well as in fully developed hippocampus slices. 
4.2. TRPV1 IS HIGHLY EXPRESSED IN A SPECIFIC 
HIPPOCAMPAL NEURONAL CELL-TYPE 
Little is known about what neurons express TRPV1 in the hippocampus. It has 
previously been suggested that only Cajal-Retzius cells express TRPV1 channels 





were hypothesized to be short-lived and not to confer a substantial influence in the 
adult hippocampus (Cavanaugh et al., 2011).  
 
When we conducted immunostainings in WT mouse hippocampal cell cultures 
using the N-T TRPV1 antibody, we found that only a small number of neurons were 
highly expressing TRPV1, which had on average twice as much fluorescence 
intensity as surrounding neurons (Figure 8 A and B). We were not able to find any 
TRPV1-positive cells using this antibody in TRPV1KO cultures. However, we found 
that these same neurons were still detected by the C-T antibody in TRPV1 KO 
hippocampal cultures, which had twice the amount of fluorescence intensity as 
surrounding neurons (Figure 8 A and B). Co-stainings for the C vs N terminus 
 
 
Figure 8. Expression of the TRPV1 N-terminal alternative splice isoform VR.5’ sv in the 
hippocampus. A) Immunocytochemistry of mouse hippocampal neurons in vitro. A subset of 
hippocampal neurons expresses high levels of TRPV1. Immunofluorescence signal for the N-T 
TRPV1 antibody (NeuroMab) is absent in TRPV1 KO hippocampal cultures (n=6 of 2 independent 
neuronal cultures) compared to WT (n=6 of 2 independent neuronal cultures). Immunofluorescence 
signal of the C-T TRPV1 antibody (Millipore) observed in WT neurons (n=12 of 4 different neuronal 
cultures) remains in TRPV1 KOs (n=12 of 4 different neuronal cultures) as quantified in (B) (error = 
SEM, significance determined by unpaired Student’s t-test ** p<0.01, *** p<0.001) (scale bar = 20 
µm). B) Fluorescent intensity of high-expressing neurons normalized to that of surrounding neurons 
of a given immunostaining. C) Both the C-T and the N-T TRPV1 antibodies detect mouse 
hippocampal neurons transfected with the TRPV1-EGFP construct. The C-T TRPV1 antibody, but 
not the N-T antibody detects neurons transfected with the VR.5’ sv-RFP construct (scale bar = 20 
µm). D) The C-T TRPV1 antibody does not recognize the highly homologous TRPV2 or TRPV4 
channels, which are highly expressed in a different subset of mouse hippocampal neurons in vitro 





antibodies showed that in these cells, the signal of the N-T antibody observed in 
WT conditions was gone in TRPV1 KO cultures (Figure 8 A and B). Interestingly, 
the C-T-specific immunofluorescence in these neurons was significantly decreased 
in TRPV1KO compared to WT cultures. 
4.2.1. High TRPV1 expressing neurons in the stratum 
oriens  
Similar to ICC, IHC of adult mouse hippocampus using the TRPV1 C-T antibody 
showed that only a small subpopulation of neurons express high levels of TRPV1, 
and such neurons were mainly present in the stratum oriens (Figure 9 A and B). 
Nevertheless, TRPV1-positive neurons are not just restricted to SO. Some of them 
are also present in the CA1, CA2 and CA3 regions. The minority of TRPV1-positive 
neurons were observed in the pyramidal layer and polymorph layer of the dentate 
gyrus. 
 
The localization of high TRPV1-expressing neurons in the SO cells recalled that of 
somatostatin-expressing OLM (oriens lacunosum moleculare) neurons, which are 
long known to be present in that region of the SO (Sik et al., 1995). We found that 
most high TRPV1-expressing neurons also express somatostatin in the SO (Figure 
9 B). 
 
Similar to the observations made in vitro, some neurons in the hippocampus were 
still recognized by the C-T specific TRPV1 antibody in slices of TRPV1 KOs, 
including somatostatin-positive neurons of the SO (Figure 9 C). Nevertheless, the 
number of detected neurons in whole hippocampus was about 40% less in TRPV1 
KO compared to WT mice, as quantified in Figure 9 C–E. Interestingly, when we 
used the N-T antibody (Neuromics) a sharper drop in the number of neurons with 
high TRPV1 expression was observed in KO hippocampus compared to WT. The 
number of neurons with high TRPV1 expression was reduced more than 80% 






Figure 9 TRPV1 is highly expressed in OLM neurons in the hippocampus. A) 
Immunohistochemistry in slices of the mouse hippocampus reveals a subset of neurons with high 
expression of TRPV1, mainly in the stratum oriens (scale bar = 100 µm). B) As showed in vitro, 
somatostatin and reelin (markers of OLM interneurons) co-localize with high TRPV1 expressing 
neurons in the stratum oriens (SO: stratum oriens, SP: stratum pyramidale, SR: stratum radiatum) 
(scale bar = 100 µm). C) Representative area of the CA1 region of a WT and TRPV1 KO 
hippocampus immunostained with the TRPV1 C-T antibody (Millipore), somatostatin and DAPI 
(scale bar = 100 µm). D) Zoom of a high TRPV1 expressing neuron in the stratum oriens in WT and 
the corresponding region in TRPV1 KO hippocampal slices (scale bar = 20µm). E) Quantitation of 
TRPV1 N-T and C-T antibody signal in WT and TRPV1 KO hippocampal slices 
Immunofluorescence of N-T TRPV1 antibody is almost absent in the hippocampus of TRPV1 KO 
animals. In some neurons in TRPV1 KO slices low signal of the C-T antibody remains (possibly 
corresponding to a TRPV1 splice isoform). But the number TRPV1 C-T positive cells is reduced in 
the hippocampus of TRPV1 KOs (Percentages of TRPVI KO normalized to the corresponding WT 
values; n=5 slices each for WT and TRPV1 KO). For B, C and D technical assistance was provided 





First, we thought that possibly the C-T antibody recognized a different TRPV 
channel highly homologous to the TRPV1 channel, but as shown in Figure 8 D we 
found TRPV2 and TRPV4 expressed in different neurons, or at least in cells not 
recognized by the C-T antibody. It is known that other splice isoforms are 
expressed in the hippocampus (e.g. VR.5’ sv), which could also be recognized by 
TRPV1 antibodies. As shown in section 4.1.1, the VR.5’ sv (which has the same C-
T sequence as TRPV1) mRNA is present in WT hippocampus and is significantly 
increased in TRPV1 KO animals. As shown in Figure 8 C, the C-T antibody 
(Millipore) recognized both TRPV1- and VR.5’ sv-transfected hippocampal neurons 
in vitro, yet the N-T antibody (Neuromab) only recognized neurons transfected with 
TRPV1. These results suggest that TRPV1 antibodies at least partially recognize 
other TRPV1 isoforms that could have different physiological properties. 
4.2.2. TRPV1 expression in oriens lacunosum moleculare 
inhibitory interneurons 
As suggested in the section above, high TRPV1 expression occurs in a specific 
neuronal cell-type with delimited localization in the adult hippocampus. In the 
stratum oriens these neurons express somatostatin (a marker for OLM neurons).  
 
We confirmed the inhibitory nature of high TRPV1-expressing neurons by verifying 
their expression of glutamate decarboxylase 65 (GAD 65), an enzyme involved in 
GABA synthesis (Erlander and Tobin, 1991). As shown in Figure 4 A, ICC of rat 
hippocampal neurons in vitro indicates that the vast majority of the total counted 
neurons that express high levels of TRPV1 co-localized with GAD-65, as quantified 
in Figure 10 B. According to a previous study using a TRPV1 reporter mouse 
(Cavanaugh et al., 2011) TRPV1 should be expressed in reelin-positive neurons, 
specifically, in Cajal-Retzius cells, that are known to express reelin (Del Río et al., 
1997). As shown in Figure 10 A and B (in vitro) and Figure 9 B (slices) we 
corroborated that TRPV1 is highly expressed in reelin-containing neurons. In vitro, 





of the reelin-positive neurons were not positive for TRPV1 (Figure 10 B). Of total 
TRPV1 neurons, 62% colocalized with somatostain (Figure 10 B). Interestingly, 
none of the high TRPV1-expressing neurons expressed VIP or Parvalbumin 
(markers for other inhibitory neurons) (Figure 10 B). 
 
Because reelin is an important signaling molecule necessary for the proper 
formation of cortical and hippocampal laminae during both pre- and post-natal 
development (Caviness and Rakic, 1978; Stranahan et al., 2013) and since we 
have found a substantial co-localization of TRPV1 in reelin-expressing neurons we 
inquire if TRPV1 KO animal would have an altered hippocampal and brain barrel 
architecture. Nonetheless we fail to detect any obvious structural alteration in the 
conformation of the brain (Figure 11 A). 
 
 
Figure 10 High TRPV1 expression in a subset of hippocampal inhibitory interneurons in 
vitro. A) Immunocytochemical analysis in rat hippocampal cultures at DIV 12 identifies a 
subpopulation of inhibitory interneurons (GAD65 positive) with elevated TRPV1 channel expression 
which co-express somatostatin and reelin (markers for OLM neurons) but not parvalbumin or VIP. 
B) Quantification of co-localization of immunofluorescence signal of different markers with TRPV1 
neurons in rat hippocampal cell cultures at DIV12; data normalized to the total number of neurons 
counted (considered as 100) for each analysis. C) Inhibitory interneurons expressing high levels of 
TRPV1 have an increased number mGluR7-positive puncta (cells analyzed: TRPV1/VR.5’ sv n=54, 
TRPV1/somatostatin n=62, TRPV1/reelin n= 52, TRPV1/VIP n=22, TRPV1/PV n=26, 
TRPV1/GAD65 n=60, TRPV1/mGluR7 n=22; obtained from 3-6 independent neuronal cultures). 






We found that neurons having increased immunofluorescent signal using the C-T 
antibody in vitro not only expressed reelin but they also were positive for 
somatostatin (Figure 15). In hippocampal slices TRPV1 positive neurons of the SO 
were also expressing somatostatin and reelin (Figure 9 B) indicating that these 
kind of neurons are not Cajal-Retzius cells but they belong to a different population 
of inhibitory interneurons; colocalization of these two markers has been previously 
reported in SO in OLM neurons (Alcántara et al., 1998; Chittajallu et al., 2013). 
Thus, the TRPV1 expressing neurons in SO are most likely OLM interneurons and 
not Cajal-Retzius neurons. 
 
To further test the idea that TRPV1 is expressed in higher levels in OLM neurons 
we performed ICC against the metabotropic glutamate receptor 7 (mGluR7) which 
has been reported to be present in presynaptic terminals innervating OLM neurons 
(Shigemoto et al., 1996, 1997; Tomioka et al., 2014). We found that 80% of 
TRPV1-expressing neurons in vitro had high levels of mGluR7 in terminals 
contacting them, whereas only 10% of neurons expressed exclusively either 






4.3. TRPV1 EXPRESSION IN OLM NEURONS 
MODULATES EXCITATORY SYNAPTIC STRENGTH  
OLM neurons are known to modulate excitatory synaptic transmission through 
GABAergic inhibition of distal dendrite tufts of pyramidal neurons at the Schaffer 
collateral pathway of the CA1 region (Klausberger et al., 2004). It has been just 
recently found that OLM neurons mostly receive excitatory inputs from pyramidal 
neurons of the CA1 region of the hippocampus (Sun et al., 2014). Less is known 
about the inhibitory input to OLM neurons. It has been suggested that OLM 
neurons receive GABAergic innervation from bistratified or trilaminar interneurons 
(Leão et al., 2012), interneuron-specific type III expressing VIP neurons (Acsády et 
 
Figure 11 TRPV1 deficient mice have a normal cortical and hippocampal laminar 
architecture. A) There was no obvious alteration in gross morphology of the adult brain in TRPV1 
KOs compared to WT, assayed by Neurotrace and DAPI staining (scale bar = 1 mm). Technical 





al., 1996; Blasco-Ibáñez and Freund, 1995) and even from other OLM neurons 
populating the CA1 region of the hippocampus (Kogo et al., 2004). 
4.3.1. TRPV1 channel activity influences excitatory pre-
synaptic strength in OLM neurons  
We found that OLM neurons having high TRPV1 expression are highly innervated 
by excitatory synaptic boutons both in vivo (Figure 12 A) and in vitro (Figure 12 B) 
compared to surrounding neurons. OLM neurons growing in vitro also have more 
GABA-positive synaptic terminals contacting them compared to other neurons, 
although this difference is not as extreme the difference in glutamatergic terminals. 
 
Is TRPV1 linked to the augmented excitatory and inhibitory innervation of OLM 
neurons? First we evaluated if in vitro, weak and strong pharmacological activation 
of TRPV1 using either 50 nM or 1 µM capsaicin incubation (ca. 21-24 h) would 
have any influence on presynaptic strength. Immunocytochemically we inspected 
characteristics of excitatory and inhibitory presynaptic strength by monitoring the 
amount of vGluT1 (pre-synaptic excitatory marker) and vGAT (pre-synaptic 
inhibitory marker) puncta number as well as the fluorescent intensity of both 
markers together with the analysis of concomitant signal for Syt1u – an antibody 
against the lumenal domain of synaptotagmin1, which is taken up by recycling 







Analysis of the fluorescence intensity and number of presynaptic marker puncta 
(corresponding to synapses) showed that in control conditions high TRPV1 
expressing neurons had at least twice as the vGluT1 (a marker for excitatory 
synaptic boutons) intensity and puncta number corresponding to synapes, 
compared to surrounding low-expressing TRPV1 neurons (Figure 13 A-E). The 
number of vGluT1-stained excitatory synapses increased upon 50 nM capsaicin 
treatment, and increased even more with a higher concentration of 1 µM capsaicin 
stimulation, while vGluT1 fluorescence intensity in both high and low-expressing 
TRPV1 cells did not change upon capsaicin treatment. Interestingly, 1 µM 
capsaicin also doubled the number of vGluT1 puncta on surrounding neurons 
compared to untreated conditions. However syt1u fluorescence intensity 
decreased in both high and low TRPV1-expressing neurons treated with 1 µM 
capsaicin. When we applied a TRPV1 antagonist, SB-366791, together with 1 µM 
 
Figure 12. Increased excitatory innervation of high TRPV1 expressing OLM neurons. A) 
Representative image of IHC of hippocampal slices of WT and TRPV1 KO mice showing the 
stratum oriens (scale bar = 50 µm). B) High-expressing TRPV1 neurons in hippocampal cell 
cultures have an elevated number of vGluT1 positive puncta, which is reduced in TRPV1 KOs 





capsaicin, the observed effect of capsaicin treatment was reverted. On average, 
treatment with 1 µM SB antagonist reduced both the number and intensity of 
vGluT1 immunostained puncta (Figure 13 A-E).  
 
Figure 13 Post-synaptic TRPV1 promotes excitatory innervation of OLM cells. A) Quadruple 
ICC of rat neurons immunostained for TRPV1, vGluT1, syt1 internalized by recycling synaptic 
vesicles during depolarization, and MAP2 in rat hippocampal cultures in the indicated conditions 
(scale bar = 20 µm). B) ICC of vGluT1 and MAP2 in mouse hippocampal cultures SB-366791 (scale 
bar = 5 µm). C) Quantitation of excitatory synapse number (number of vGluT1-positive puncta) on 
high-expressing TRPV1 hippocampal neurons compared to surrounding cells in the indicated 
conditions. D) Quantitation of vGluT1 intensity (total excitatory synaptic vesicle number) in pre-
synaptic terminals contacting high-expressing TRPV1 or surrounding neurons of rat hippocampal 
cell cultures, in the indicated conditions. E) Quantitation of syt1 uptake in depolarizing conditions 
(total number of recycling excitatory synaptic vesicles) in vGluT1-positive terminals contacting high-
expressing TRPV1 or surrounding neurons, in the indicated conditions (Images: WT Control n=24, 
WT cap. 50nM n=12, WT cap. 1 µM n=9, WT cap. 1 µM + SB 1 µM n=12, WT SB 1 µM n=12, 
TRPV1 KO control n=9, TRPV1 KO cap 1 µM n=9; from 3-8 different neuronal preparations; error 
bar = SEM; significance determined by unpaired Student’s t-test * p<0.05, ** p<0.01, *** p<0.001; 
black asterisks: significant difference between high-expressing and surrounding neurons in each 
condition, blue asterisks: significant difference between conditions for high-expressing TRPV1 cells, 
or between conditions for surrounding cells; fluorescent intensity and synapse number for all 






In control, 50 nM and 1 µM capsaicin conditions, high TRPV1-expressing neurons 
also had more inhibitory synapses than other cells. Unexpectedly, we saw that 1 
µM capsaicin treatment mildly reduced the number of vGAT stained puncta in 
 
Figure 14 Inhibitory innervation of OLM neurons is less affected by post-synaptic TRPV1 
expression. A) Quadruple ICC of rat neurons immunostained for TRPV1, vGAT, syt1 internalized 
by recycling synaptic vesicles during depolarization, and MAP2 in rat hippocampal cultures in the 
indicated conditions (scale bars = 20 µm). B) ICC of vGluT1 and MAP2 in mouse hippocampal 
cultures C) Quantitation of excitatory synapse number (number of vGAT-positive puncta) on high-
expressing TRPV1 hippocampal neurons compared to surrounding cells in the indicated conditions. 
D) Quantitation of vGAT intensity (total excitatory synaptic vesicle number) in presynaptic terminals 
contacting high-expressing TRPV1 or surrounding neurons of rat hippocampal cell cultures, in the 
indicated conditions (scale bars = 5 µm). E) Quantitation of syt1 uptake in depolarizing conditions 
(total number of recycling excitatory synaptic vesicles) in vGAT-positive terminals contacting high-
expressing TRPV1 or surrounding neurons, in the indicated conditions (Images: WT Control n=23, 
WT cap. 50nM n=11, WT cap. 1 µM n=9, WT cap. 1 µM + SB 1 µM n=12, WT SB 1 µM n=12, 
TRPV1 KO control n=9, TRPV1 KO cap 1 µM n=9, images obtained from 3-8 independent neuronal 
cell cultures; error bar = SEM; significance determined by unpaired Student’s t-test * p<0.05, ** 
p<0.01, *** p<0.001; black asterisks: significant difference between high-expressing and 
surrounding neurons in each condition, blue asterisks: significant difference between conditions for 
high-expressing TRPV1 cells, or between conditions for surrounding; fluorescent intensity and 
synapse number for all conditions was normalized to the corresponding average value for 





neurons with lower TRPV1 immunofluorescence (Figure 14 A-E). The SB-366791 
TRPV1 channel blocker reverted the effects of capsaicin by increasing the number 
of vGAT puncta to control levels. Intriguingly, when SB-366791 was applied alone, 
it also increased the number of vGAT-positive puncta only on low TRPV1-
expressing neurons (Figure 14 A-E). 
4.3.2. TRPV1 expression increases excitatory but not 
inhibitory synapse innervation in OLM neurons 
Since we detected that modifying activity of TRPV1 expressed in OLM neurons can 
regulate the formation of excitatory synapses onto OLM neurons we used the 
TRPV1 KO model to confirm the synaptogenic effects of TRPV1 in this subclass of 
interneurons. OLM neurons in TRPV1 KO cultures were identified using 
somatostatin and reelin as markers. Only neurons colocalizing with both markers 
were selected for analysis. Independent measurements in TRPV1 KO vs WT 
mouse hippocampal neurons were also conducted using the TRPV1 C-T antibody 
signal as a marker (which remained in TRPV1 KO animals) (see section 4.3.1). 
 
OLM neurons had on average twice as many vGluT1 synapses as surrounding 
neurons in WT conditions (Figure 15 A-B) Impressively, we found that the number 
of excitatory terminals forming onto OLM neurons was drastically reduced (by 3 
times) in TRPV1 KO cultures compared to WT. The decrease was so pronounced 
that we could not find a significant difference in the number of excitatory synapses 
on OLM neurons vs non-OLM neurons (Figure 15 A-B). As shown for rat cultures 
(Figure 13 B-E), 1 µM capsaicin doubled the number of glutamatergic inputs onto 
OLM neurons in WT hippocampal cultures (Figure 15 A-B). The effects of 1 µM 
capsaicin on excitatory synapse number were absent in TRPV1 KO OLM neurons 
(identified with somatostatin and reelin) (Figure 15 A and B). In general, the same 
results were observed when using the C-T antibody signal as a marker for 







Figure 15. TRPV1 promotes excitatory innervation of OLM neurons. A) Quadruple ICC of 
DIV12-13 WT and TRPV1 KO hippocampal neurons shows that OLM neurons co-expressing 
somatostatin and reelin have increased excitatory innervation (vGluT1 signal) compared to 
surrounding cells (quantified in B). Neuronal processes are shown by MAP2 staining. TRPV1 KO 
neurons have a dramatic reduction in excitatory innervation, compared to WT. 1 µM capsaicin 
treatment increased the number of vGluT1-positive synapse in WT neurons (n=20 images for all 
conditions) C) Quadruple ICC of mouse hippocampal cell cultures for vGAT, to mark inhibitory 
synapses, reelin, somatostatin, and MAP2. No difference was observed in the number of inhibitory 
synapses in WT and TRPVI KO neuronal cultures. Inhibitory synapse number is not influenced by 1 
µM capsaicin treatment, quantified in (D) Although OLM neurons tend to have slightly more vGAT-
positive synapse, the difference is minor. (n=20 images for all conditions of 2 independent neuronal 
cell culture dissection; error bar = SEM, statistical significance determined by Student’s unpaired t-
test, * p<0.05, ** p<0.01, *** p<0.001; values fluorescent intensity for all conditions normalized to 






We found that TRPV1 acts as a synaptogenic regulator of excitatory synapses, but 
TRPV1 activation, blockade or removal did not significantly affect the amount of 
inhibitory synapses on OLM interneurons. OLM neurons in TRPV1 KO cultures had 
the same amount of vGAT-stained synapses as WT neurons, and the number of 
VGAT-positive synapses in these neurons was not altered by 1 µM capsaicin 
treatment (Figure 15 B-C).  
 
These results reflect previously unknown synaptogenic properties of TRPV1 in 
OLM neurons, which may affect synaptic plasticity coordinated by inhibitory 
interneurons in the SO.  
4.4. HETEROLOGOUS TRPV1 OVEREXPRESSION 
INCREASES EXCITATORY INNERVATION 
To determine if TRPV1 can promote excitatory synapse formation in cells that don’t 
normally express it at high levels, DIV2 hippocampal neurons were transfected with 
TRPV1 expressed under the β-actin promoter to express TRPV1 during 
synaptogenesis in vitro and validate if overexpression of TRPV1 would affect 
synapse formation. It is important to note that TRPV1 is expressed at E18 when 
embryonic rat hippocampal preparation was conducted (Figure 6 C). Neurons were 
fixed at DIV 12-13, that is 10-11 days after transfection. 
4.4.1. TRPV1 overexpression at DIV2 in hippocampal 
neurons increases excitatory innervation 
Low efficiency transfection of TRPV1 channel at DIV2 and overexpression for 10 
days caused an increase in the number of glutamatergic terminals contacting 
transfected neurons. Not only the number of excitatory terminals was increased, 





immunofluorescence signal (Figure 16 A-D). We corroborated this effect by 
measuring mEPSC amplitude and frequency in TRPV1-transfected neurons, where 
the frequency (thought to correspond to an increase in synapse number or synaptic 
vesicle release probability) and not the amplitude was higher than in EGFP 
transfected neurons (Figure 16 E). Blockade of the channel at DIV4 reverted the 
effects of TRPV1 overexpression on glutamatergic pre-synaptic strength (i.e. 
number of synapses, vGluT1 and syt1u fluorescence intensity) to levels similar to 
EGFP transfected neurons (Figure 16 A-D). 
 
When TRPV1 and VR.5’ sv were co-transfected at DIV2 this also caused an 
increase in the number (and syt1u intensity) of vGluT1-positive synapses 
contacting the transfected neuron (Figure 16 F-I). The increase in excitatory 
synapse number induced by TRPV1/VR.5’ sv co-transfection was similar to that 
observed when TRPV1 was transfected alone. The number and strength of 
excitatory synapses terminating on neurons transfected with VR.5’ sv only were not 
significantly changed compared to control transfections (Figure 16 F-I).  
 
Unexpectedly, heterologous expression of TRPV1 in cultured hippocampal 
neurons before synapse formation also had significant effect on GABAergic pre-
synaptic strength by decreasing both the average fluorescent intensity of vGAT 
immunostained synapses and of the corresponding syt1u signal (Figure 17 A-C). 
The number of inhibitory inputs formed on the transfected neurons remained 
unchanged (Figure 17 D). The frequency and amplitude of mIPSCs in TRPV1 
transfected neurons were similar to EGFP-transfected control neurons (Figure 17 
E). Treatment of TRPV1 transfected neurons with SB at DIV4 decreased the 
average intensity of vGAT-positive puncta and reverted the effects observed in the 








Figure 16. TRPV1 and TRPV1/VR.5’ sv overexpression in neurons increases excitatory 
innervation. A) Triple ICC for vGluT1 and syt1u of rat hippocampal neurons transfected with 
TRPV1-IRES-GFP or EGFP before synapse formation on DIV2 (scale bars = 10 µm). B) 
Quantitation of the excitatory synaptic strength, assayed by vGluT1 signal and overlapping syt1u 
fluorescence intensity (C) D) Quantitation of excitatory synapse number (number of vGluT1 puncta) 
on TRPV1-expressing cells with and without treatment with SB-366791 compared to EGFP 
(Images: EGFP; n=60, TRPV1; n=30, TRPV1 + SB-366791; n=15; images obtained from 5-20 
different neuronal cultures; all values normalized to the average value obtained for EGFP 
transfected neurons). E) TRPV1-overexpressing neurons have increased mEPSC frequency 
compared to control EGFP–expressing neurons, and amplitude remained unchanged, consistent 
with an increase in synapse number in TRPV1-overexpressing neurons (cells: EGFP n=29, TRPV1 
DIV2 n=27). F) Triple ICC for vGluT1 and syt1u of rat hippocampal neurons transfected with 
TRPV1/VR.5’ sv, VR.5’ sv or EGFP before synapse formation on DIV2 (svale bars = 10 µm) G) 
Quantitation of excitatory synapse number, excitatory synaptic strength, assayed by vGluT1 signal 
(H) and overlapping syt1u fluorescence intensity (I) (Images: EGFP n=15-21, TRPV1 DIV2 n=11-
15, TRPV1/VR.5’ sv DIV2 n=12-15, VR.5’ sv DIV2 n=10-13; images obtained from 4-7 different cell 
culture preparation; error = SEM; significance determined by Student’s unpaired t-test * p<0.05, ** 
p<0.01, *** p<0.001; all values normalized to the average value obtained for EGFP transfected 







Figure 17. TRPV1/VR.5’ sv overexpression in neurons decreases inhibitory innervation. A) 
ICC for vGAT and syt1u of rat hippocampal neurons transfected with TRPV1-IRES-GFP or EGFP 
before synapse formation on DIV2 (scale bars = 10 µm). B) Quantitation of the excitatory synaptic 
strength, assayed by vGluT1 signal and overlapping syt1u fluorescence intensity (C) D) 
Quantitation of inhibitory synapse number (number of vGAT puncta) on TRPV1-expressing cells 
with and without treatment with SB-366791 compared to EGFP (Images: EGFP n=60, TRPV1 DIV2 
n=27, TRPV1 DIV2 + SB-366791 1 µM DIV4 n=15; images taken from 5-20 different neuronal cell 
cultures; synapse number for all conditions was normalized to the corresponding average value for 
surrounding neurons in WT cell cultures). E) TRPV1-overexpressing neurons have no change in 
mIPSC frequency or amplitude, compared to control EGFP–expressing neurons (cells: EGFP n=27, 
TRPV1 DIV2 n=24). F) Triple ICC for vGAT and syt1u of hippocampal neurons transfected with 
TRPV1/VR.5’ sv, VR.5’ sv and EGFP before synapse formation on DIV2 (scale bars = 10 µm). G) 
Quantitation of inhibitory synapse number, excitatory synaptic strength, assayed by vGAT signal (H) 
and overlapping syt1u fluorescence intensity (I) (Images: EGFP n=12-15, TRPV1 DIV2 n=12-15, 
TRPV1/VR.5’ sv DIV2 n=9-12, VR.5’ sv DIV2 n=9-11; images taken from 3-5 independent cell 
cultures; error = SEM; significance determined by unpaired Student’s t-test * p<0.05, ** p<0.01, *** 
p<0.001; synapse number for all conditions was normalized to the corresponding average value for 
surrounding neurons in WT cell cultures). Immunostainings for F and analysis for G, H and I 





When TRPV1 and VR.5’ sv were co-transfected at DIV2 this caused a decrease in 
the number vGAT synapses contacting transfected neurons (Figure 17 F and G). 
The number and strength of inhibitory synapses terminating on neurons 
transfected with VR.5’ sv only were not significantly changed compared to control 
transfections (Figure 17 F-I). 
4.5. TRPV1 EFFECTS ON SCHAFFER COLLATERAL LTP 
AND LTD  
4.5.1. TRPV1 does not affect LTD in the Schaffer 
collateral pathway of the CA1 region of hippocampus 
Previous studies have shown that TRPV1 activation is involved in changes in LTD 
induction in the nucleus accumbens (Grueter et al., 2010), dentate gyrus (Chávez 
et al., 2010) and in LTD modulation at excitatory synapses onto CA1 interneurons 
in the hippocampus (Gibson et al., 2008), which is absent in TRPV1 KO animals 
(Brown et al., 2013). In field recordings in the Schaffer collateral pathway we did 
not find any change in the induction of LTD in TRPV1 KO animals compared to 
hippocampal slices of WT mice (Figure 19 A). 
4.5.2. TRPV1-induced innervation of OLM neurons is 
necessary for gating of CA3 hippocampal information  
Nicotine is known to gate and promote the induction of LTP in the Schaffer 
collateral pathway through activation of the highly specific nicotinic acetylcholine 
receptor α2 subunit (nAChr2) (Fujii et al., 1999; Nakauchi et al., 2007a). Just 
recently, it has been reported that only OLM neurons express such receptor 





pathway is mediated through an OLM-dependent disinhibitory mechanism (Leão et 
al., 2012).  
 
 
We tested if TRPV1 would have an effect in the LTP mechanism of the Schaffer 
collateral pathway by inducing LTP using a 1XTET LTP induction in acute WT and 
TRPV1 KO hippocampal slices.  
 
Interestingly, a 1 TET protocol resulted in a significant decrease in LTP in the 
Schaffer collateral pathway in recordings from TRPV1 KO compared to WT (Figure 
19 B). This suggested that TRPV1 plays a role in normal hippocampal functioning 
and plasticity. 
 
TRPV1-KOs have a dramatic reduction in excitatory innervation of OLM neurons, 
which we hypothesized would result in decreased disinhibition of the SC pathway 
and the reduced LTP that we, and others (Marsch et al., 2007), have observed. If 
this is the case, we hypothesized that activation of TRPV1 channels in OLM cells 
with nicotine would bypass the innervation defects in OLM cells in TRPV1 KOs and 
 
Figure 18. OLM neurons gate synaptic plasticity in the Schaffer collateral. A) Scheme of 
putative connections of a TRPV1-expressing OLM cell in the stratum oriens. OLM cells inhibit the 
temporoammonic (TA) pathway from the entorhinal cortex, and dis-inhibit the Schaffer collateral 
pathway from the CA3 region, thus promoting CA3 input, and reducing EC input, to CA1 pyramidal 
cells. If excitatory innervation in TRPV1-lacking OLM cells is reduced, inhibition of the TA pathway 
would be weakened, and dis-inhibition of the Schaffer collateral pathway would be weakend, i.e. 
TRPV1 KOs would increase inhibition in the Schaffer collateral pathway resulting in decreased 
Schaffer collateral LTP. B) Illustration of stimulating and recording electrode positions for LTP and 





rescue the LTP deficits. Indeed, when we treated TRPV1 KO slices with 5 µM 
nicotine prior and during the recordings we found a rescue of LTP to levels similar 
to WT slices treated with and without nicotine (Figure 19 C). 
 
 
Figure 19. TRPV1 KOs show reduced Schaffer collateral LTP that is rescued by nicotine 
treatment. A) LTD induced by low-frequency stimulation of the Schaffer collateral pathway is 
unchanged in TRPV1 KOs. B) LTP induced by 1XTET-LTP in the Schaffer collateral is reduced in 
TRPV1 KOs compared WT. C) As in (B), LTP in the Schaffer collateral pathway is significantly 
reduced in TRPV1 KOs and is restored to WT levels by 5 µM nicotine treatment 20 minutes before 





4.6. REGULATION OF TRPV1 EXPRESSION IN 
HIPPOCAMPAL NEURONS IN VITRO 
In the PNS, TRPV1 plays a pivotal role in the perception of noxious stimuli such as 
pain, heat, acidity and pungent agents such as capsaicin (Caterina et al., 1997, 
2000). Diverse exogenous and endogenous factors have been reported to activate, 
sensitize, desensitize, block and regulate expression of TRPV1, especially during 
nociception. For instance upregulation of TRPV1 expression has been proposed to 
occur during nerve injury (Hudson et al., 2001), hyperalgesia (Davis et al., 2000; 
Miranda et al., 2007) and inflammatory pain (Ji et al., 2002; Luo et al., 2004; 
Schicho et al., 2004; Schwartz et al., 2013). In the model of inflammatory pain, 
NGF has arisen as an important mediator (Ji et al., 2002) that upregulates TRPV1 
expression (Anand et al., 2006; Winston et al., 2001) and trans-location into the 
plasma membrane (Zhang et al., 2005) of afferent neurons. In the CNS, particularly 
in the hippocampus just a few studies have pointed out that TRPV1 expression is 
increased in patients with mesial temporal lobe epilepsy (Sun et al., 2012) and 
after seizures in rat models for temporal lobe epilepsy (Bhaskaran and Smith, 
2010). A more recent study found that mRNA levels of TRPV1 (together with 
receptors of the endocannabinoid system) were increased in brain and 









4.7. NGF UPREGULATES TRPV1 EXPRESSION IN 
HIPPOCAMPAL NEURONS 
4.7.1. NGF increases TRPV1 expression in hippocampal 
neurons in vitro 
As mentioned above, NGF is known to increase TRPV1 expression in afferent 
neurons (i.e. from the dorsal root ganglia). We were interested to compare if 
TRPV1 expression in young (DIV2-5) and mature (DIV12-13) hippocampal neurons 
could be modified by NGF. We incubated hippocampal neurons with 1 ng/ml NGF 
for 21-24 h and then measured TRPV1 expression using ICC and WB. 
 
As shown in Figure 20 C and D NGF treatment of cultured rat hippocampal 
neurons caused an increase in the fluorescence intensity of C-T TRPV1 antibody 
signal in cultures both before and after the main period of synaptogenesis. The 
increase in TRPV1 expression was more pronounced in mature (DIV12-13) than in 
young (DIV2-5) cell cultures. To further verify the NGF-induced increase in TRPV1 
expression we quantified protein expression signal detected by the N-T TRPV1 
antibody by WB. The changes we observed by ICC were corroborated with WB for 







4.7.2. High expression of TRPV1 in OLM neurons is driven 
by NGF  
NGF has long been reported to be expressed in brain and hippocampus (Gall and 
Isackson, 1989; Korsching et al., 1985). In the hippocampus NGF has been 
 
Figure 20. NGF promotes expression of TRPV1 in hippocampal neurons. A) ICC of rat 
hippocampal cell cultures for TRPV1 and NGF. NGF is highly expressed in somas of high-
expressing TRPV1 hippocampal neurons, compared to surrounding neurons, quantified in (B) 
(values of fluorescence intensity of NGF in high-expressing nerons normalized to the average value 
of surrounding neurons (considered as 1); n=15 images from 3 different neuronal cutures). C) 
Treatment of hippocampal neurons with 1 ng/ml NGF at DIV12-13 overnight increases TRPV1 
expression assayed by immunostaining, quantified in (D); Control n=26, NGF n=12; images 
obtained from 4-9 independent neuronal cultures; error = SEM; significance determined by unpaired 
Student’s t-test * p<0.05, ** p<0.01, *** p<0.001 and confirmed by Western blot (E); 3 repetitions 
are shown. F) TRPV1 transfection at DIV2 does not increase NGF expression in hippocampal 
neurons immunostained at DIV 12-13; n=6 images from 2 independent neuronal cultures. Scale 
bars = 20 µM. Experiments and immunostainings for C and analysis for D done in collaboration with 





observed in subsets of inhibitory interneurons in multiple regions including neurons 
in the SO (Bizon et al., 1999; Pascual et al., 1998) that receive axonal projections 
from cholinergic septohippocampal neurons (Rocamora et al., 1996), i.e. OLM 
neurons, where we see high levels of TRPV1. Thus it is possible that NGF could 
drive TRPV1 expression in OLM neurons, since it is known that expression of 
TRPV1 in DRGs is regulated by NGF (Ernsberger, 2009). NGF has also been 
reported to be present in inhibitory neurons expressing TRPV1 in the human 
hippocampus (Sun et al., 2012) and to be necessary for proper maintenance of 
TRPV1 expression levels in nociceptors (Luo et al., 2007). 
 
As shown in Figure 20 A high TRPV1-expressing OLM neurons also expressed 
high levels of NGF. Quantitation of immunofluorescence signal of NGF in high 
TRPV1 expressing neurons showed that NGF was always higher in these neurons 
than in surrounding neurons with lower TRPV1 levels (Figure 20 B). TRPV1 and 
NGF are increased by the same amount in OLM neurons, possibly suggesting that 
the magnitude of TRPV1 expression directly depends on the amount of NGF 
expressed. 
 
To assess the opposite scenario, if high TRPV1 expression would concomitantly 
upregulate the expression of NGF, we transfected hippocampal neurons in vitro at 
DIV12, but as shown in Figure 20 F, TRPV1 overexpression in hippocampal 
neurons could not initiate NGF expression in any of the transfected cells. 
 
In summary, these results show evidence that NGF can upregulate TRPV1 
expression in most hippocampal neurons in early and late developmental stages in 
vitro. In a subset of hippocampal inhibitory interneurons, NGF is highly expressed 
and these neurons also have high levels of TRPV1. TRPV1 expression alone does 





4.8. TRPV1 UPREGULATION UPON NEURONAL 
ACTIVATION: A LINK BETWEEN TRPV1 AND BDNF 
In DRG, BDNF is known to be expressed in a population of small- to medium-sized 
sensory neurons (Barakat-Walter, 1996; Merighi et al., 2008; Obata and Noguchi, 
2006; Wetmore and Olson, 1995) including a population of TRPV1-positive cells 
(Xia et al., 2012) and NGF-responsive neurons (Apfel et al., 1996; Michael et al., 
1997). BDNF has been associated with neuro-inflammatory pain (Xia et al., 2012; 
Zhao et al., 2006), hyperalgesia (Groth and Aanonsen, 2002), neuropathic pain 
(Fukuoka et al., 2001; Khan and Smith, 2015; Obata and Noguchi, 2006) and 
inflammation (Cho et al., 1997a, 1997b). In neurons from the DRG, NGF, besides 
driving TRPV1 expression (as mentioned in the last section) can also regulate 
expression of BDNF (Apfel et al., 1996; Merighi et al., 2008; Michael et al., 1997). 
Similar to TRPV1, corresponding with the fact that BDNF is jointly upregulated 
during inflammation (Cho et al., 1997a, 1997b), axotomy (Michael et al., 1997; 
Tonra et al., 1998), hyperalgesia (Yajima et al., 2002) and neuro-inflammatory pain 
(Xia et al., 2012). In the neuronal pain model, BDNF is known for its pronociceptive 
properties (reviewed in Khan and Smith, 2015) possibly by decreasing 
desensitization of TRPV1 channels (Ciobanu et al., 2009; Obata and Noguchi, 
2006). Activation of TRPV1 on the other hand has been reported to cause an 
increase in BDNF release (Lever et al., 2001). Although one study suggested that 
BDNF increases TRPV1 expression in DRG cells (Ciobanu et al., 2009), the 
potential control of TRPV1 expression by BDNF remains uncertain (Price et al., 
2005). In the hippocampus, to our knowledge, there has not been any study linking 









4.8.1. TRPV1 overexpression increases BDNF 
 
Figure 21. High TRPV1 expression correlates with increased BDNF levels in hippocampal 
neurons. A) ICC of rat hippocampal cell cultures immunostained with TRPV1 and BDNF. B) High 
TRPV1 expressing neurons have twice as much BDNF signal as surrounding neurons (values for 
high TRPV1-expressing neurons normalized to the average fluorescent intensity of neurons 
surrounding it; n=24 images). C) High-expressing TRPV1 mouse neurons have increased BDNF on 
neuronal processes (quantified in D, left panel, as the number of BDNF-positive puncta/ µm), 
compared to TRPV1 knockout neurons, identified by the remaining signal from the C-terminus 
TRPV1 antibody (Millipore). The BDNF signal intensity of analyzed puncta was 50% lower in 
TRPV1 KO neurons compared to WT (D, right panel) (WT and TRPV1 KO n=9). E) Transfection on 
DIV2 with TRPV1 increases BDNF in transfected neurons immunostained at DIV14. This increase 
in BDNF is blocked by 1 µM SB treatment at DIV4 and DIV10 (EGFP n=18, TRPV1 DIV2 n=21, 
TRPV1 DIV2 + SB 1 µM DIV4 n=9, TRPV1 DIV2 + SB 1 µM DIV10 n=12; images taken from 3-7 
independent neuronal cell cultures; error = SEM; significance determined by Student’s unpaired t-





Activation of TRPV1 channels overexpressed in hippocampal neurons could 
potentially lead to hyperactivity of the transfected neuron. Therefore, we were 
interested if TRPV1 transfection in hippocampal neurons at DIV2 and DIV10 would 
lead to an increase in neuronal activity that was detected using antibodies against 
BDNF, which is known to be upregulated by neuronal activity (Patterson et al., 
1992; Zafra et al., 1990). As shown in Figure 21 E, when TRPV1 was transfected 
before the main period of synaptogenesis, an increase in the detected signal for 
BDNF was observed when compared to surrounding cells and to EGFP transfected 
neurons. When we treated transfected neurons with the TRPV1-specific antagonist 
SB either two or eight days after transfection, the BDNF augmentation was 
reverted, suggesting that TRPV1 overexpression and activation account for a rise 
in neuronal activity and an increase in BDNF (Figure 21 E; right panel). 
4.8.2. High TRPV1-expressing neurons have increased 
BDNF expression 
When we found that a population of hippocampal inhibitory interneurons highly 
expresses the TRPV1 channel, we were interested if this neuron population would 
have augmented levels of BDNF, as TRPV1-transfected neurons do. As depicted 
in Figure 21 A and B, hippocampal neurons in vitro with increased TRPV1 
expression showed, on average, greater levels of BDNF expression compared to 
lower-expressing TRPV1 neurons. To test if TRPV1 correlates with a rise in BDNF 
expression, we compared OLM neurons from mouse WT vs TRPV1 KO cell 
cultures. Interestingly, the detection pattern obtained by the BDNF antibody in 
mouse cultures was different than in rat cultures. While in rat cultures the 
localization of BDNF was somatic, in mouse cultures the detected signal was 
punctate, distributed in what appear to be terminals contacting the high TRPV1-
expressing neuron (Figure 21 C and D). On average, the quantitation showed that 
in TRPV1 KO conditions (where TRPV1-expressing neurons are detected by low 
signal from the C-T antibody) this subpopulation of neurons had significantly less 





4.8.3. Elevated neuronal activity increases both TRPV1 
and BDNF levels 
As mentioned before, neuronal activity drives expression of BDNF, and in the PNS 
TRPV1 and BDNF expression are often upregulated under similar conditions. We 
aimed to detect if TRPV1, like BDNF, would also be upregulated after an elevation 
in neuronal activity. We used 50 µM forskolin in order to raise cAMP levels and 
subsequent neuronal activity in cultured hippocampal neurons. As expected, 50 µM 
forskolin boosted BDNF and cFos levels when applied to DIV3 as well as to DIV10 
rat hippocampal cultures (Figure 22 and Figure 23). Fluorescence intensity of the 
TRPV1 C-T antibody was concomitantly higher in samples treated with forskolin. 
 
Figure 22. TRPV1 expression is increased by neuronal activity in hippocampal neurons. A) 
ICC of TRPV1, BDNF, and c-fos at DIV3 ; 50 µM forskolin treatment overnight increases TRPV1, 
BDNF and cFos signal (scale bar = 20 µm), quantified in (B) (control n= 20, forskolin n=15 images 
acquired from 5-7 separate neuronal cultures; error = SEM; significance determined by unpaired 





Contrary to these results, quantified TRPV1 protein levels detected with the TRPV1 
N-T antibody by WB remained unchanged upon 50 µM forskolin treatment. 
 
When we used 10 µM bicuculline as an alternative way to raise neuronal activity by 
blocking GABAa receptors, hence increasing excitation, in DIV10 cultured 
hippocampal neurons, we found that BDNF, cFos as well as the TRPV1 
fluorescence signal was higher than in untreated samples (Figure 23). 
Nevertheless, the elevation of these three markers was not as widespread as in 
forskolin treatments, where it was observed in most of the analyzed cells (Figure 
22 for DIV3 and Figure 23 for DIV10). In the presence of bicuculline some cells had 
a brighter immunofluorescence signal than others. The expected change in protein 
levels for TRPV1 was, however, not able to be detected with WB (data not shown). 
 
Together, these results suggest that an increase in neuronal activity (revealed by 
an elevation in BDNF and cFos) ultimately led to an increase in levels of TRPV1 
detected by immunofluorescence. TRPV1 endogenous expression or 
overexpression was correlated with BDNF suggesting that TRPV1 activation can 
increase neuronal activity. Still it remains uncertain how upregulation of TRPV1 
after the induction of neuronal network activity occurs and if changes in TRPV1 








Figure 23. TRPV1 expression is increased by neuronal activity in hippocampal neurons. A) 
ICC of TRPV1, BDNF, and c-fos at DIV13 ; 50 µM forskolin or 10 µM bicuculline treatment overnight 
increases TRPV1, BDNF and cFos signal (scale bar = 20 µm), quantified in (B) (control n=24, 
forskolin n=19, bicuculline n=20; images acquired from 5-8 separate neuronal cultures; error = 
SEM; significance determined by unpaired Student’s t-test * p<0.05, ** p<0.01, *** p<0.001). 






4.9. DOES BDNF INCREASE EXCITATORY INNERVATION 
UPON HIGH TRPV1 EXPRESSION? 
Since the early nineties, there has been increasing evidence that neuronal activity 
has a pivotal role in synaptic transmission that can ultimately lead to changes in 
the number and strength of synapses (Bliss and Collingridge, 1993; Linden, 1994; 
Malenka and Nicoll, 1999). Neuronal activity also promotes BDNF expression and 
secretion (Patterson et al., 1992; Zafra et al., 1990) especially at synapses where it 
contributes to an enhancement in synaptic transmission (Bonhoeffer, 1996; Katz 
and Shatz, 1996; Thoenen, 1995). In excitatory synapses BDNF release can also 
occur from the post- to the pre-synaptic part, thus serving as a retrograde 
messenger modulating pre-synaptic neurotransmitter release (Hartmann, 2001; 
Matsuda et al., 2009). This background allowed us to hypothesize that if high 
TRPV1 expressing neurons are positive for concomitant high levels of BDNF, this 
neurotrophin could be acting as a retrograde messenger provoking the proliferation 
of excitatory innervation terminating on high TRPV1-expressing neurons and 
TRPV1-transfected hippocampal neurons at DIV2. 
4.9.1. BDNF controls excitatory presynaptic strength but 
not excitatory innervation to TRPV1 transfected neurons. 
As documented in section 4.4, heterologous TRPV1 expression on DIV2 leads to 
an increase in vGluT1 antibody signal (and co-localizing Sy1u fluorescence 
intensity) as wells as in excitatory synapse number contacting TRPV1-
overexpressing neurons (Figure 16). TRPV1 overexpression at DIV2 enhances 
neuronal activity (indicated by BDNF levels), but BDNF could differentially alter 
synaptic strength depending on the day at which TRPV1 was transfected. Using 
the BDNF TrKB-IgG scavenger to prevent secreted BDNF from reaching 
endogenous TrkB receptors, we tested if changes in excitatory presynaptic 









Figure 24. TRPV1 overexpression in neurons increases excitatory innervation through a 
BDNF-independent mechanism. A) Triple ICC for vGluT1 and syt1u of rat hippocampal neurons 
transfected with TRPV1-IRES-GFP or EGFP before synapse formation on DIV2. B) Quantitation of 
the excitatory synaptic strength, assayed by vGluT1 signal and overlapping syt1u fluorescence 
intensity (C) D) Quantitation of excitatory synapse number (number of vGluT1 puncta) on TRPV1-
expressing cells with and without treatment with 100ng/ml TrKB-IgG at DIV3 compared to EGFP 
(Images: EGFP; n=60, TRPV1; n=30, TRPV1 + TrKB-IgG; n=12 images obtained from 4-20 
different neuronal cultures; all values normalized to the average value obtained for EGFP 
transfected neurons; error = SEM; significance determined by Student’s unpaired t-test * p<0.05, ** 







Neurons overexpressing TRPV1 at DIV2 were treated with 100ng/ml TrkB-IgG 
scavenger at DIV3 and incubated for 10 days before fixation. The observed effects 
of TRPV1 overexpression on excitatory presynaptic strength, identified by the 
amount of fluorescent signal of Syt1u on vGluT1 stained synaptic boutons, was 
reverted to a level similar to EGFP-transfected control neurons (Figure 24 A and 
C). On the other hand, the TrkB-IgG scavenger did not prevent the formation of 
excess excitatory synapses onto TRPV1 transfected neurons; quite the contrary, it 
tended to slightly increase the quantity of glutamatergic synapses (Figure 24 A and 
D). 
4.9.2. BDNF does not regulate excitatory or inhibitory 
innervation in OLM neurons 
As mentioned in section 4.3, in hippocampal neuronal cultures, neurons highly 
expressing TRPV1, most likely corresponding to OLM neurons had higher BDNF 
levels compared to other neurons. We also found that BDNF produced changes in 
glutamate release caused by early TRPV1 overexpression. In addition BDNF has 
been postulated to be released from post-synaptic regions in order to retrogradely 
regulate pre-synaptic strength (see section 2.7.2). Therefore it is imaginable that 
BDNF could be responsible for changes observed in pre-synaptic strength of 
excitatory synapses onto OLM neurons. To test this we added 100ng/ml TrkB-IgG 
scavenger to hippocampal neuronal rat cultures at DIV2 and fixed them at DIV13 
for imaging. As shown in Figure 25 we did not see any changes in the number of 
individual glutamatergic inputs positive for vGluT1 nor in the average fluorescence 
intensity of vGluT1 puncta in OLM neurons in TrkB-IgG treated cell cultures 







4.10. TRPV1 REPORTER MOUSE  
4.10.1. The cre-lox P system  
The mechanism of gene expression in the coliphage P1 known as the cre-lox P 
system basically consists of the recombinase enzyme cre that will only catalyze  
homologous recombination at a 34 bp DNA sequence known as lox P (Abremski 
and Hoess, 1984; Hoess et al., 1982; Sauer, 1987; Sauer and Henderson, 1988; 
 
 
Figure 25. BDNF is not required for increased excitatory and inhibitory innervation of high 
TRPV1 expressing neurons. A) ICC of DIV14 rat neurons for TRPV1, vGluT1 and MAP2, or with 
TRPV1, vGAT and MAP2 (C). Treatment with 100ng/ml TrkB-IgG scavenger at DIV 2 (fixed DIV13) 
did not significantly alter the number or intensity of of vGluT1 (B) or VGAT (D) positive terminals 
contacting neurons highly expressing TRPV1 (n=12 images each for vGluT1 and vGAT in control 
and TrKB-IgG treated cells of 3 different neuronal cultures ; error = SEM; significance determined 





Sternberg and Hamilton, 1981). Hence this system would allow a “sequence-
specific” recombination of a region of interest flanked by lox P. This genetic tool 
has made possible the generation of animal models carrying these sequences at 
specific sites in their genome, which permits control of conditional (cre dependent) 
targeting of specific gene sequences (lox P flanking) (Orban et al., 1992), thus 
allowing spatial and temporal modifications of the expression of a desired gene. 
 
Ideally the cre sequence would be present downstream of the sequence of a 
desired gene, the expression of which will be controlled by its intrinsic promoter, 
whereas the sequence to be modified should be flanked by lox P. Depending on 
the orientation and position in the chromosome of the lox P sequence, the resulting 
modification could lead to a “knock out” or deletion, translocation or inversion of the 
target gene (Bouabe and Okkenhaug, 2013; Gu et al., 1994; Orban et al., 1992). 
 
Using cre-lox P mouse lines, the creation of cell-specific as well as developmental-
timed reporter mouse lines have become easily accessible. Unlike conventional 
knock in reporter mice, the flexibility of this system allows the generation of multiple 
mutants using a single cre or lox P line. To date there is already an extensive list of 
mouse lines for different promoters driving cre expression as well as of targeted 
floxed DNA sequences. A large database of cre and lox P transgenic mice have 
recently become available (reviewed in Bouabe and Okkenhaug, 2013). 
 
Because of the wide variety of neuronal cell types in the brain, in neurobiology one 
of the purposes for using these lines is to generate reporter mice for specific 
neuronal populations. This can be achieved by crossing cre lines targeting proteins 
that are expressed in confined cellular populations with lox P lines that would allow 
the expression of reporter fluorescent molecules upon cre activity (reviewed in 
(Abe and Fujimori, 2013). 
 
Despite the progress achieved using this system and the large number of specific 





unwanted issues and limitations that could occur if certain considerations are not 
attended to during the generation of a cre-lox P line (Heffner et al., 2012; Matthaei, 
2007; Schmidt-Supprian and Rajewsky, 2007). Some transgenic mouse strains 
have been reported to have a number of unexpected or undesired phenotypes that 
were not initially evident (Balordi and Fishell, 2007; Eckardt et al., 2004; Heffner et 
al., 2012; Kobayashi and Hensch, 2013; Lu et al., 2008; Means et al., 2005; Pilon 
et al., 2008; Weng et al., 2008). Thus it is recommended that results obtained 
using this system need to be carefully controlled, and it is of paramount importance 
that each research group characterizes the transgenic model themselves in order 
to avoid possible unknown latent side effects of any employed strain. 
4.10.2. The TRPV1-tdTomato reporter mouse line 
As mentioned in section 4.2 we were interested in localizing the expression of 
TRPV1 in the hippocampus. We used various methods to conclude that functional 
TRPV1 channels are expressed in hippocampal neurons. By using immunohisto- 
and cyto-chemical assays we found TRPV1 protein expression in the hippocampus 
of adult mice is confined to a subset of inhibitory interneurons in the stratum oriens; 
immunolabeling against different neuronal markers allowed us to determine that 
such neurons corresponded to OLM neurons.  
 
Despite the extensive use of immunohisto- and cyto-chemistry for the cellular and 
subcellular localization of a myriad of cell-specific proteins, this method is known to 
have limitations including non-specific staining, that can ultimately lead to 
unreliable results and misinterpretation (de Matos et al., 2010; Ward and Rehg, 
2014; Yaziji and Barry, 2006). Such limitations can be tackled by the use of a 
reporter mouse strain to induce the conditional expression of a reporter gene (e.g. 
tdTomato) driven by a specific promoter. In an attempt to identify the expression 
pattern of TRPV1 in the hippocampus a TRPV1-cre mouse line has been recently 





concluded that in the hippocampus TRPV1 expression is restricted exclusively to 
Cajal-Retzius cells expressing reelin.  
 
To corroborate this result and our findings using immune-histochemical procedures 
we bred a transgenic reporter mouse by crossing the TRPV1-Cre (Cavanaugh et 
al., 2011) with a “cre-responding” Rosa26 tomato mouse line (Madisen et al., 
2010b) that has lox P sequences flanking a stop cassette (downstream of a CAG 
promoter) that prevents the transcription of the red fluorescent protein tdTomato. In 
the resulting offspring, the expression of tdTomato should be limited to cells 
expressing TRPV1. 
4.10.2.1. Expression pattern of tdTomato signal in the F1 TRPV1-
tdTomato transgenic mouse 
As mentioned above, we bred a TRPV1 reporter mouse line that would 
conditionally express tdTomato under control of the TRPV1 promoter. Since we 
were interested in testing if TRPV1 is expressed in the hippocampus, we prepared 
brain slices from F1 animals. Before slices were obtained we genotyped each 
mouse to ensure they were TRPV1-Cre-Rosa26-tdTomato positive.  
 
Using the F1 TRPV1 reporter mouse we detected high expression of tdTomato 
fluorescence in regions corresponding to the piriform cortex, caudate putamen, 
subthalamic nucleus, anterior hypothalamic area, posterior hypothalamic nucleus, 
lateral amygdaloid nucleus, perirhinal cortex and hippocampus (see Figure 26 and 
Figure 27). In the hippocampus a strong fluorescence was detected in the 
lacunosum moleculare layer, radiatum layer, dentate gyrus, fascicola cinereum, 
and in the stratum oriens only a small number of neurons was found to be positive 








Figure 26. tdTomato expression pattern in brain in the TRPV1cre X Rosa26-tdTomato 
reporter mouse line. Representative images of three different brain areas having tdTomato signal; 
for every brain region an example of each antibody it is shown. (A) IHC shows expression of the 
tdTomato reporter gene in the piriform cortex, where the C-T (Neuromics) antibody does not co-
localize with the tdTomato-positive neurons. B) In the Hypothalamus the C-T antibody (Millipore) 
also failed to detect the neurons labeled with the tdTomato signal. C) The N-T antibody (Neuromab) 
did not colocalize with the tdTomato-positive neurons in the lateral amygdala. For each 





We compared the signal provided by tdTomato to that given by IHC using three 
commercial antibodies specific for TRPV1. Surprisingly the three commercial 
TRPV1 antibodies against the C or N-T epitope provided an immunofluorescent 
signal with a distribution that did not completely match that of tdTomato.  
 
For a more detailed comparison, we examined four areas of the brain at high 
magnification that had the most prominent expression of tdTomato (i.e. the 




In the hippocampus (Figure 27 A), it is important to mention that none of the 
TRPV1 antibodies seemed to recognize hippocampal regions positive for 
tdTomato. As mentioned before Figure 9 in the stratum oriens we found a 
 
Figure 27. Hippocampal expression pattern of tdTomato signal in the TRPV1cre X Rosa26-
tdTomato reporter mouse line. A) IHC shows that in the hippocampus the brightest tdTomato 
signal is in processes of neurons of the dentate gyrus. B) Representative images of the stratum 
oriens showing that both the N-T and C-T (Neuromics and Millipore) antibodies recognized a subset 





restricted population of neurons that were recognized by all of the TRPV1 
antibodies tried in this study (Table 1). In Figure 27 B it is shown that both the C-T 
antibody from Neuromics and the N-T antibody from Neuromab, gave a positive 
immunofluorescence signal in a small population of neurons (likely corresponding 
to OLM neurons). Nevertheless, we were not able to see any tdTomato 
fluorescence in those neurons. It is likely that the neurons detected using the C-T 
antibody from Millipore also correspond to OLM neurons, but we found only one 
single cell positive for both tdTomato and the C-T antibody (Figure 27 B). 
 
In the hypothalamic area and piriform cortex only the C-T antibodies yielded low 
immunofluorescence in some cells that concomitantly expressed tdTomato (Figure 
26 A and B). In the amygdaloid nucleus we found robust expression of tdTomato, 
but we were not able to detect TRPV1 fluorescence using any of the three 
antibodies tested. 
4.10.2.2. F2 TRPV1-tdTomato transgenic mice show a ubiquitous 
tdTomato expression pattern 
In order to increase the size of the TRPV1-tdTomato mouse colony we crossed 
siblings of the F1 generation. Strikingly, when we performed the same 
immunohistochemical analyses as mentioned in the previous section we found a 
pattern of increased expression of tdTomato across the brain. The number and 
intensity of this unexpected ubiquitous tdTomato expression pattern varied 
between animals of the first generation (F1) and homozygotic F2 animals (Figure 
28 A). 
 
As shown in Figure 28 B we genotyped animals from the F2 generation in order to 
select homozygotes for IHC and further breeding. We first noticed that the 
homozygous mice from the second generation had conspicuously red skin and 






IHC in brain slices of animals from the second F2 generation revealed a completely 
different expression pattern of tdTomato compared to slices of the F1 generation. 
We focused our analysis on the hippocampus – the brain structure where most of 
our research was performed. In the F1 generation we saw a consistent specific 
small subset of cells expressing tdTomato signal in the brain and hippocampus of 
offspring of TRPV1-cre male X tdTomato female and vice versa. Suspiciously, in 
the homozygote F2 generation, tdTomato fluorescence was extremely high and 
homogenous, compared to F1 animals. We could not find any homozygotic animal 
in the F2 generation with the same tdTomato expression pattern as the F1 
generation in either the brain or hippocampus. 
 
 
Figure 28. Differences in the tdTomato expression pattern in the hippocampus of the F1 and 
F2 generation. A) Immunohistochemical comparison of the tdTomato signal in an F1 brain slice 
compared to a heterozygote and a homozygote from the F2 generation, showing inconsistent 
expression patterns. B) PCR confirming the genotype of each mouse shown in (A). For each 
representative image n=3 independent genotyping or immunostaining experiments for each 







































5.1. TRPV1 EXPRESSION IN THE HIPPOCAMPUS 
5.1.1. TRPV1 and VR.5’ sv are differentially expressed in 
the mouse DRG and hippocampus 
The expression of TRPV1 in the hippocampus has been a subject of intense 
debate in the last decade. While some groups have found direct and indirect 
evidence for the expression of TRPV1 in the hippocampus, others have claimed 
that it is absent in this brain area. 
 
Our results (Figure 4 and Figure 6) confirmed that TRPV1 is expressed in the 
hippocampus at both mRNA and protein levels, is in accordance with a number of 
reports that have previously found (using a wide variety of methods) evidence of 
TRPV1 transcripts and protein expressed in the hippocampus (Bennion et al., 
2011; Cavanaugh et al., 2011; Cristino et al., 2006a, 2008; Han et al., 2012; Huang 
et al., 2014; Merrill et al., 2012; Mezey et al., 2000; Puente et al., 2014; Roberts et 
al., 2004; Sanchez et al., 2001; Schumacher et al., 2000; Tóth et al., 2005). We 
used the TRPV1 KO model to test the fidelity of the antibody used for biochemical 
data and detection of TRPV1 protein expression (Figure 6 A and F). By q-PCR we 
also validated the deletion of exon 13 that encodes part of the fifth and all of the 
sixth transmembrane domain, including the putative pore region (Caterina et al., 
2000) in the TRPV1 KO model in both DRG and hippocampus (Figure 4). 
 
Consistent with previous results we found that in DRG the mRNA levels for exons 
encoding the pore region, N-T and C-T exceed the levels detected in the 





A). Although compared to the amount TRPV1 mRNA in DRG, the levels detected 
in the hippocampus appear to be negligible, the modest expression corresponds to 
reports that the hippocampus is the brain area with the lowest expression of 
TRPV1 (Han et al., 2012; Menigoz and Boudes, 2011) where it is possibly 
restricted only to a discrete type of neurons (Cavanaugh et al., 2011).  
 
Our results are also consistent with previous reports showing that the alternative N-
T splice isoform VR.5’ sv, is expressed in the hippocampus. VR.5’ sv is known be 
present at the same level as TRPV1 in the hippocampus, unlike the proposed ratio 
of expression of 1:20 (VR.5’s sv: TRPV1) in DRG (Sanchez et al., 2001; 
Schumacher et al., 2000). Similar to these previous reports we found that in DRGs 
of adult mice the ratio of mRNA of VR.5’ sv compared to TRPV1 (N-T and pore 
reagion) was 1:15 (VR.5’ sv: TRPV1) and even 1:44 when compared to TRPV1 C-
T (Figure 5 A). In the hippocampus of adult mice we estimated that the mRNA level 
of VR.5’ sv was actually 10 to 14 times higher than for the TRPV1 pore region and 
TRPV1 N-T respectively (Figure 5 B), unlike the 1:1 ratio measured by other 
groups (Sanchez et al., 2001; Schumacher et al., 2000). Intriguingly, VR.5’ sv 
mRNA expression hippocampus was two times lower than TRPV1 C-T (Figure 5 
B). This could be because the primers for C-T detect both VR.5’ sv and TRPV1, 
and hence reflect an aggregate expression of both proteins. A second alternative is 
that there is another TRPV1 splice variant bearing the C-T, for example TRPV1 β 
which has a mutated N-T but contains the same C-T as full-length TRPV1 (Wang 
et al., 2004). It would be highly interesting to test if in the hippocampus a different 
TRPV1 transcriptomic profile exists compared to DRG or other brain areas. 
5.1.2. Quantification of TRPV1 expression during 
development 
Less is known about the developmental expression of TRPV1 in the CNS during 
ontogeny. One study showed that TRPV1 is already expressed at E13 in 





al., 2013). Yet this study only focused on a very specific type of tissue. In post-
natal development of mice another study found that TRPV1 expression increased 
from P21 to 8 weeks after birth (when it reached the highest point) before 
decreasing, to similar levels as P21, at 16 weeks (Huang et al., 2014). In our study 
we show for the first time the expression profile of TRPV1 from E13-P21. We show 
that TRPV1 expression steadily increases during late embryogenesis and post-
natal stages persisting at least until P-21 (Figure 6 C). 
5.1.3. Remaining expression of the TRPV1 C-T in TRPV1 
KOs 
The pore region of TRPV1 is deleted in the TRPV1 KOs. But in the hippocampus of 
TRPV1 KO animals we detected a 350-fold increase in mRNA expression of the 
TRPV1 C-T by Q-PCR (Figure 4 A and C). We also found that in the hippocampus 
(but not in DRG) of TRPV1 KO animals the amount of VR.5’ sv mRNA tripled that 
detected in WT samples (Figure 4 B and C). It is possible that the increase in C-T 
and the VR.5’ sv-specific amplicons in TRPV1 KO adult hippocampus represents a 
compensation of due to the absence of full length TRPV1 receptors (Barbaric et al., 
2007; Martins et al., 2014; O’Sullivan et al., 2006) by an increase in the expression 
of paralogous genes or even alternative splice variants (e.g. VR.5’ sv) that could 
serve as a “backup” through genetic redundancy (Barbaric et al., 2007).  
 
Several cases of mutant mice have shown that aberrant splicing can occur, leading 
to expression even at protein levels. Our results suggest that either a naturally-
occurring or an aberrant TRPV1-like protein or splice variant possessing the C-T 
persist in TRPV1 KOs. As shown in Figure 8 A and B, a subset of hippocampal 
neurons in vitro that express TRPV1 was still recognized by the C-T antibody, but 
not by the N-T antibody, in TRPV1 KOs, where the N-T antibody recognizes full-
length TRPV1 by WB (Figure 6 A and F). Moreover the C-T antibody recognized 
hippocampal neurons transfected with the VR.5’ sv construct (Figure 8 C), thus 





remains in the TRPV1 KOs. The C-T antibody also detected a distinct type of 
inhibitory interneuron (mainly in the oriens lacunosum moleculare layer) in WT and 
TRPV1 KO hippocampal slices, thus a TRPV1-like remnant or splice isoform likely 
remains in TRPVI KOs (Figure 9). The remaining fluorescence signal could also be 
of a homologue of the TRPV1 channel, e.g. TRPV2 and TRPV4, which are 40-50% 
homologous to TRPV1 (Liedtke et al., 2000; Park et al., 2011b; Plant and 
Strotmann, 2007). TRPV2 and TRPV4 partially co-localize with C and δ fibers of 
sensory neurons and small-sized DRG neurons, respectively (Caterina et al., 1999; 
Facer et al., 2007; Ma, 2001). TRPV2 has been reported in multiple brain regions, 
primarly in those involved in osmoregulation and autonomic responses (Nedungadi 
et al., 2012), and can form functional hetero-multimers with TRPV1 in neurons of 
the cerebral cortex (Liapi and Wood, 2005). TRPV4 expression has been observed 
in pyramidal neurons, some inhibitory neurons and astrocytes of the hippocampus 
(Shibasaki et al., 2007). However we found that in hippocampal cell cultures, high 
TRPV1 expressing neurons did not co-localize with TRPV2 or with TRPV4 (Figure 
8 D), which, interestingly each is present in distinct cell sub-populations.  
 
Unlike the dramatic increase in the C-T and VR.5’ sv splice isoform mRNA levels 
detected in TRPV1 KO animals, we measured a 40-50% decrease in fluorescence 
intensity of the C-T antibody in both hippocampal cell cultures and slices from 
TRPV1 KOs compared to WT (Figure 8 A and B; Figure 9 C-E). This likely reflects 
the fact that the amount of mRNA does not always match the amount of translated 
protein (Vogel and Marcotte, 2012). For instance, in the case of TRPV1, prolonged 
exposure to prostaglandin E2 and bradykinin increase TRPV1 and TRPV1b mRNA 
without changing protein levels in cultured sensory neurons (Mistry et al., 2014). 
The reduction in C-T protein levels in TRPV1 KOs could indicate the persistence of 
a TRPV1 isoform. More studies are required to understand the regulation of the 
abundance and stability of TRPV1 and its isoforms (Barbaric et al., 2007; 





5.1.4. TRPV1 is expressed functionally in a subset of OLM 
inhibitory interneurons 
In CA1 pyramidal neurons postsynaptic TRPV1 expression has been observed at 
both excitatory and inhibitory terminals contacting interneurons of the stratum 
radiatum, while in CA3 pyramidal neurons pre-synaptic TRPV1 in axons contacting 
CA1 inhibitory interneurons has been hypothesized to control LTD in these 
inhibitory interneurons (Cristino et al., 2006b; Gibson et al., 2008; Lee et al., 2015; 
Micale et al., 2008; Tóth et al., 2005). In the dentate gyrus, TRPV1 was also 
hypothesized to be post-synaptic at excitatory synapses projecting from the 
perforant path (Puente et al., 2014) where its activation modulates LTD (Chávez et 
al., 2010). We found that TRPV1 is both pre- and post-synaptic using a trypsin 
cleavage assay of synaptosomes from brain homogenates (Figure 6 D and E), but 
our results using this methodology do not specify in which neuronal cell-type or 
location. 
 
The studies mentioned above detailed a pre- or post-synaptic localization of 
TRPV1 in excitatory neurons, but not in inhibitory interneurons themselves. TRPV1 
was reported to control of plasticity of inhibitory interneurons, but via TRPV1 in 
excitatory boutons contacting these interneurons (Gibson et al., 2008; Lee et al., 
2015).  
 
We detected that high TRPV1-expressing neurons in cultured hippocampal 
neurons positively correlated with GAD 65 (Figure 10 A and B), in agreement with 
one previous study suggesting the expression of TRPV1 in GABAergic neurons 
(Sun et al., 2012). At least 12 different types of inhibitory interneurons are present 
only in the CA1 region of the hippocampus (Klausberger and Somogyi, 2008; 
Müller and Remy, 2014). Hippocampal interneurons are usually classified 
depending on their anatomical location within the hippocampus and the specific 
protein and peptides they express, such as calretinin, cholecystokinin, 





somatostatin (Somogyi and Klausberger, 2005). To classify TRPV1-expressing 
interneurons we tested co-localization of TRPV1 with the markers above and with 
reelin, which had previously been found to be colocalized with TRPV1-expressing 
neurons (Cavanaugh et al., 2011). TRPV1 colocalized with 40-50% of reelin- and 
somatostatin-positive neurons but not with Parvalbumin 25 (PV 25) or 
vasointestinal peptide (VIP) positive neurons (Figure 10 A and B). Reelin is an 
important signaling molecule necessary for the proper formation of cortical and 
hippocampal laminae during both pre- and post-natal development (Caviness and 
Rakic, 1978; Stranahan et al., 2013). Since TRPV1 and reelin colocalized, it could 
be possible that TRPV1 also plays a role in morphogenesis of brain structures. 
Nevertheless we found no disruptions in the morphology of the brain (Figure 11). 
 
In the developing and adult mouse hippocampus only a few neurons have been 
found to express TRPV1, which corresponded to reelin-positive neurons. The 
authors claimed that these cells corresponded to Cajal-Retzius neurons that would 
eventually disappear from the mature hippocampus (Cavanaugh et al., 2011). 
Although the number of Cajal-Retzius cells dramatically decreases postnatally, a 
different population of neurons in the hippocampus, that originate from the medial 
ganglionic eminence have been identified that also express reelin throughout 
adulthood (Abraham and Meyer, 2003; Pesold et al., 1998; Ramos-Moreno et al., 
2006). 
 
Previous studies have shown that most reelin-expressing neurons do not 
colocalize with parvalbumin and VIP but do colocalize with somatostatin (75%) in 
the stratum oriens (Alcántara et al., 1998; Miyoshi et al., 2010). We found that 
neurons co-expressing reelin and somatostatin in the stratum oriens concomitantly 
had higher levels of TRPV1 (Figure 9 B). Furthermore 90% of these neurons also 
possess higher pre-synaptic mGluR7 innervation (Figure 9 C), most likely from 
excitatory synapses of pyramidal neurons contacting somato-dendrites of TRPV1-
expressing neurons (Shigemoto et al., 1996, 1997; Tomioka et al., 2014). 





identified are oriens lacunosum moleculare (OLM) neurons, which are inhibitory 
interneurons located in the stratum oriens that are positive for somatostatin and 
reelin and highly innervated by mGluR7 (Chittajallu et al., 2013; Tomioka et al., 
2014). Our observation is supported by the anecdotal report of TRPV1 being 
expressed in some interneurons in the SO (Cristino et al., 2006b), however this 
study did not provide more information regarding the identity of these cells. 
 
The presence of TRPV1 in OLM neurons is supported by the compelling 
observation that OLM neurons (compared to pyramidal neurons) are more 
susceptible to higher temperatures (40°C - 43°C) experienced during febrile 
temperatures, what leads to an enhancement of the excitability of OLM-
somatostatin neurons and of their firing frequency due to heat (Kim and Connors, 
2012). Intriguingly our results showed that reelin is expressed in somatostatin-
positive neurons co-expressing TRPV1. Most studies distinguish OLM interneurons 
as being positive for somatostatin, the most commonly used marker for OLM 
neurons (Maccaferri et al., 2000; Müller and Remy, 2014). More recent studies 
suggest that OLM interneurons are not a homogeneous group of inhibitory 
neurons, but that there are at least 2 types: both express somatostatin and 
mGluR1 (Chittajallu et al., 2013; Ferraguti et al., 2004; Maccaferri et al., 2000) but 
one expresses PV25 and originates from the medial ganglionic eminence while 
another type that originates from the caudal ganglionic eminence expresses reelin 
and 5-HT3AR (Chittajallu et al., 2013). Moreover nAChr2 has also been confirmed 
to be expressed in OLM neurons (but not in all somatostatin-positive neurons) 
(Leão et al., 2012). Our data suggest that TRPV1-positive OLM cells belong to the 
subpopulation expressing somatostatin, reelin (and not PV) and nAChr2 which 
were previously found to concomitantly express the 5-HT3AR (Chittajallu et al., 
2013). This is supported by the observation that upon increased temperatures 








5.1.5. TRPV1-expressing OLM neurons: NGF and BDNF  
We made the novel observation that NGF is highly expressed in TRPV1-
expressing neurons (Figure 20 A and B). It has previously been reported that NGF 
is mainly expressed in the cortex and the hippocampus in GABAergic neurons 
(Biane et al., 2014; Pascual et al., 1998; Rocamora et al., 1996). In the 
hippocampus, recalling OLM neurons, it is expressed in inhibitory interneurons 
including somatostatin-expressing interneurons of the stratum oriens that receive 
septo-hippocampal cholinergic inputs (Acsády et al., 1996; Guo et al., 2012; Leão 
et al., 2012; Rocamora et al., 1996; Widmer et al., 2006). Additionally in patients 
with mesial temporal lobe epilepsy TRPV1 and NGF were found to be upregulated 
in some inhibitory neurons of the cerebral cortex and hippocampus (Sun et al., 
2012). It is widely accepted that the binding of NGF to TrKA receptors in sensory 
neurons leads to downstream signaling cascades driving TRPV1 expression and 
insertion into the plasma membrane (Anand et al., 2006; Ji et al., 2002; Winston et 
al., 2001; Zhang et al., 2005). We found that 1 ng/ml NGF also increased TRPV1 
protein levels in hippocampal neuronal cultures (Figure 20 C-E), but TRPV1 
transfection did not increase NGF expression in the transfected neuron (Figure 20 
F). How NGF co-localization correlates with TRPV1 expression in these cells 
remains unknown. One possibility is that instead of expressing NGF, the TRPV1-
expressing cells take up NGF that is secreted by contacting cells. Another 
possibility is that NGF is expressed in TRPV1-expressing cells and as soon as it is 
released it binds to TrkA or p75 receptors in the same neuron leading to a positive 
feed-back loop maintaining TRPV1 expression. A problem with this hypothesis is 
that in the hippocampus the expression of TrkA is controversial; in fact it has been 
claimed that the only source of TrkA that contact NGF-expressing interneurons 
from the hippocampus are cholinergic neurons on the medial septum-diagonal 
band of Broca (Conner et al., 2009; Guo et al., 2012). On the other hand p75 
receptor expression appears to be more widespread in the hippocampus, mainly 
post-synaptically located in CA1 dendritic spines and shafts (Dougherty and Milner, 





expression in inhibitory interneurons with high-TRPV1 levels controls the 
expression of TRPV1 in these neurons either through interaction with TrKA or p75 
remains an open question (Fahnestock et al., 2001; Lewin and Nykjaer, 2014). 
 
We found another neurotrophic factor, BDNF (Figure 21 A-D) was also co-localized 
with high TRPV1-expressing neurons BDNF, TrKB (the BDNF receptor) and p75 (a 
receptor for both BDNF and NGF) are expressed throughout different brain regions 
including the hippocampus (Gray et al., 2013; Hofer et al., 1990; Klein et al., 1990; 
Lein et al., 2007; Pioro and Cuello, 1990). In the hippocampus, BDNF is highly 
expressed exclusively in excitatory neurons (e.g. pyramidal and granule cells) of 
the CA3, CA1 and dentate gyrus in the soma and pre-synaptic terminals of 
excitatory synapses (Conner et al., 1997; Gray et al., 2013; Yang et al., 2009; 
Zafra et al., 1990; Zakharenko et al., 2003). If BDNF is post-synaptically expressed 
and secreted (especially from CA1 pyramidal neurons) to regulate synaptic 
plasticity is still controversial (Dieni et al., 2012; Hartmann, 2001; Tanaka et al., 
2008; Will et al., 2013). We found high somatic (in rat neuronal cultures) (Figure 21 
A and B) and dendritic (in mouse neuronal cultures) (Figure 21 C and D). BDNF 
levels in high TRPV1-expressing neurons. The difference in the pattern of 
expression could be caused by the specificity of the antibody, which is higher for 
mouse tissue. The dendritic (not somatic) pattern of expression seen in murine 
hippocampal cell cultures agrees more with the acceptance of BDNF not being 
expressed in inhibitory neurons. However, the dendritic BDNF positive puncta 
could represent trafficking dense core vesicles transporting BDNF (Dean et al., 
2009) that is released onto axons of excitatory neurons contacting TRPV1-positive 
inhibitory interneurons. In the hippocampus the TrKB receptor is prominently 
expressed in axons as well as in dendritic shafts and spines of pyramidal and 
granule cells but is also expressed in inhibitory interneurons including cholinergic 
neurons of the stratum oriens (Drake et al., 1999; Marty et al., 1996; Spencer et al., 
2008; Spencer-Segal et al., 2011; Zachrisson et al., 1996). Interestingly the low-






5.1.6. Expression of functional TRPV1 in hippocampal 
neurons 
Is TRPV1 expressed in OLM-neurons fully functional? In fact, we found that only a 
small fraction of hippocampal neurons reacted (by influxing Ca2+) upon acute (1 
µM) capsaicin stimulation and as expected none of the TRPVI KO hippocampal 
neurons responded to capsaicin application (Figure 7). Capsaicin is a specific 
TRPV1 agonist, known to activate only these receptors (Caterina et al., 1999, 
2000). Thus the responses observed in WT (that were absent in TRPV1 KO 
neurons) must be through TRPV1 activation. Even if the capsaicin-response in 
these cells was obvious we cannot be completely certain that the neurons 
undergoing neuronal depolarization detected upon capsaicin during the experiment 
were actually expressing TRPV1. The observed depolarization could reflect 
activation of cells contacting the TRPV1 expressing neurons or even a third-party 
synaptic partner. A previous study using a TRPV1 reporter mouse line failed to 
detect Ca2+ influx after 10 µM capsaicin application in neurons of the dentate gyrus 
(Cavanaugh et al., 2011). Our study suggests that in mouse hippocampal neurons 
functional TRPV1 channels exist, which were absent in TRPV1 KO hippocampal 
neurons. Future studies using calcium imaging of neurons from a Somatostatin-
tdTomato mouse line to identify OLM neurons will verify if the capsaicin-induced 
calcium responses we observe are specifically due to TRPV1 in OLM cells. 
5.1.7. TRPV1 expression and activation regulate 
excitatory synaptic innervation in OLM neurons 
Perhaps the most striking discovery in this study was the observation that high-
TRPV1 expressing neurons were highly innervated by both excitatory (Figure 13) 
and inhibitory synapses (Figure 14). Our results show that neurons of the stratum 
oriens with increased TRPV1 expression were concomitantly decorated with a 





quantifying synaptic input onto different interneurons identified PV-expressing 
interneurons of the stratum radiatum to be highly innervated by glutamatergic 
synapses compared to other neuronal subtypes (Gulyás et al., 1999; Mátyás et al., 
2004). To our knowledge the data provided in our study is the first to reveal that 
high-TRPV1 expressing OLM cells also receive abundant excitatory innervation. 
One study reported a high co-localization of mGluR7 with vGluT1 (and Elfn1) in 
excitatory terminals contacting OLM neurons (Tomioka et al., 2014). Furthermore 
OLM neurons highly express mGluR1 (Ferraguti et al., 2004). OLM neurons are 
known to be innervated mainly by CA1 excitatory synapses arising from pyramidal 
neurons (Sun et al., 2014). Dendrites of CA3 OLM neurons have been observed to 
project to the CA3 stratum radiatum (Gulyás et al., 1993). The main inhibitory 
synapses made onto OLM neurons originate from presumptive bistratified 
interneurons (Leão et al., 2012) and even from other OLM neurons (Acsády et al., 
1996; Ferraguti et al., 2004; Kogo et al., 2004). There is to date no clear 
mechanism describing how excitatory and inhibitory pre-synaptic strength to OLM 
neurons is regulated. Here we describe for the first time that post-synaptic TRPV1 
in OLM neurons serves as a synaptogenic factor prompting the formation of 
excitatory synapses onto these neurons without affecting inhibitory synapse 
number. 
 
Analysis of high TRPV1-expressing neurons and somatostatin/reelin-positive 
(OLM) neurons in vitro revealed more excitatory and inhibitory synapses (Figure 
13, Figure 14 and Figure 15) on these neurons with greater excitatory and 
inhibitory presynaptic strength, assayed by higher vGluT1 and vGAT and 
overlapping syt1u fluorescence intensity than surrounding neurons. TRPV1 has 
been suggested to affect the dynamics of filopodia and to regulate synaptic vesicle 
recycling via a localization to synaptic vesicles (Goswami and Hucho, 2007; 
Goswami et al., 2007, 2010). In our studies the significance of postsynaptic TRPV1 
expression for the formation of excitatory synapses was confirmed first by the 
transfection of heterologous TRPV1 in hippocampal neurons in vitro at DIV2 





vGluT1-positive synapses onto these neurons and the mEPSC frequency recorded 
from them (Figure 16 A, D and E), which reflects an increase in pre-synaptic 
release probability or number of synapses. Second, with the observation that 
TRPV1 KO OLM neurons had a tremendous reduction in the number of excitatory 
vGluT1 synapses formed onto these neurons (Figure 15 A and B).  
 
The functional state of the channel was also important since activation with low (50 
nM) or standard (1 µM) capsaicin concentration for 21 h led to an increase in 
excitatory synapse number in a dose-dependent manner (Figure 13; Figure 15 A 
and B); this findings are, to some extent, similar to previous studies indicating that 
TRPV1 activation in the first sensory synapse of sensory neurons to DRG, 
dorsolateral periaqueductal gray neurons and in spinothalamic neurons increased 
excitatory synaptic input to the depolarized cell (Kim et al., 2009; Sikand and 
Premkumar, 2007; Xing and Li, 2007). On the other hand, we found that blockade 
of TRPV1 with 1 µM SB-366791 prevented the effects of capsaicin and decreased 
the number of excitatory synapses (when applied alone) to a similar extent as that 
observed in TRPV1 KO cultures (Figure 13 A-C). In TRPV1 overexpressing cells 
SB-366791 decreased the number of excitatory synapses below the number 
observed on untreated EGFP-expressing neurons (Figure 16 A and D). 
Interestingly neither treatment affected vGluT1 or syt1u intensity.  
 
Pre-synaptic TRPV1 activation is known to increase Ca2+, thus prompting 
glutamate release (without affecting GABAergic synaptic transmission) in sensory 
neurons, and specific neuronal populations from spinal cord, brainstem, substantia 
nigra, locus coeruleus, hypothalamus and striatum (Doyle et al., 2002; Marinelli et 
al., 2002, 2003; Medvedeva et al., 2008; Musella et al., 2009; Sasamura et al., 
1998; Yang et al., 1998). Similar to these reports, our results also failed to detect 
changes in the number and strength of GABAergic boutons contacting high-TRPV1 
expressing OLM neurons upon treatment with capsaicin (50 nM and 1 µM) and 1 
µM SB-366791 (Figure 15 C and D; Figure 14 A-E). Surprisingly we found that 





number of GABA synapses contacting low TRPV1-expressing neurons (Figure 14 
B and C). More difficult to explain are the results obtained from TRPV1-transfected 
neurons at DIV2 where the overexpression of TRPV1 resulted in decreased 
GABAergic neurotransmitter release without changing the number of GABAergic 
inputs or mIPSC amplitude and frequency (Figure 17 A-E) Capsaicin application 
caused a depression in GABAergic synaptic transmission in the dentate gyrus, 
through a post-synaptic mechanism without altering GABA release (Chávez et al., 
2014). Still the mechanism by which TRPV1 influences inhibitory synaptic 
transmission remains obscure. 
 
In the hippocampus pre-synaptic TRPV1 activation depresses glutamate release 
from terminals contacting interneurons in the stratum radiatum (Gibson et al., 
2008). Our results on the other hand propose that post-synaptic TRPV1 activation 
decreases glutamate release onto both high TRPV1 expressing interneurons and 
other surrounding neurons. An effect of post-synaptic TRPV1 was also reported in 
the dentate gyrus, but in this case TRPV1 activation decreased synaptic strength 
by promoting endocytosis of AMPA receptors on the post-synaptic side of the 
membrane (Chávez et al., 2010). An effect of post-synaptic TRPV1 on pre-synaptic 
function, similar to our observation was reported in the nucleus accumbens, where 
post-synaptic TRPV1 activation activated pre-synaptic CB1 to decrease 
neurotransmitter release (Grueter et al., 2010).  
 
As mentioned in section 5.1.5, high-TRPV1 expressing neurons are decorated with 
BDNF puncta that are absent in TRPV1 KOs (Figure 21 C and D), suggesting that 
TRPV1 promotes increases in BDNF. Moreover, TRPV1 transfection at DIV2 
increased BDNF in these neurons (Figure 21 E). BDNF is known to serve both as 
an anterograde (secreted from the pre- to the post-synapse) and retrograde (post- 
to pre-synaptic) factor that potentiates both excitatory and inhibitory synaptic 
transmission in the hippocampus upon increased neuronal activity (Bolton et al., 
2000; Hartmann, 2001). Thus, we tested if BDNF is necessary for the augmented 





interneurons. Blockade of secreted BDNF with 100ng/ml TrkB-IgG scavenger did 
not affect innervation of these neurons or intensity of vGluT1 or vGAT signal. 
Although blockade at DIV2 slightly increased the number of excitatory synapses on 
high-expressing TRPV1 neurons, this change was not significant (Figure 25). In 
addition, the increase in excitatory innervation caused by transfection of TRPV1 at 
DIV 2 was not prevented with 100ng/ml TrKB-IgG treatment at DIV 3. On the 
contrary, TrkB-IgG treatment slightly increased the number of excitatory terminals 
on TRPV1-transfected neurons (Figure 24). Together these results rule out BDNF 
as a candidate molecule that increases innervation of high TRPV1-expressing 
OLM interneurons.  
5.1.8. Possible TRPV1 endogenous ligands and binding 
partners in the hippocampus 
What is the endogenous ligand that activates TRPV1 in hippocampal neurons? 
Since ingested capsaicin does not cross the blood brain barrier and in a normal 
physiological state pH and temperature stay constant, these three well-known and 
TRPV1 agonists are unlikely candidates to trigger TRPV1 channel activation in the 
hippocampus. However in the PNS as well as in the hippocampus multiple 
molecules have been proposed to activate TRPV1. In the CNS three endogenous 
agonists have been proposed to activate TRPV1 in the hippocampus: anandamide, 
12-HPETE and N-arachydonoyl-dopamine (NADA) (Ahern, 2003; Al-Hayani et al., 
2001; Gibson et al., 2008; Huang et al., 2002). Enzymes responsible for the 
synthesis of anandamide (N-acylphosphatidylethanolamine-specific phospholipase 
D) and 12-HPETE (12-lipoxygenase) (Di Marzo et al., 1994; Hwang et al., 2000) 
have both been detected in pyramidal neurons of the CA3 region. 12-lipoxygenase 
has also been detected in CA1 pyramidal neurons as well as in some interneurons 
in the stratum radiatum (Cristino et al., 2008; Feinmark et al., 2003; Merrill et al., 
2012). Induction of LTD in inhibitory interneurons of the stratum radiatum was 
reported to be dependent on post-synaptic 12-HPETE synthesis triggered by the 





fashion to activate pre-synaptic TRPV1 at excitatory synapses leading to a 
decrease in neurotransmitter release onto the post-synaptic interneuron (Gibson et 
al., 2008). In another study of excitatory synapses in the dentate gyrus, post-
synaptic mGluR5 activation causes anandamide synthesis, which intracellularly 
activates TRPV1 receptors which cause an internalization of AMPA receptors 
through the calcineurin / dynamin signaling pathway, thus depressing excitatory 
synaptic transmission (Chávez et al., 2010). In cortical neurons in vitro NADA has 
been suggested to cause the recruitment of TRPV1 to filopodia during their 
elongation, which may affect synaptogenesis (Goswami et al., 2010). Because 
TRPV1 can be activated by multiple agonists it is difficult to isolate a single 
endogenous agonist causing an effect on TRPV1. Moreover many agonists of 
TRPV1 in the hippocampus are not specific only for TRPV1 but also activate other 
receptors such as the CB1 receptor (Bisogno et al., 2000; Devane et al., 1992; 
Marzo, 2010), which is activated by anandamide. To date a single unique 
endogenous TRPV1 agonist has not been isolated in the CNS. 
 
It is not only agonists that mediate the activity of TRPV1 channels. TRPV1 
channels can form homo-tetrameric as well as hetero-tetrameric complexes with 
other TRP channels such as the TRPA1, TRPV2, TRPV3 (Liapi and Wood, 2005; 
Smith et al., 2002; Staruschenko et al., 2010) and other TRPV1 alternative splice 
isoforms, such as VR.5’ sv (Eilers et al., 2007). VR.5’ sv is thought to function as a 
dominant-negative regulator of TRPV1 activity by reducing its response to 
capsaicin by 70% (Eilers et al., 2007). When we transfected VR.5’ sv alone (at 
DIV2) it did not significantly alter the number and strength of vGAT or vGluT1 
synapses contacting transfected neurons (Figure 16 F-I and Figure 17 F-I 
respectively). On the other hand when TRPV1 was co-transfected at DIV2 with 
VR.5’ sv we found a significant increase in excitatory synapses similar to the levels 
produced by TRPV1 alone, a significant increase in syt1u at excitatory synapses, 
and a significant decrease in inhibitory synapse number (Figure 16 F-I and Figure 
17 F-I). Thus, in terms of synapse formation and strength VR.5’ sv appeared to 





are due to the multimerization of TRPV1 and VR.5’ sv. It is still unclear if both 
isoforms are expressed in OLM neurons. It would be interesting to determine if in 
certain conditions such as temporal lobe epilepsy VR.5’ sv (like TRPV1) is also 
upregulated to stabilize channel activity. 
5.1.9. Regulation of TRPV1 expression in hippocampal 
neurons: link to epilepsy 
TRPV1 expression is upregulated in animal models, and in patients, with temporal 
lobe epilepsy (Anand et al., 2006; Bhaskaran and Smith, 2010; Ji et al., 2002; Sun 
et al., 2012). NGF is also upregulated during seizure activity (Bengzon et al., 1992; 
Gall and Isackson, 1989), and NGF induces TRPV1 expression, thus these two 
molecules may act in the same pathway in epilepsy. One indisputable 
characteristic of epileptogenesis is hyperexcitability caused by an imbalance in 
excitation and inhibition which in part is caused by malfunction and death of 
GABAergic interneurons (Badawy et al., 2009). In the epileptic rat model (induced 
by pilocarpine injection) TRPV1 activation with 1 µM capsaicin was reported to 
increase basal excitatory synaptic transmission in hippocampal CA1-CA3 
pyramidal neurons, while blockade with 10 µM capsazepine decreased it 
(Saffarzadeh et al., 2016). Although in our experiments we did not induce epileptic 
seizures, we did test the effects of blocking GABAergic inhibitory synaptic 
transmission with bicuculline, to mimic a malfunction of inhibitory interneurons 
(Sillito, 1975). As expected, bicuculline application for 21 h increased excitation 
and neuronal activity, leading to an increase in BDNF and cFos – two markers of 
neuronal activity (Morgan and Curran, 1986; Morgan et al., 1987; Zafra et al., 
1990, 1992). Interestingly, treatment with bicuculline also significantly increased 
fluorescence intensity of the C-T TRPV1 antibody in most cells of hippocampal 







To determine if TRPV1 expression was increased by neuronal activity in general 
we also tested the effects of forskolin, which increases cAMP levels and increases 
neuronal activity (Shoback and Brown, 1984). When added either before or after 
synapse formation in hippocampal cultures, forskolin caused an increase in the 
fluorescence intensity of the TRPV1 C-T antibody (Figure 22 and Figure 23) in 
addition to the expected increase of BDNF and cFos levels. There has not been a 
previous report of forskolin-dependent TRPV1 upregulation, but forskolin blocks 
TRPV1 desensitization caused by repeated capsaicin application (Schnizler et al., 
2008). Intriguingly using WB we failed to detect the bicuculline- or forskolin-induced 
upregulation of TRPV1 seen with ICC. Because we used the N-T antibody for WB 
and the C-T antibody for ICC, the discrepancy in results could mean that a splice 
isoform (e.g VR.5’ sv) that is only detected by the C-T antibody is upregulated by 
these treatments. In the case of bicuculline, only a subset of cells showed 
increased TRPV1, which may not be detected by WB.  
 
It is still not clear how TRPV1 expression is controlled in the hippocampus. Our 
results suggest for the first time that NGF upregulates TRPV1 expression in the 
hippocampus, this is an important observation that together with the changes 
observed with neuronal activity places TRPV1 at the forefront as a potential 
indicator or regulator of a misbalance in neuronal activity and excitability that can 
lead to neuropathies such as status epilepticus. 
 
Interestingly, in patients with temporal lobe epilepsy that exhibit kindling and 
epileptic seizures and in rodents treated with pilocarpine or kainaic acid (the most 
common animal models for temporal lobe epilepsy), reorganization of the 
excitatory hippocampal synaptic network is a key feature of epileptogenesis and 
development of chronic seizures (Curia et al., 2008; Scheibel et al., 1974). One of 
the most susceptible regions is the hilus and the mossy fiber pathway. Temporal 
lobe epilepsy has been correlated with increased sprouting and aberrant 
innervation of granule neurons, CA3 and CA1 pyramidal neurons but also  





Kotti et al., 1997; Mathern et al., 1995; Ouardouz et al., 2010; Sanabria et al., 
2001). Since NGF and pilocarpine (a known to cholinomimetic agent) induce the 
aberrant sprouting observed in animals with induced kindling and epilepsy, 
(whereas the cholinergic antagonist, scopolamine, prevents it) and TrkA receptors  
co-localize with cholinergic receptors in hippocampal neurons (that receive NGF 
and cholinergic input from the fimbria and fornix) it has been hypothesized that the 
actions of NGF in sprouting could potentially be regulated by the cholinergic 
system (Adams et al., 1997, 2002). Moreover, epileptic episodes increase the 
number of excitatory inputs and facilitate excitatory synaptic transmission onto 
somatostatin interneurons of the outer molecular layer as well as interneurons of 
the stratum oriens and stratum lacunosum moleculare (Mathern et al., 1995, 1998; 
Ouardouz and Carmant, 2012).  
 
Inhibitory interneurons normally fire rhythmically at theta (4-12 Hz) or gamma 
frequencies (30-80 Hz), to tune the excitability of neuronal networks in a temporal 
pattern (White et al., 2000). During epileptic pathophysiology spatial and temporal 
inhibition is disrupted, thus changing the oscillatory activity of the whole system. 
For instance injection of kainaic acid abruptly diminished the oscillations at theta 
frequencies, whereas high frequency gamma oscillations are enhanced 
(Arabadzisz et al., 2005; Dugladze et al., 2007). In animals with persistent epileptic 
seizures the firing frequency of OLM interneurons in particular shifted their activity 
from their normal theta frequency (Klausberger and Somogyi, 2008; Müller and 
Remy, 2014) to gamma oscillations possibly due to an enhancement of the 
frequency of spontaneous excitatory inputs to these interneurons (Dugladze et al., 
2007). Increased firing rates of OLM neurons cause increased gamma oscillations 
in distal dendrites of hippocampal pyramidal neurons (Tort et al., 2007). Thus 
hyper-activation of this specific type of interneuron can have profound effects in the 
total excitatory and inhibitory output of the hippocampal neuronal system. OLM 
neurons are especially sensitive to febrile temperatures, causing them to become 





showing that regulation of glutamatergic innervation of OLM neurons expressing 
TRPV1 is in part driven by the activity of the channel.  
 
In our experiments, capsaicin treatment activated TRPV1 in OLM neurons, which 
increased the number of excitatory synaptic inputs to these neurons. Because 
repeated glutamatergic firing of OLM neurons is transformed into oscillations at low 
frequency, thus inhibiting post-synaptic theta oscillations (Müller and Remy, 2014), 
TRPV1 expression and signaling could precisely control glutamatergic synapse 
formation during theta oscillations. 
5.1.10. TRPV1 affects synaptic plasticity in the 
hippoocampus 
5.1.10.1. TRPV1 does not influence LTD in the Schaffer collateral 
pathway 
TRPV1 activation with 1 mM capsaicin decreases LTD induced by low frequency 
stimulation (3Hz) (Li et al., 2008). However the concentration of capsaicin used in 
that study exceeds the concentration sufficient to evoke TRPV1-based neuronal 
depolarization, and may result in desensitization. Using a gradient of more 
standard concentrations of capsaicin (1-10 µM) a later study did not find any effect 
on LTD induction upon 5 Hz stimulation in the CA3-CA1 Schaffer collateral 
pathway (Bennion et al., 2011). However, LTD in TRPV1 KO mice compared to 
wild-type (whithout the addition of capsaicin) has not been tested. We induced LTD 
in the Schaffer collateral pathway of wild-type and TRPV1 KO mice with a 1 Hz low 
frequency stimulation protocol. We did not find any differences in LTD in TRPV1 








5.1.10.2. TRPV1 affects LTP in the Schaffer collateral pathway 
TRPV1 KO animals have been reported to have decreased LTP following a 1XTET 
induction protocol in the Schaffer collateral pathway (Marsch et al., 2007). On the 
other hand the TRPV1 agonist capsaicin increased LTP in the CA1 region, and this 
increase was blocked by the TRPV1 specific antagonist SB-366791 (Bennion et 
al., 2011; Li et al., 2008). Together these were the first observations showing the 
importance of TRPV1 in normal LTP induction. Later the mechanism was proposed 
to be mediated through LTD in inhibitory interneurons of the stratum radiatum 
(Gibson et al., 2008). These authors proposed that activation of mGluR1 receptors 
in interneurons of the stratum radiatum caused the synthesis of 12-HPETE that 
acts as a retrograde messenger to activate pre-synaptic TRPV1 channels 
expressed in excitatory terminals of CA3 pyramidal neurons, which decreases 
glutamate release to the interneuron in the stratum radiatum of the CA1 region, 
thereby disinhibiting CA1 pyramidal cells, resulting in an enhancement of LTP 
(Gibson et al., 2008). Further studies concluded that TRPV1 acts via GABAergic 
inhibition during LTP since a capsaicin-induced increase in LTP of the Schaffer 
collateral was abolished in the presence of picrotoxin (a potent GABA-A receptor 
antagonist) (Bennion et al., 2011), and picrotoxin restored the decreased LTP in 
TRPV1 KO hippocampi to normal WT levels (Brown et al., 2013).  
5.1.10.3. Selective activation of OLM neurons rescues the 
impairment of LTP in TRPV1 KOs 
We performed 1XTET stimulation to induce LTP and confirmed the reduction of 
LTP in TRPV1 KOs in the Schaffer collateral observed in previous studies (Figure 
19 B). Our results indicate that OLM neurons from TRPV1 KO mice have decrease 
excitatory innervation (most likely from CA1 pyramidal neurons). Such a decrease 
should be translated into a reduced inhibitory output from the OLM neurons to 
feedforward inhibitory interneurons of the stratum radiatum, thus intensifying the 





interneurons of the stratum radiatum. As mentioned previously, OLM interneurons 
are the only neurons in the hippocampus that express the nAChr2, thus nicotine 
specifically activates OLM neurons (Leão et al., 2012; Nakauchi et al., 2007b). We 
hypothesized that if the reduction in LTP in TRPV1 KOs is due to decreased 
excitatory innervation of OLM neurons, bypassing this defect by activating OLM 
neurons with nicotine should rescue the LTP deficits in TRPV1 KOs. To test this, 
we repeated the LTP experiment in the presence of 5 µM nicotine to activate OLM 
neurons. While nicotine caused a mild increase in LTP in WT hippocampal slices, 
as previously reported (Nakauchi et al., 2007b), strikingly, nicotine rescued the 
completely rescued LTP in TRPV1 KOs to wild-type levels (Figure 19 C).  
 
This confirms that TRPV1 is expressed in OLM interneurons and that the LTP 
deficits observed in TRPV1 knockouts are due to decreased excitatory innervation 
of OLM neurons. In contrast to the hypothesis provided by Gibson and 
collaborators (2008) suggesting that LTD in interneurons of the stratum radiatum 
during LTP (and upon 1 µM capsaicin application) results from a decrease in 
excitatory pre-synaptic strength to straum radiatum interneurons. Alternatively, we 
infer that the HFS or capsaicin-induced LTD in interneurons of the stratum 
radiatum could arise from activation of TRPV1 in OLM neurons what would 
increase the inhibitory input from OLM neurons to interneurons of the stratum 
radiatum. 
 
In addition, Gibson and collaborators (2008) proposed that activation of pre-
synaptic TRPV1 located in excitatory terminals contacting interneurons of the 
stratum radiatum caused the observed LTD in these interneurons by depressing 
excitatory neurotransmitter release. However, most of the literature points out that 
when TRPV1 is activated in glutamatergic pre-synaptic terminals it rather prompts 
glutamate release (instead of reducing it) (Jennings et al., 2003; Marinelli et al., 
2003; Sasamura et al., 1998; Starowicz et al., 2007). An increase of glutamate 
release onto inhibitory interneurons would cause them to release GABA and 





Gibson and colleagues (2008) found that upon high frequency stimulation mGluR1 
activation in stratum radiatum interneurons led to 12-HPETE synthesis. They 
suggest that 12-HPETE retrogradely diffuses to excitatory synapses (terminating 
onto interneurons of the stratum radiatum) where it activates TRPV1 and promotes 
LTD of these interneurons. We did not monitor changes in 12-HPETE synthesis or 
use it to test TRPV1 activation. Yet the findings of Gibson et al. are highly relevant 
because 12-HPETE could be a potential candidate that activates TRPV1 in a 
retrograde fashion from interneurons of the stratum radiatum to OLM neurons, thus 
controlling a TRPV1-mediated signaling cascade and possibly increasing 
GABAergic release to the SR which could disinhibit and thereby enhance Schaffer 
collateral-CA1 LTP. 
 
Our study contributes an essential finding to both the understanding of the function 
of TRPV1 in the hippocampus, and understanding of the OLM circuit in gating 
plasticity in the hippocampus. TRPV1 could be an essential part of a mechanism 
regulating the excitatory input to OLM neurons that is necessary for a correct 
balance of excitation and inhibition in synaptic plasticity. Some fundamental 
players have recently been discovered, for example OLM neurons also express the 
extracellular leucine-rich repeat fibronectin-connecting protein (Elfn1), which 
recruits mGluR7 receptors to excitatory pre-synaptic terminals of pyramidal 
neurons contacting OLM cells. The interaction of OLM Elfn1 and mGluR7 regulate 
excitatory synaptic strength onto OLM interneurons - by decreasing  the probability 
of  glutamatergic release - without affecting the number of excitatory synapses on 
OLM neurons (Müller and Remy, 2014; Sylwestrak and Ghosh, 2012; Tomioka et 
al., 2014). It will be interesting to further investigate if the mechanism of action of 
TRPV1 to promote plastic changes in excitatory synaptic strength is associated 
with the Elfn1-mGluR7 machinery. 
 
Reelin and somatostatin are both expressed in OLM neurons. Secreted 
somatostatin binds to pre-synaptic somatostatin receptors (putatively somatostatin 





inhibitory) postsynaptic responses of CA1 pyramidal neurons (Grilli et al., 2004; 
Tallent and Siggins, 1997). Reelin also affects presynaptic excitatory release 
probability in CA1 pyramidal neurons, and treatment with reelin enhances LTP 
induction in the CA1 region (Chen et al., 2005; Hellwig et al., 2011). 
 
CB1 and TRPV1 are both activated by similar agonists to control synaptic 
transmission (Marzo, 2010). Ablation of CB1 expression in GABAergic 
interneurons in the hippocampus depressed LTP in the CA3-CA1 pathway and 
greatly decreased the total dendritic branches and spines in CA1 pyramidal 
neurons, whereas removal of CB1 from glutamatergic neurons exerted the 
opposite effect by increasing LTP as well as the density of spines and total 
branching (Monory et al., 2015). The list of factors and signaling pathways that 
could, together with TRPV1, coordinate synaptic plasticity is extensive. It remains 
to be tested, for example, if TRPV1 also gates plasticity in the temporoamonic 
pathway, and what the endogenous agonist(s) are that regulate the activity of 
TRPV1 in the hippocampus. OLM neurons are highly sensitive to epileptic and 
febrile seizures, thus TRPV1 could be an important factor for driving the etiology of 
neurological disorders such as temporal lobe epilepsy. 
5.2. TRPV1 REPORTER MOUSE LINE 
A relatively new knock in mouse line has been developed using the cre-lox P 
system to allow specific visualization of cells expressing TRPV1, where a cre 
recombinase is expressed under the control of the TRPV1 promoter (Cavanaugh et 
al., 2011). We crossed this mouse line with a mouse line carrying a mutation at the 
Rosa26 locus with an insertion of a loxP cassette flanking a stop codon preventing 
the expression of the tdTomato fluorescent reporter gene (Madisen et al., 2010b). 
When cre is expressed the stop codon is removed thus allowing the expression of 






Similar to the observations obtained in the original study we saw highly confined 
expression of the tdTomato fluorescence signal throughout the brain of adult mice 
of the F1 generation. Following the results of Cavanaugh and collaborators (2011) 
we confirmed expression in the hypothalamic area (Figure 26 B) and few sparse 
neurons in the stratum oriens of the hippocampus (Figure 27 B). In addition, we 
found a strong tdTomato-positive putative axonal arborisation in the outer 
molecular layer of the hippocampus (Figure 27 A), which was not shown in the 
original study. Our finding using antibodies that TRPV1 is expressed in OLM 
neurons of the stratum oriens could not be confirmed using this reporter mouse line 
because except for one neuron, none of the apparent OLM neurons recognized by 
antibodies used for IHC colocalized with tdTomato (Figure 27 B). 
 
Unexpectedly we found that the expression pattern of tdTomato of the homozygotic 
F2 generation had a mosaic expression of tdTomato, where fluorescence was 
observed nonspecifically and ubiquitously throughout the brain. A similar 
promiscuous expression using cre loxP recombination has been observed for 
different lines, however the undesired leakage of cre expression occurred only in 
the second generation, thus siblings of the first generation should be unaffected 
(Heffner et al., 2012; Weng et al., 2008).  
 
According to these reports the first generation should provide reliable tdTomato 
expression only in TRPV1 expressing neurons. Nonetheless in our experiments 
using the F1 generation we found that tdTomato expression in the hippocampus 
did not correspond to that detected using commercial antibodies. One possibility is 
that the antibodies we were using were non-specific, which is known to be a 
common problem in the field (de Matos et al., 2010; Ward and Rehg, 2014; Yaziji 
and Barry, 2006).  
 
At first glance it appears that antibodies used in our study might identify a different 
protein other than TRPV1, because tdTomato-positive cells were not detected by 





neurons in KO animals. However, we found that the remaining signal is likely a 
splice variant or aberrant translation of TRPV1 in TRPV1 KO animals. In addition, 
we confirmed functionally that the neurons detected by TRPV1 antibodies (OLM 
neurons) do in fact express TRPV1 since we could rescue deficits in LTP in TRPV1 
KO hippocampi by selectively activating these neurons with 5 µM nicotine. 
 
It is not completely unreasonable to predict that the expression of tdTomato in the 
TRPV1-tdTomato reporter line even in the first generation is off target. In fact, due 
to increasing reports of unexpected phenotypes of several cre lines, a Cre strain 
characterization pipeline at The Jackson Laboratory Cre Repository has been 
developed. In their webpage, they alert the scientific community to be cautious with 
the use of cre lines since multiple lines report off-target cells, have variable 
efficiency of cre loxP recombination, differential inheritance of cre, and toxic cre 
side-effects among other complications. Finally the developers of the TRPV1-cre 
line could not rule out the possibility that the expression pattern in the F1 
generation could reflect a transient expression during early development 
(Cavanaugh et al., 2011). Although this could help to trace the fate of TRPV1-
expressing neurons, it would provide an inaccurate representation of the adult-
expression pattern. Since TRPV1 expression in OLM neurons seems to be lower 
than in other brain areas, the detection threshold may not be enough to allow 













6. CONCLUDING REMARKS 
We found that in the stratum oriens, TRPV1 (and possibly VR.5’ SV) is highly 
expressed in a subset of inhibitory interneurons classified as OLM neurons where it 
promotes high innervation by glutamatergic synaptic terminals, possibly from 
pyramidal neurons of the CA1 region of the hippocampus. Deletion of functional 
TRPV1 dramatically reduced the excitatory innervation on OLM neurons 
expressing the nACh2 receptor, which ultimately led to a decrease in LTP in the 
SC pathway of the hippocampus. LTP in TRPV1 KOs was rescued by 5 µM 
nicotine-induced activation of nACh2 receptors on OLM cells possibly by 
increasing dis-inhibition of the SC-CA1 pathway through a still unknown inhibitory 
intermediate.  
 
The present study elucidates the role of TRPV1 expression in the hippocampus, 
the cellular and subcellular localization of functional TRPV1 channels and its role in 
modulating synaptic strength. Furthermore we demonstrate that TRPV1 plays a 
role in glutamatergic synaptogenesis on OLM neurons and in the effect of these 
neurons on LTP induction in the SC in the hippocampus. 
 
Our results also propose different ways in which TRPV1 expression is upregulated 
in hippocampal neurons. Our results indicate that as in the PNS, NGF is also 
capable of causing an increase in TRPV1 expression in hippocampal neurons. We 
also report that neuronal activity increases TRPV1 levels in hippocampal neurons. 
 
We have also found that transfection and increased endogenous expression of 
TRPV1 (likely restricted to OLM neurons) correlates with high BDNF expression. 
TRPV1 channel activation was necessary for changes in BDNF upon TRPV1 
heterologous expression, since blockade of the channel led to a restoration in 
BDNF fluorescent intensity in TRPV1-expressing neurons to levels similar to 




surrounding neurons. We found that changes in presynaptic strength (syt1u) of 
excitatory terminals contacting TRPV1 transfected neurons at DIV2 are plausibly 
controlled by postsynaptic BDNF release. However both the pre-synaptic strength 
and abundant innervation of glutamatergic synapses on OLM neurons (with high 
endogenous TRPV1 expression) appear not be caused by BDNF. The induction of 
more glutamate release onto TRPV1 transfected neurons could be due to a 
retrograde secretion of BDNF, whereas in OLM neurons another mechanism could 
be responsible. 
 
Additionally, our results show that the TRPV1-cre reporter mouse line generated by 
Cavanaugh and collaborators might have some inconsistencies. Although we were 
able to see expression of the reporter gene (tdTomato) conditionally expressed 
upon cre activity in some of the brain regions that the original designers of the line 
reported in the original publication, the immunofluorescence signal detected for 
three commercial antibodies against TRPV1 only partially co-localized with the 
tdTomato signal in analyzed areas. In the hippocampus we only saw one cell that 
was positive for both tdTomato and immune-histochemical fluorescence, but the 
tdTomato fluorescence in other cells did not correspond to the signal provided by 
IHC using TRPV1 antibodies. 
 
Prior to the generation of the TRPV1-cre reporter mouse line a series of 
publications suggested that in the hippocampus the expression and functionality of 
TRPV1 existed. Cavanaugh et al., 2011 disagreed with these reports citing a 
highly-restricted expression throughout the hippocampus using the TRPV1 reporter 
mouse. We discovered that the TRPV1-cre mouse line might not be an accurate 
reporter of TRPV1 expression. Given our results conclusions formulated using this 
model should be compared with other methodologies in order to avoid 







Abe, T., and Fujimori, T. (2013). Reporter Mouse Lines for Fluorescence Imaging. 
Dev. Growth Differ. 55, 390–405. 
Abdel-Salam OME (ed.) (2014). Capsaicin as a Therapeutic Molecule (Basel: 
Springer Basel). 
Abraham, H., and Meyer, G. (2003). Reelin-expressing neurons in the postnatal 
and adult human hippocampal formation. Hippocampus 13, 715–727. 
Abremski, K., and Hoess, R. (1984). Bacteriophage P1 site-specific recombination. 
Purification and properties of the Cre recombinase protein. J. Biol. Chem. 259, 
1509–1514. 
Acsády, L., Arabadzisz, D., and Freund, T.F. (1996). Correlated morphological and 
neurochemical features identify different subsets of vasoactive intestinal 
polypeptide-immunoreactive interneurons in rat hippocampus. Neuroscience 73, 
299–315. 
Adamczyk, P., Miszkiel, J., McCreary, A.C., Filip, M., Papp, M., and Przegaliński, 
E. (2012). The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor 
antagonists on cocaine addictive behavior in rats. Brain Res. 1444, 45–54. 
Adams, B., Sazgar, M., Osehobo, P., Zee, C.E.E.M.V. der, Diamond, J., 
Fahnestock, M., and Racine, R.J. (1997). Nerve Growth Factor Accelerates 
Seizure Development, Enhances Mossy Fiber Sprouting, and Attenuates Seizure-
Induced Decreases in Neuronal Density in the Kindling Model of Epilepsy. J. 
Neurosci. 17, 5288–5296. 
Adams, B., Vaccarella, L., Fahnestock, M., and Racine, R.J. (2002). The 
cholinergic system modulates kindling and kindling-induced mossy fiber sprouting. 
Synap. N. Y. N 44, 132–138. 
Aguiar, D.C.T. Ana Luisa B.Guimarães, Francisco S.Moreira, Fabrício A. (2009). 
Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid 
type 1 (TRPV1) channels in the medial prefrontal cortex of rats. 
Psychopharmacology (Berl.) 205, 217–225. 
Ahern, G.P. (2003). Activation of TRPV1 by the Satiety Factor Oleoylethanolamide. 
J. Biol. Chem. 278, 30429–30434. 
Ahern, G.P., Wang, X., and Miyares, R.L. (2006). Polyamines Are Potent Ligands 





Ahmed, S., Reynolds, B.A., and Weiss, S. (1995). BDNF enhances the 
differentiation but not the survival of CNS stem cell- derived neuronal precursors. J. 
Neurosci. 15, 5765–5778. 
Ahmed, S., Holt, M., Riedel, D., and Jahn, R. (2013). Small-scale isolation of 
synaptic vesicles from mammalian brain. Nat. Protoc. 8, 998–1009. 
Alcántara, S., Ruiz, M., D’Arcangelo, G., Ezan, F., Lecea, L. de, Curran, T., Sotelo, 
C., and Soriano, E. (1998). Regional and Cellular Patterns of reelin mRNA 
Expression in the Forebrain of the Developing and Adult Mouse. J. Neurosci. 18, 
7779–7799. 
Al-Hayani, A., Wease, K.N., Ross, R.A., Pertwee, R.G., and Davies, S.N. (2001). 
The endogenous cannabinoid anandamide activates vanilloid receptors in the rat 
hippocampal slice. Neuropharmacology 41, 1000–1005. 
Amadesi, S., Cottrell, G.S., Divino, L., Chapman, K., Grady, E.F., Bautista, F., 
Karanjia, R., Barajas-Lopez, C., Vanner, S., Vergnolle, N., et al. (2006). Protease-
activated receptor 2 sensitizes TRPV1 by protein kinase Cɛ- and A-dependent 
mechanisms in rats and mice. J. Physiol. 575, 555–571. 
Amaya, F., Oh-hashi, K., Naruse, Y., Iijima, N., Ueda, M., Shimosato, G., 
Tominaga, M., Tanaka, Y., and Tanaka, M. (2003). Local inflammation increases 
vanilloid receptor 1 expression within distinct subgroups of DRG neurons. Brain 
Res. 963, 190–196. 
Amaya, F., Shimosato, G., Nagano, M., Ueda, M., Hashimoto, S., Tanaka, Y., 
Suzuki, H., and Tanaka, M. (2004). NGF and GDNF differentially regulate TRPV1 
expression that contributes to development of inflammatory thermal hyperalgesia. 
Eur. J. Neurosci. 20, 2303–2310. 
Anand, U., Otto, W.R., Casula, M.A., Day, N.C., Davis, J.B., Bountra, C., Birch, R., 
and Anand, P. (2006). The effect of neurotrophic factors on morphology, TRPV1 
expression and capsaicin responses of cultured human DRG sensory neurons. 
Neurosci. Lett. 399, 51–56. 
Aneiros, E., Cao, L., Papakosta, M., Stevens, E.B., Phillips, S., and Grimm, C. 
(2011). The biophysical and molecular basis of TRPV1 proton gating. EMBO J. 30, 
994–1002. 
Apfel, S.C., Wright, D.E., Wiideman, A.M., Dormia, C., Snider, W.D., and Kessler, 
J.A. (1996). Nerve Growth Factor Regulates the Expression of Brain-Derived 
Neurotrophic Factor mRNA in the Peripheral Nervous System. Mol. Cell. Neurosci. 
7, 134–142. 
Arabadzisz, D., Antal, K., Parpan, F., Emri, Z., and Fritschy, J.-M. (2005). 





are associated with distinct EEG patterns and selective neurochemical alterations 
in the contralateral hippocampus. Exp. Neurol. 194, 76–90. 
Babb, T.L., Brown, W.J., Pretorius, J., Davenport, C., Lieb, J.P., and Crandall, P.H. 
(1984). Temporal lobe volumetric cell densities in temporal lobe epilepsy. Epilepsia 
25, 729–740. 
Badawy, R.A.B., Harvey, A.S., and Macdonell, R.A.L. (2009). Cortical 
hyperexcitability and epileptogenesis: understanding the mechanisms of epilepsy - 
part 1. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 16, 355–365. 
Bailey, C.H., Kandel, E.R., and Harris, K.M. (2015). Structural Components of 
Synaptic Plasticity and Memory Consolidation. Cold Spring Harb. Perspect. Biol. 7, 
a021758. 
Balordi, F., and Fishell, G. (2007). Mosaic Removal of Hedgehog Signaling in the 
Adult SVZ Reveals That the Residual Wild-Type Stem Cells Have a Limited 
Capacity for Self-Renewal. J. Neurosci. 27, 14248–14259. 
Barakat-Walter, I. (1996). Brain-derived neurotrophic factor-like immunoreactivity is 
localized mainly in small sensory neurons of rat dorsal root ganglia. J. Neurosci. 
Methods 68, 281–288. 
Barbaric, I., Miller, G., and Dear, T.N. (2007). Appearances can be deceiving: 
phenotypes of knockout mice. Brief. Funct. Genomic. Proteomic. 6, 91–103. 
Barde, Y.A., Edgar, D., and Thoenen, H. (1982). Purification of a new neurotrophic 
factor from mammalian brain. EMBO J. 1, 549–553. 
Bellocchio, E.E., Reimer, R.J., Fremeau, R.T., and Edwards, R.H. (2000). Uptake 
of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science 
289, 957–960. 
Bengzon, J., Söderström, S., Kokaia, Z., Kokaia, M., Ernfors, P., Persson, H., 
Ebendal, T., and Lindvall, O. (1992). Widespread increase of nerve growth factor 
protein in the rat forebrain after kindling-induced seizures. Brain Res. 587, 338–
342. 
Benninger, F., Freund, T.F., and Hájos, N. (2008). Control of excitatory synaptic 
transmission by capsaicin is unaltered in TRPV1 vanilloid receptor knockout mice. 
Neurochem. Int. 52, 89–94. 
Bennion, D., Jensen, T., Walther, C., Hamblin, J., Wallmann, A., Couch, J., 
Blickenstaff, J., Castle, M., Dean, L., Beckstead, S., et al. (2011). Transient 
receptor potential vanilloid 1 agonists modulate hippocampal CA1 LTP via the 





Bevan, S., and Winter, J. (1995). Nerve growth factor (NGF) differentially regulates 
the chemosensitivity of adult rat cultured sensory neurons. J. Neurosci. 15, 4918–
4926. 
Bevan, S., Quallo, T., and Andersson, D.A. (2014). TRPV1. In Mammalian 
Transient Receptor Potential (TRP) Cation Channels, B. Nilius, and V. Flockerzi, 
eds. (Berlin, Heidelberg: Springer Berlin Heidelberg), pp. 207–245. 
Bezaire, M.J., and Soltesz, I. (2013). Quantitative Assessment of CA1 Local 
Circuits: Knowledge Base for Interneuron-Pyramidal Cell Connectivity. 
Hippocampus 23, 751–785. 
Bhaskaran, M.D., and Smith, B.N. (2010). Effects of TRPV1 activation on synaptic 
excitation in the dentate gyrus of a mouse model of temporal lobe epilepsy. Exp. 
Neurol. 223, 529–536. 
Bhave, G., Zhu, W., Wang, H., Brasier, D.J., Oxford, G.S., and Gereau, R.W. 
(2002). cAMP-Dependent Protein Kinase Regulates Desensitization of the 
Capsaicin Receptor (VR1) by Direct Phosphorylation. Neuron 35, 721–731. 
Bhave, G., Hu, H.-J., Glauner, K.S., Zhu, W., Wang, H., Brasier, D.J., Oxford, G.S., 
and Gereau, R.W. (2003). Protein kinase C phosphorylation sensitizes but does 
not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). 
Proc. Natl. Acad. Sci. 100, 12480–12485. 
Biane, J., Conner, J.M., and Tuszynski, M.H. (2014). Nerve growth factor is 
primarily produced by GABAergic neurons of the adult rat cortex. Front. Cell. 
Neurosci. 8. 
Birnbaumer, L., Yidirim, E., and Abramowitz, J. (2003). A comparison of the genes 
coding for canonical TRP channels and their M, V and P relatives. Cell Calcium 33, 
419–432. 
Bisogno, T., Melck, D., Bobrov MYu, Gretskaya, N.M., Bezuglov, V.V., De 
Petrocellis, L., and Di Marzo, V. (2000). N-acyl-dopamines: novel synthetic CB(1) 
cannabinoid-receptor ligands and inhibitors of anandamide inactivation with 
cannabimimetic activity in vitro and in vivo. Biochem. J. 351, 817–824. 
Bizon, J.L., Lauterborn, J.C., and Gall, C.M. (1999). Subpopulations of striatal 
interneurons can be distinguished on the basis of neurotrophic factor expression. J. 
Comp. Neurol. 408, 283–298. 
Black, D.L. (2003). Mechanisms of Alternative Pre-Messenger RNA Splicing. Annu. 
Rev. Biochem. 72, 291–336. 
Blasco-Ibáñez, J.M., and Freund, T.F. (1995). Synaptic input of horizontal 
interneurons in stratum oriens of the hippocampal CA1 subfield: structural basis of 





Blednov, Y.A., and Harris, R.A. (2009). Deletion of vanilloid receptor (TRPV1) in 
mice alters behavioral effects of ethanol. Neuropharmacology 56, 814–820. 
Bliss, T.V., and Collingridge, G.L. (1993). A synaptic model of memory: long-term 
potentiation in the hippocampus. Nature 361, 31–39. 
Bolton, M.M., Pittman, A.J., and Lo, D.C. (2000). Brain-Derived Neurotrophic 
Factor Differentially Regulates Excitatory and Inhibitory Synaptic Transmission in 
Hippocampal Cultures. J. Neurosci. 20, 3221–3232. 
Bonci, A., Bernardi, G., Grillner, P., and Mercuri, N.B. (2003). The dopamine-
containing neuron: maestro or simple musician in the orchestra of addiction? 
Trends Pharmacol. Sci. 24, 172–177. 
Bonhoeffer, T. (1996). Neurotrophins and activity-dependent development of the 
neocortex. Curr. Opin. Neurobiol. 6, 119–126. 
Bouabe, H., and Okkenhaug, K. (2013). Gene Targeting in Mice: a Review. 
Methods Mol. Biol. Clifton NJ 1064, 315–336. 
Boulanger, L., and Poo, M. (1999). Gating of BDNF-Induced Synaptic Potentiation 
by cAMP. Science 284, 1982–1984. 
Boutilier, J., Ceni, C., Pagdala, P.C., Forgie, A., Neet, K.E., and Barker, P.A. 
(2008). Proneurotrophins Require Endocytosis and Intracellular Proteolysis to 
Induce TrkA Activation. J. Biol. Chem. 283, 12709–12716. 
Boyken, J., Grønborg, M., Riedel, D., Urlaub, H., Jahn, R., and Chua, J.J.E. 
(2013). Molecular Profiling of Synaptic Vesicle Docking Sites Reveals Novel 
Proteins but Few Differences between Glutamatergic and GABAergic Synapses. 
Neuron 78, 285–297. 
Brauchi, S., Orta, G., Salazar, M., Rosenmann, E., and Latorre, R. (2006). A Hot-
Sensing Cold Receptor: C-Terminal Domain Determines Thermosensation in 
Transient Receptor Potential Channels. J. Neurosci. 26, 4835–4840. 
Brauchi, S., Orta, G., Mascayano, C., Salazar, M., Raddatz, N., Urbina, H., 
Rosenmann, E., Gonzalez-Nilo, F., and Latorre, R. (2007). Dissection of the 
components for PIP2 activation and thermosensation in TRP channels. Proc. Natl. 
Acad. Sci. 104, 10246–10251. 
Brimble, M.J., and Dyball, R.E.J. (1977). Characterization of the responses of 
oxytocin- and vasopressin-secreting neurones in the supraoptic nucleus to osmotic 
stimulation. J. Physiol. 271, 253–271. 
Brown, R.E., Jarvis, K.L., and Hyland, K.J. (1989). Protein measurement using 






Brown, T.E., Chirila, A.M., Schrank, B.R., and Kauer, J.A. (2013). Loss of 
interneuron LTD and attenuated pyramidal cell LTP in Trpv1 and Trpv3 KO mice. 
Hippocampus 23, 662–671. 
Buzsáki, G., Horváth, Z., Urioste, R., Hetke, J., and Wise, K. (1992). High-
frequency network oscillation in the hippocampus. Science 256, 1025–1027. 
Cajal, S.R.Y. (1894). The Croonian Lecture: La Fine Structure des Centres 
Nerveux. Proc. R. Soc. Lond. 55, 444–468. 
Calejesan, A.A., Kim, S.J., and Zhuo, M. (2000). Descending facilitatory 
modulation of a behavioral nociceptive response by stimulation in the adult rat 
anterior cingulate cortex. Eur. J. Pain Lond. Engl. 4, 83–96. 
Canduela, M.-J., Mendizabal-Zubiaga, J., Puente, N., Reguero, L., Elezgarai, I., 
Ramos-Uriarte, A., Gerrikagoitia, I., and Grandes, P. (2015). Visualization by High 
Resolution Immunoelectron Microscopy of the Transient Receptor Potential 
Vanilloid-1 at Inhibitory Synapses of the Mouse Dentate Gyrus. PLoS ONE 10, 
e0119401. 
Cao, E., Liao, M., Cheng, Y., and Julius, D. (2013). TRPV1 structures in distinct 
conformations reveal activation mechanisms. Nature 504, 113–118. 
Caterina, M.J. (2007). Transient receptor potential ion channels as participants in 
thermosensation and thermoregulation. Am. J. Physiol. - Regul. Integr. Comp. 
Physiol. 292, R64–R76. 
Caterina, M.J., Schumacher, M.A., Tominaga, M., Rosen, T.A., Levine, J.D., and 
Julius, D. (1997). The capsaicin receptor: a heat-activated ion channel in the pain 
pathway. Nature 389, 816–824. 
Caterina, M.J., Rosen, T.A., Tominaga, M., Brake, A.J., and Julius, D. (1999). A 
capsaicin-receptor homologue with a high threshold for noxious heat. Nature 398, 
436–441. 
Caterina, M.J., Leffler, A., Malmberg, A.B., Martin, W.J., Trafton, J., Petersen-Zeitz, 
K.R., Koltzenburg, M., Basbaum, A.I., and Julius, D. (2000). Impaired nociception 
and pain sensation in mice lacking the capsaicin receptor. Science 288, 306–313. 
Cavanaugh, D.J., Chesler, A.T., Jackson, A.C., Sigal, Y.M., Yamanaka, H., Grant, 
R., O’Donnell, D., Nicoll, R.A., Shah, N.M., Julius, D., et al. (2011). Trpv1 Reporter 
Mice Reveal Highly Restricted Brain Distribution and Functional Expression in 
Arteriolar Smooth Muscle Cells. J. Neurosci. 31, 5067–5077. 
Caviness, Jr, and Rakic,  and P. (1978). Mechanisms of Cortical Development: A 





Cesare, P., and McNaughton, P. (1996). A novel heat-activated current in 
nociceptive neurons and its sensitization by bradykinin. Proc. Natl. Acad. Sci. 93, 
15435–15439. 
Chao, M.V. (2003). Neurotrophins and their receptors: A convergence point for 
many signalling pathways. Nat. Rev. Neurosci. 4, 299–309. 
Chapman, E.R. (2002). Synaptotagmin: A Ca2+ sensor that triggers exocytosis? 
Nat. Rev. Mol. Cell Biol. 3, 498–508. 
Chávez, A.E., Chiu, C.Q., and Castillo, P.E. (2010). TRPV1 activation by 
endogenous anandamide triggers postsynaptic long-term depression in dentate 
gyrus. Nat. Neurosci. 13, 1511–1518. 
Chávez, A.E., Hernández, V.M., Rodenas-Ruano, A., Chan, C.S., and Castillo, 
P.E. (2014). Compartment-Specific Modulation of GABAergic Synaptic 
Transmission by TRPV1 Channels in the Dentate Gyrus. J. Neurosci. 34, 16621–
16629. 
Chen, Y., Beffert, U., Ertunc, M., Tang, T.-S., Kavalali, E.T., Bezprozvanny, I., and 
Herz, J. (2005). Reelin Modulates NMDA Receptor Activity in Cortical Neurons. J. 
Neurosci. 25, 8209–8216. 
Chiara, G.D., and Imperato, A. (1988). Drugs abused by humans preferentially 
increase synaptic dopamine concentrations in the mesolimbic system of freely 
moving rats. Proc. Natl. Acad. Sci. 85, 5274–5278. 
Chittajallu, R., Craig, M.T., McFarland, A., Yuan, X., Gerfen, S., Tricoire, L., 
Erkkila, B., Barron, S.C., Lopez, C.M., Liang, B.J., et al. (2013). Dual origins of 
functionally distinct O-LM interneurons revealed by differential 5-HT3AR 
expression. Nat. Neurosci. 16, 1598–1607. 
Cho, H.-J., Kim, S.-Y., Park, M.-J., Kim, D.-S., Kim, J.-K., and Chu, M.-Y. (1997a). 
Expression of mRNA for brain-derived neurotrophic factor in the dorsal root 
ganglion following peripheral inflammation. Brain Res. 749, 358–362. 
Cho, H.-J., Kim, J.-K., Zhou, X.-F., and Rush, R.A. (1997b). Increased brain-
derived neurotrophic factor immunoreactivity in rat dorsal root ganglia and spinal 
cord following peripheral inflammation. Brain Res. 764, 269–272. 
Chu, C., Zavala, K., Fahimi, A., Lee, J., Xue, Q., Eilers, H., and Schumacher, M.A. 
(2011). Transcription factors Sp1 and Sp4 regulate TRPV1 gene expression in rat 
sensory neurons. Mol. Pain 7, 44. 
Chung, M.-K., Güler, A.D., and Caterina, M.J. (2008). TRPV1 shows dynamic ionic 





Ciobanu, C., Reid, G., and Babes, A. (2009). Acute and chronic effects of 
neurotrophic factors BDNF and GDNF on responses mediated by thermo-sensitive 
TRP channels in cultured rat dorsal root ganglion neurons. Brain Res. 1284, 54–
67. 
Ciura, S., and Bourque, C.W. (2006). Transient Receptor Potential Vanilloid 1 Is 
Required for Intrinsic Osmoreception in Organum Vasculosum Lamina Terminalis 
Neurons and for Normal Thirst Responses to Systemic Hyperosmolality. J. 
Neurosci. 26, 9069–9075. 
Clapham, D.E. (2003). TRP channels as cellular sensors. Nature 426, 517–524. 
Cohen, S., Levi-Montalcini, R., and Hamburger, V. (1954). A NERVE GROWTH-
STIMULATING FACTOR ISOLATED FROM SARCOM AS 37 AND 180*. Proc. 
Natl. Acad. Sci. U. S. A. 40, 1014–1018. 
Conner, J.M., Lauterborn, J.C., Yan, Q., Gall, C.M., and Varon, S. (1997). 
Distribution of Brain-Derived Neurotrophic Factor (BDNF) Protein and mRNA in the 
Normal Adult Rat CNS: Evidence for Anterograde Axonal Transport. J. Neurosci. 
17, 2295–2313. 
Conner, J.M., Franks, K.M., Titterness, A.K., Russell, K., Merrill, D.A., Christie, 
B.R., Sejnowski, T.J., and Tuszynski, M.H. (2009). NGF Is Essential for 
Hippocampal Plasticity and Learning. J. Neurosci. 29, 10883–10889. 
Cristino, L., de Petrocellis, L., Pryce, G., Baker, D., Guglielmotti, V., and Di Marzo, 
V. (2006a). Immunohistochemical localization of cannabinoid type 1 and vanilloid 
transient receptor potential vanilloid type 1 receptors in the mouse brain. 
Neuroscience 139, 1405–1415. 
Cristino, L., de Petrocellis, L., Pryce, G., Baker, D., Guglielmotti, V., and Di Marzo, 
V. (2006b). Immunohistochemical localization of cannabinoid type 1 and vanilloid 
transient receptor potential vanilloid type 1 receptors in the mouse brain. 
Neuroscience 139, 1405–1415. 
Cristino, L., Starowicz, K., De Petrocellis, L., Morishita, J., Ueda, N., Guglielmotti, 
V., and Di Marzo, V. (2008). Immunohistochemical localization of anabolic and 
catabolic enzymes for anandamide and other putative endovanilloids in the 
hippocampus and cerebellar cortex of the mouse brain. Neuroscience 151, 955–
968. 
Curia, G., Longo, D., Biagini, G., Jones, R.S.G., and Avoli, M. (2008). The 
pilocarpine model of temporal lobe epilepsy. J. Neurosci. Methods 172, 143–157. 
Davis, J.B., Gray, J., Gunthorpe, M.J., Hatcher, J.P., Davey, P.T., Overend, P., 





receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405, 183–
187. 
Dean, C., Liu, H., Dunning, F.M., Chang, P.Y., Jackson, M.B., and Chapman, E.R. 
(2009). Synaptotagmin-IV Modulates Synaptic Function and LTP by Regulating 
BDNF Release. Nat. Neurosci. 12, 767–776. 
Del Río, J.A., Heimrich, B., Borrell, V., Förster, E., Drakew, A., Alcántara, S., 
Nakajima, K., Miyata, T., Ogawa, M., Mikoshiba, K., et al. (1997). A role for Cajal–
Retzius cells and reelin in the development of hippocampal connections. Nature 
385, 70–74. 
Derbenev, A.V., Monroe, M.J., Glatzer, N.R., and Smith, B.N. (2006). Vanilloid-
Mediated Heterosynaptic Facilitation of Inhibitory Synaptic Input to Neurons of the 
Rat Dorsal Motor Nucleus of the Vagus. J. Neurosci. 26, 9666–9672. 
Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., 
Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992). Isolation and 
structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 
1946–1949. 
Dhaka, A., Uzzell, V., Dubin, A.E., Mathur, J., Petrus, M., Bandell, M., and 
Patapoutian, A. (2009). TRPV1 Is Activated by Both Acidic and Basic pH. J. 
Neurosci. 29, 153–158. 
Dieni, S., Matsumoto, T., Dekkers, M., Rauskolb, S., Ionescu, M.S., Deogracias, 
R., Gundelfinger, E.D., Kojima, M., Nestel, S., Frotscher, M., et al. (2012). BDNF 
and its pro-peptide are stored in presynaptic dense core vesicles in brain neurons. 
J. Cell Biol. 196, 775–788. 
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., 
and Piomelli, D. (1994). Formation and inactivation of endogenous cannabinoid 
anandamide in central neurons. Nature 372, 686–691. 
Docherty, R.J., Yeats, J.C., Bevan, S., and Boddeke, H.W.G.M. (1996). Inhibition 
of calcineurin inhibits the desensitization of capsaicin-evoked currents in cultured 
dorsal root ganglion neurones from adult rats. Pflüg. Arch. 431, 828–837. 
Dougherty, K.D., and Milner, T.A. (1999). p75NTR immunoreactivity in the rat 
dentate gyrus is mostly within presynaptic profiles but is also found in some 
astrocytic and postsynaptic profiles. J. Comp. Neurol. 407, 77–91. 
Doyle, M.W., Bailey, T.W., Jin, Y.-H., and Andresen, M.C. (2002). Vanilloid 
Receptors Presynaptically Modulate Cranial Visceral Afferent Synaptic 





Drake, C.T., Milner, T.A., and Patterson, S.L. (1999). Ultrastructural Localization of 
Full-Length trkB Immunoreactivity in Rat Hippocampus Suggests Multiple Roles in 
Modulating Activity-Dependent Synaptic Plasticity. J. Neurosci. 19, 8009–8026. 
Dray, A., Forbes, C.A., and Burgess, G.M. (1990). Ruthenium red blocks the 
capsaicin-induced increase in intracellular calcium and activation of membrane 
currents in sensory neurones as well as the activation of peripheral nociceptors in 
vitro. Neurosci. Lett. 110, 52–59. 
Dreifuss, J.J., Kalnins, I., Kelly, J.S., and Ruf, K.B. (1971). Action potentials and 
release of neurohypophysial hormones in vitro. J. Physiol. 215, 805–817. 
Dugladze, T., Vida, I., Tort, A.B., Gross, A., Otahal, J., Heinemann, U., Kopell, 
N.J., and Gloveli, T. (2007). Impaired hippocampal rhythmogenesis in a mouse 
model of mesial temporal lobe epilepsy. Proc. Natl. Acad. Sci. 104, 17530–17535. 
Eckardt, D., Theis, M., Döring, B., Speidel, D., Willecke, K., and Ott, T. (2004). 
Spontaneous ectopic recombination in cell-type-specific Cre mice removes loxP-
flanked marker cassettes in vivo. Genesis 38, 159–165. 
Eilers, H., Lee, S.-Y., Hau, C.W., Logvinova, A., and Schumacher, M.A. (2007). 
The rat vanilloid receptor splice variant VR.5’sv blocks TRPV1 activation. 
Neuroreport 18, 969–973. 
Erlander, M.G., and Tobin, A.J. (1991). The structural and functional heterogeneity 
of glutamic acid decarboxylase: A review. Neurochem. Res. 16, 215–226. 
Ernsberger, U. (2009). Role of neurotrophin signalling in the differentiation of 
neurons from dorsal root ganglia and sympathetic ganglia. Cell Tissue Res. 336, 
349–384. 
Facer, P., Casula, M.A., Smith, G.D., Benham, C.D., Chessell, I.P., Bountra, C., 
Sinisi, M., Birch, R., and Anand, P. (2007). Differential expression of the capsaicin 
receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in 
normal human tissues and changes in traumatic and diabetic neuropathy. BMC 
Neurol. 7, 11. 
Fahnestock, M., Michalski, B., Xu, B., and Coughlin, M.D. (2001). The Precursor 
Pro-Nerve Growth Factor Is the Predominant Form of Nerve Growth Factor in Brain 
and Is Increased in Alzheimer’s Disease. Mol. Cell. Neurosci. 18, 210–220. 
Feinmark, S.J., Begum, R., Tsvetkov, E., Goussakov, I., Funk, C.D., Siegelbaum, 
S.A., and Bolshakov, V.Y. (2003). 12-Lipoxygenase Metabolites of Arachidonic 
Acid Mediate Metabotropic Glutamate Receptor-Dependent Long-Term Depression 
at Hippocampal CA3-CA1 Synapses. J. Neurosci. 23, 11427–11435. 
Fernandes, E., Fernandes, M., and Keeble, J. (2012). The functions of TRPA1 and 





Ferraguti, F., Cobden, P., Pollard, M., Cope, D., Shigemoto, R., Watanabe, M., and 
Somogyi, P. (2004). Immunolocalization of metabotropic glutamate receptor 1α 
(mGluR1α) in distinct classes of interneuron in the CA1 region of the rat 
hippocampus. Hippocampus 14, 193–215. 
Ferrini, F., Salio, C., Vergnano, A.M., and Merighi, A. (2007). Vanilloid receptor-1 
(TRPV1)-dependent activation of inhibitory neurotransmission in spinal substantia 
gelatinosa neurons of mouse. Pain 129, 195–209. 
Freund, T. f., and Buzsáki, G. (1996). Interneurons of the hippocampus. 
Hippocampus 6, 347–470. 
Fujii, S., Ji, Z., Morita, N., and Sumikawa, K. (1999). Acute and chronic nicotine 
exposure differentially facilitate the induction of LTP. Brain Res. 846, 137–143. 
Fukuoka, T., Kondo, E., Dai, Y., Hashimoto, N., and Noguchi, K. (2001). Brain-
Derived Neurotrophic Factor Increases in the Uninjured Dorsal Root Ganglion 
Neurons in Selective Spinal Nerve Ligation Model. J. Neurosci. 21, 4891–4900. 
Funakoshi, K., Nakano, M., Atobe, Y., Goris, R.C., Kadota, T., and Yazama, F. 
(2006). Differential development of TRPV1-expressing sensory nerves in 
peripheral organs. Cell Tissue Res. 323, 27–41. 
Gall, C.M., and Isackson, P.J. (1989). Limbic seizures increase neuronal 
production of messenger RNA for nerve growth factor. Science 245, 758–761. 
Gamazon, E.R., and Stranger, B.E. (2014). Genomics of alternative splicing: 
evolution, development and pathophysiology. Hum. Genet. 133, 679–687. 
García-Sanz, N., Fernández-Carvajal, A., Morenilla-Palao, C., Planells-Cases, R., 
Fajardo-Sánchez, E., Fernández-Ballester, G., and Ferrer-Montiel, A. (2004). 
Identification of a Tetramerization Domain in the C Terminus of the Vanilloid 
Receptor. J. Neurosci. 24, 5307–5314. 
García-Sanz, N., Valente, P., Gomis, A., Fernández-Carvajal, A., Fernández-
Ballester, G., Viana, F., Belmonte, C., and Ferrer-Montiel, A. (2007). A Role of the 
Transient Receptor Potential Domain of Vanilloid Receptor I in Channel Gating. J. 
Neurosci. 27, 11641–11650. 
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